Evidence review: Gonadotrophin releasing hormone analogues for children and adolescents with gender dysphoria

This document will help inform Dr Hilary Cass' independent review into gender identity services for children and young people. It was commissioned by NHS England and Improvement who commissioned the Cass review. It aims to assess the evidence for the clinical effectiveness, safety and cost-effectiveness of gonadotrophin releasing hormone (GnRH) analogues for children and adolescents aged 18 years or under with gender dysphoria.

The document was prepared by NICE in October 2020.

The content of this evidence review was up to date on 14 October 2020. See <u>summaries of</u> <u>product characteristics</u> (SPCs), <u>British National Formulary</u> (BNF) or the <u>Medicines and</u> <u>Healthcare products Regulatory Agency</u> (MHRA) or <u>NICE</u> websites for up-to-date information.

Contents

1. Introduction	3
2. Executive summary of the review	3
Critical outcomes	4
Important outcomes	5
Discussion	. 12
Conclusion	. 13
3. Methodology	. 14
Review questions	. 14
Review process	. 14
4. Summary of included studies	. 15
5. Results	. 19
6. Discussion	. 40
7. Conclusion	. 45
Appendix A PICO document	. 47
Appendix B Search strategy	. 50
Appendix C Evidence selection	. 73
Appendix D Excluded studies table	. 74
Appendix E Evidence tables	. 76
Appendix F Quality appraisal checklists	. 98
Appendix G Grade profiles	. 99
Glossary	129
References	130

1. Introduction

This review aims to assess the evidence for the clinical effectiveness, safety and costeffectiveness of gonadotrophin releasing hormone (GnRH) analogues for children and adolescents aged 18 years or under with gender dysphoria. The review follows the NHS England Specialised Commissioning process and template and is based on the criteria outlined in the PICO framework (see <u>appendix A</u>). This document will help inform Dr Hilary Cass' independent review into gender identity services for children and young people.

Gender dysphoria in children, also known as gender identity disorder or gender incongruence of childhood (<u>World Health Organisation 2020</u>), refers to discomfort or distress that is caused by a discrepancy between a person's gender identity (how they see themselves¹ regarding their gender) and that person's sex assigned at birth and the associated gender role, and/or primary and secondary sex characteristics (<u>Diagnostic and</u> <u>Statistical Manual of Mental Disorders 2013</u>).

GnRH analogues suppress puberty by delaying the development of secondary sexual characteristics. The intention is to alleviate the distress associated with the development of secondary sex characteristics, thereby providing a time for on-going discussion and exploration of gender identity before deciding whether to take less reversible steps. In England, the GnRH analogue triptorelin (a synthetic decapeptide analogue of natural GnRH, which has marketing authorisations for the treatment of prostate cancer, endometriosis and precocious puberty [onset before 8 years in girls and 10 years in boys]) is used for this purpose. The use of triptorelin for children and adolescents with gender dysphoria is <u>off-label</u>.

For children and adolescents with gender dysphoria it is recommended that management plans are tailored to the needs of the individual, and aim to ameliorate the potentially negative impact of gender dysphoria on general developmental processes, support young people and their families in managing the uncertainties inherent in gender identity development and provide on-going opportunities for exploration of gender identity. The plans may also include psychological support and exploration and, for some individuals, the use of GnRH analogues in adolescence to suppress puberty; this may be followed later with gender-affirming hormones of the desired sex (<u>NHS England 2013</u>).

2. Executive summary of the review

Nine observational studies were included in the evidence review. Five studies were retrospective observational studies (<u>Brik et al. 2020</u>, <u>Joseph et al. 2019</u>, <u>Khatchadourian et al. 2014</u>, <u>Klink et al. 2015</u>, <u>Vlot et al. 2017</u>), 3 studies were prospective longitudinal observational studies (<u>Costa et al. 2015</u>, <u>de Vries et al. 2011</u>, <u>Schagen et al. 2016</u>) and 1 study was a cross-sectional study (<u>Staphorsius et al. 2015</u>). Two studies (Costa et al. 2015

¹ Gender refers to the roles, behaviours, activities, attributes and opportunities that any society considers appropriate for girls and boys, and women and men (<u>World Health Organisation, Health Topics: Gender</u>).

and Staphorsius et al. 2015) provided comparative evidence and the remaining 7 studies used within-person, before and after comparisons.

The terminology used in this topic area is continually evolving and is different depending on stakeholder perspectives. In this evidence review we have used the phrase 'people's assigned sex at birth' rather than natal or biological sex, gonadotrophin releasing hormone (GnRH) analogues rather than 'puberty blockers' and gender-affirming hormones rather than 'cross sex hormones'. The research studies included in this evidence review may use historical terms which are no longer considered appropriate.

In children and adolescents with gender dysphoria, what is the clinical effectiveness of treatment with GnRH analogues compared with one or a combination of psychological support, social transitioning to the desired gender or no intervention?

Critical outcomes

The critical outcomes for decision making are the impact on gender dysphoria, mental health and quality of life. The quality of evidence for these outcomes was assessed as very low certainty using modified GRADE.

Impact on gender dysphoria

The study by <u>de Vries et al. 2011</u> in 70 adolescents with gender dysphoria found that treatment with GnRH analogues before starting gender-affirming hormones does not affect gender dysphoria (measured using the Utrecht Gender Dysphoria Scale [UGDS]). The mean (±SD) gender dysphoria (UGDS) score was not statistically significantly different at baseline compared with follow-up (n=41, 53.20 [±7.91] versus 53.9 [±17.42], p=0.333).

Impact on mental health

The study by <u>de Vries et al. 2011</u> in 70 adolescents with gender dysphoria found that treatment with GnRH analogues before starting gender-affirming hormones may reduce depression (measured using the Beck Depression Inventory-II [BDI-II]). The mean [±SD] BDI score was statistically significantly lower (improved) from baseline compared with follow-up (n=41, 8.31 [±7.12] versus 4.95 [±6.72], p=0.004).

The study by <u>de Vries et al. 2011</u> in 70 adolescents with gender dysphoria found that treatment with GnRH analogues before starting gender-affirming hormones does not affect anger (measured using the Trait Anger Scale [TPI]). The mean [±SD] anger (TPI) score was not statistically significantly different at baseline compared with follow-up (n=41, 18.29 [±5.54] versus 17.88 [±5.24], p=0.503).

The study by <u>de Vries et al. 2011</u> in 70 adolescents with gender dysphoria found that treatment with GnRH analogues before starting gender-affirming hormones does not affect anxiety (measured using the Trait Anxiety Scale [STAI]). The mean [±SD] anxiety (STAI) score was not statistically significantly different at baseline compared with follow-up (n=41, 39.43 [±10.07] versus 37.95 [±9.38], p=0.276).

Impact on quality of life

No evidence was identified.

Important outcomes

The important outcomes for decision making are impact on body image, psychosocial impact, engagement with health care services, impact on extent of and satisfaction with surgery and stopping treatment. The quality of evidence for all these outcomes was assessed as very low certainty using modified GRADE.

Impact on body image

The study by <u>de Vries et al. 2011</u> in 70 adolescents with gender dysphoria found that treatment with GnRH analogues before starting gender-affirming hormones does not affect body image (measured using the Body Image Scale [BIS]). The mean [\pm SD] body image (BIS) scores were not statistically significantly different from baseline compared with follow-up for primary sexual characteristics (n=57, 4.10 [\pm 0.56] versus 3.98 [\pm 0.71], p=0.145), secondary sexual characteristics (n=57, 2.74 [\pm 0.65] versus 2.82 [\pm 0.68], p=0.569) or neutral body characteristics (n=57, 2.41 [\pm 0.63] versus 2.47 [\pm 0.56], p=0.620).

Psychosocial impact

The study by <u>de Vries et al. 2011</u> in 70 adolescents with gender dysphoria found that treatment with GnRH analogues before starting gender-affirming hormones may improve psychosocial impact over time (measured using the Children's Global Assessment Scale [CGAS]). The mean [±SD] CGAS score was statistically significantly higher (improved) from baseline compared with follow-up (n=41, 70.24 [±10.12] versus 73.90 [±9.63], p=0.005).

This study also found that psychosocial functioning may improve over time (measured using the Child Behaviour Checklist [CBCL] and the self-administered Youth Self-Report [YSR]). The mean [\pm SD] CBCL scores were statistically significantly lower (improved) from baseline compared with follow-up for Total T score (n=54, 60.70 [\pm 12.76] versus 54.46 [\pm 11.23], p<0.001), internalising T score (n=54, 61.00 [\pm 12.21] versus 52.17 [\pm 9.81], p<0.001) and externalising T score (n=54, 58.04 [\pm 12.99] versus 53.81 [\pm 11.86], p=0.001). The mean [\pm SD] YSR scores were statistically significantly lower (improved) from baseline compared with follow-up for Total T score (n=54, 55.46 [\pm 11.56] versus 50.00 [\pm 10.56], p<0.001), internalising T score (n=54, 56.04 [\pm 12.49] versus 49.78 [\pm 11.63], p<0.001) and externalising T score (n=54, 56.04 [\pm 12.49] versus 49.78 [\pm 11.63], p<0.001) and externalising T score (n=54, 56.04 [\pm 12.49] versus 49.78 [\pm 11.63], p<0.001) and externalising T score (n=54, 56.04 [\pm 12.49] versus 49.78 [\pm 11.63], p<0.001) and externalising T score (n=54, 56.04 [\pm 12.49] versus 49.78 [\pm 11.63], p<0.001) and externalising T score (n=54, 56.04 [\pm 12.49] versus 49.78 [\pm 11.63], p<0.001) and externalising T score (n=54, 56.04 [\pm 10.098 [\pm 9.35], p=0.009). The proportion of adolescents scoring in the clinical range decreased from baseline to follow up on the CBCL total problem scale (44.4% versus 22.2%, p=0.001) and the internalising scale of the YSR (29.6% versus 11.1%, p=0.017).

The study by <u>Costa et al. 2015</u> in 201 adolescents with gender dysphoria who had 6 months of psychological support followed by either GnRH analogues and continued psychological support or continued psychological support only, found that during treatment with GnRH analogues psychosocial impact in terms of global functioning may improve over time (measured using the CGAS). In the group receiving GnRH analogues, the mean [±SD] CGAS score was statistically significantly higher (improved) after 6 months (n=60, 64.70 [±13.34]) and 12 months (n=35, 67.40 [±13.39]) compared with baseline (n=101, 58.72 [±11.38], p=0.003 and p<0.001, respectively). However, there was no statistically significant difference in global functioning (CGAS scores) between the group receiving GnRH analogues plus psychological support and the group receiving psychological support only at any time point.

The study by <u>Staphorsius et al. 2015</u> in 40 adolescents with gender dysphoria (20 of whom were receiving GnRH analogues) gave mean [\pm SD] CBCL scores for each group, but statistical analysis is unclear (transfemales receiving GnRH analogues 57.4 [\pm 9.8], transfemales not receiving GnRH analogues 58.2 [\pm 9.3], transmales receiving GnRH analogues 57.5 [\pm 9.4], transmales not receiving GnRH analogues 63.9 [\pm 10.5]).

Engagement with health care services

The study by <u>Brik et al. 2018</u> in 143 children and adolescents with gender dysphoria receiving GnRH analogues found that 9 adolescents in the original sampling frame (9/214, 4.2%) were excluded from the study because they stopped attending appointments.

The study by <u>Costa et al. 2015</u> in 201 adolescents with gender dysphoria who had 6 months of psychological support followed by either GnRH analogues and continued psychological support or continued psychological support only had a large loss to follow-up over time. The sample size at baseline and 6 months was 201, which dropped by 39.8% to 121 after 12 months and by 64.7% to 71 at 18 months follow-up. No explanation of the reasons for loss to follow-up are reported.

Impact on extent of and satisfaction with surgery

No evidence was identified.

Stopping treatment

The study by <u>Brik et al. 2018</u> in 143 children and adolescents with gender dysphoria receiving GnRH analogues reported the reasons for stopping GnRH analogues. During the follow-up period 6.2% (9/143) of adolescents had stopped GnRH analogues after a median duration of 0.8 years (range 0.1 to 3.0). Five adolescents stopped treatment because they no longer wished to receive gender-affirming treatment for various reasons. In 4 adolescents (all transmales), GnRH analogues were stopped mainly because of adverse effects (such as mood and emotional lability), although they wanted to continue treatments for gender dysphoria.

The study by <u>Khatchadourian et al. 2014</u> in 27 adolescents with gender dysphoria who started GnRH analogues reported the reasons for stopping them. Eleven out of 26 where data was available (42%) stopped GnRH analogues during follow up.

In children and adolescents with gender dysphoria, what is the short-term and longterm safety of GnRH analogues compared with one or a combination of psychological support, social transitioning to the desired gender or no intervention?

Evidence was available for bone density, cognitive development or functioning, and other safety outcomes. The quality of evidence for all these outcomes was assessed as very low certainty using modified GRADE.

Bone density

The study by <u>Joseph et al. 2019</u> in 70 adolescents with gender dysphoria found that GnRH analogues may reduce the expected increase in lumbar or femoral bone density (measured with the z-score). However, the z-scores were largely within 1 standard deviation of normal,

and actual lumbar or femoral bone density values were not statistically significantly different between baseline and follow-up:

- The mean z-score [±SD] for lumbar bone mineral apparent density (BMAD) was statistically significantly lower at 1 year compared with baseline in transfemales (baseline 0.859 [±0.154], 1 year -0.228 [±1.027], p=0.000) and transmales (baseline -0.186 [±1.230], 1 year -0.541 [±1.396], p=0.006).
- The mean z-score [±SD] for lumbar BMAD was statistically significantly lower after receiving GnRH analogues for 2 years compared with baseline in transfemales (baseline 0.486 [±0.809], 2 years -0.279 [±0.930], p=0.000) and transmales (baseline -0.361 [±1.439], 2 years -0.913 [±1.318], p=0.001).
- The mean z-score [±SD] for femoral neck bone mineral density (BMD) was statistically significantly lower after receiving GnRH analogues for 2 years compared with baseline in transfemales (baseline 0.0450 [±0.781], 2 years -0.600 [±1.059], p=0.002) and transmales (baseline -1.075 [±1.145], 2 years -1.779 [±0.816], p=0.001).

The study by <u>Klink et al. 2015</u> in 34 adolescents with gender dysphoria found that GnRH analogues may reduce the expected increase in lumbar (transmales only), but not femoral bone density. However, the z-scores are largely within 1 standard deviation of normal. Actual lumbar or femoral bone density values were not statistically significantly different between baseline and follow-up (apart from BMD measurements in transmales):

 The mean z-score [±SD] for lumbar BMAD was not statistically significantly different between starting GnRH analogues and starting gender-affirming hormones in transfemales, but was statistically significantly lower when starting gender-affirming hormones in transmales (GnRH analogues 0.28 [±0.90], gender-affirming hormones -0.50 [±0.81], p=0.004).

The study by <u>Vlot et al. 2017</u> in 70 adolescents with gender dysphoria found that GnRH analogues may reduce the expected increase in lumbar or femoral bone density. However, the z-scores were largely within 1 standard deviation of normal. Actual lumbar or femoral bone density values were not statistically significantly different between baseline and follow-up (apart from in transmales with a bone age \geq 14 years). This study reported change in bone density from starting GnRH analogues to starting gender-affirming hormones by bone age:

- The median z-score [range] for lumbar BMAD in transfemales with a bone age of <15 years was statistically significantly lower at starting gender-affirming hormones than at starting GnRH analogues (GnRH analogues -0.20 [-1.82 to 1.18], gender-affirming hormones -1.52 [-2.36 to 0.42], p=0.001) but was not statistically significantly different in transfemales with a bone age ≥15 years.
- The median z-score [range] for lumbar BMAD in transmales with a bone age of <14 years was statistically significantly lower at starting gender-affirming hormones than at starting GnRH analogues (GnRH analogues -0.05 [-0.78 to 2.94], gender-affirming hormones -0.84 [-2.20 to 0.87], p=0.003) and in transmales with a bone age ≥14 years (GnRH analogues 0.27 [-1.60 to 1.80], gender-affirming hormones -0.29 [-2.28 to 0.90], p≤0.0001).

- The median z-score [range] for femoral neck BMAD in transfemales with a bone age of <15 years was not statistically significantly lower at starting gender-affirming hormones than at starting GnRH analogues (GnRH analogues -0.71 [-3.35 to 0.37], gender-affirming hormones -1.32 [-3.39 to 0.21], p≤0.1) or in transfemales with a bone age ≥15 years (GnRH analogues -0.44 [-1.37 to 0.93], gender-affirming hormones -0.36 [-1.50 to 0.46]).
- The z-score for femoral neck BMAD in transmales with a bone age of <14 years was not statistically significantly lower at starting gender-affirming hormones than at starting GnRH analogues (GnRH analogues -0.01 [-1.30 to 0.91], gender-affirming hormone -0.37 [-2.28 to 0.47]) but was statistically significantly lower in transmales with a bone age ≥14 years (GnRH analogues 0.27 [-1.39 to 1.32], gender-affirming hormones -0.27 [-1.91 to 1.29], p=0.002).

Cognitive development or functioning

The study by <u>Staphorsius et al. 2015</u> in 40 adolescents with gender dysphoria (20 of whom were receiving GnRH analogues) measured cognitive development or functioning (using an IQ test, and reaction time and accuracy measured using the Tower of London task):

- The mean (±SD) IQ in transfemales receiving GnRH analogues was 94.0 (±10.3) and 109.4 (±21.2) in the control group. In transmales receiving GnRH analogues the mean (±SD) IQ was 95.8 (±15.6) and 98.5 (±15.9) in the control group.
- The mean (±SD) reaction time in transfemales receiving GnRH analogues was 10.9 (±4.1) and 9.9 (±3.1) in the control group. In transmales receiving GnRH analogue it was 9.9 (±3.1) and 10.0 (±2.0) in the control group.
- The mean (±SD) accuracy score in transfemales receiving GnRH analogues was 73.9 (±9.1) and 83.4 (±9.5) in the control group. In transmales receiving GnRH analogues it was 85.7 (±10.5) and 88.8 (±9.7) in the control group.

No statistical analyses or interpretation of the results was reported.

Other safety outcomes

The study by <u>Schagen et al. 2016</u> in 116 adolescents with gender dysphoria found that GnRH analogues do not affect renal or liver function:

- There was no statistically significant difference between baseline and 1 year results for serum creatinine in transfemales, but there was a statistically significant decrease between baseline and 1 year in transmales (p=0.01).
- Glutamyl transferase, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) levels did not significantly change from baseline to 12 months of treatment.

The study by <u>Khatchadourian et al. 2014</u> in 27 adolescents with gender dysphoria who started GnRH analogues narratively reported adverse effects from GnRH analogues in 26 adolescents:

- 1 transmale developed sterile abscesses; they were switched from leuprolide acetate to triptorelin, and this was well tolerated
- 1 transmale developed leg pains and headaches, which eventually resolved
- 1 participant gained 19 kg within 9 months of starting GnRH analogues.

In children and adolescents with gender dysphoria, what is the cost-effectiveness of GnRH analogues compared to one or a combination of psychological support, social transitioning to the desired gender or no intervention?

No cost-effectiveness evidence was found for GnRH analogues in children and adolescents with gender dysphoria.

From the evidence selected, are there any subgroups of children and adolescents with gender dysphoria that may benefit from GnRH analogues more than the wider population of interest?

Some studies reported data separately for the following subgroups of children and adolescents with gender dysphoria: sex assigned at birth males (transfemales) and sex assigned at birth females (transmales). This included some direct comparisons of these subgroups, and differences were largely seen at baseline as well as follow up. No evidence was found for other specified subgroups.

Sex assigned at birth males (transfemales) Impact on gender dysphoria

The study by <u>Costa et al. 2015</u> in 201 adolescents with gender dysphoria who had 6 months of psychological support followed by either GnRH analogues and continued psychological support or continued psychological support only, found that gender dysphoria (measured using the UGDS) in sex assigned at birth males is lower than in sex assigned at birth females. Sex assigned at birth males had a statistically significantly lower (improved) mean [\pm SD] UGDS score of 51.6 [\pm 9.7] compared with sex assigned at birth females (56.1 [\pm 4.3], p<0.001), but it was not reported if this was at baseline or follow-up.

The study by <u>de Vries et al. 2011</u> in 70 adolescents with gender dysphoria found that gender dysphoria (measured using the UGDS) in sex assigned at birth males is lower than in sex assigned at birth females at baseline and follow up. The mean [\pm SD] UGDS score was statistically significantly lower (improved) in sex assigned at birth males compared with sex assigned at birth females at baseline (n=not reported, mean UGDS score: 47.95 [\pm 9.70] versus 56.57 [\pm 3.89]) and follow up (n=not reported, 49.67 [\pm 9.47] versus 56.62 [\pm 4.00]); between sex difference p<0.001).

Impact on mental health

The study by <u>de Vries et al. 2011</u> in 70 adolescents with gender dysphoria found that the impact on mental health (depression, anger and anxiety) may be different in sex assigned at birth males compared with sex assigned at birth females. Over time there was no statistically significant difference between sex assigned at birth males and sex assigned at birth females for depression, but sex assigned at birth males had statistically significantly lower levels of anger and anxiety than sex assigned at birth females at baseline and follow up.

- The mean [±SD] depression (BDI-II) score was not statistically significantly different in sex assigned at birth males compared with sex assigned at birth females at baseline (n=not reported, mean BDI score [±SD]: 5.71 [±4.31] versus 10.34 [±8.24]) and follow-up (n=not reported, 3.50 [±4.58] versus 6.09 [±7.93]), between sex difference p=0.057
- The mean [±SD] anger (TPI) score was statistically significantly lower (improved) in sex assigned at birth males compared with sex assigned at birth females at baseline (n=not reported, mean TPI score [±SD]: 5.22 [±2.76] versus 6.43 [±2.78]) and follow-

up (n=not reported, 5.00 [\pm 3.07] versus 6.39 [\pm 2.59]), between sex difference p=0.022

• The mean [±SD] anxiety (STAI) score was statistically significantly lower (improved) in sex assigned at birth males compared with sex assigned at birth females at baseline (n=not reported, mean STAI score [±SD]: 4.33 [±2.68] versus 7.00 [±2.36]) and follow-up (n=not reported, 4.39 [±2.64] versus 6.17 [±2.69]), between sex difference p<0.001.

Impact on body image

The study by <u>de Vries et al. 2011</u> in 70 adolescents with gender dysphoria found that the impact on body image may be different in sex assigned at birth males compared with sex assigned at birth females. Sex assigned at birth males are less dissatisfied with their primary and secondary sex characteristics than sex assigned at birth females at both baseline and follow up, but the satisfaction with neutral body characteristics is not different.

- The mean [±SD] BIS score for primary sex characteristics was statistically significantly lower (improved) in sex assigned at birth males compared with sex assigned at birth females at baseline (n=not reported, mean BIS score [±SD]: 4.02 [±0.61] versus 4.16 [±0.52]) and follow up (n=not reported, 3.74 [±0.78] versus 4.17 [±0.58]) between sex difference p=0.047.
- The mean [±SD] BIS score for secondary sex was statistically significantly lower (improved) in sex assigned at birth males compared with sex assigned at birth females at baseline (n=not reported, mean BIS score [±SD]: 2.66 [±0.50] versus 2.81 [±0.76]) and follow up (n=not reported, 2.39 [±0.69] versus 3.18 [±0.42]), between sex difference p=0.001.
- The mean [±SD] BIS score for neutral body characteristics was not statistically significantly different in sex assigned at birth males compared with sex assigned at birth females at baseline (n=not reported, 2.60 [±0.58] versus 2.24 [±0.62], between sex difference p=0.777).

Psychosocial impact

The study by <u>Costa et al. 2015</u> in 201 adolescents with gender dysphoria who had 6 months of psychological support followed by either GnRH analogues and continued psychological support or continued psychological support only, found that sex assigned at birth males had statistically significant lower mean [\pm SD] CGAS scores at baseline compared with sex assigned at birth females (n=201, 55.4 [\pm 12.7] versus 59.2 [\pm 11.8], p=0.03), but no conclusions could be drawn.

The study by <u>de Vries et al. 2011</u> in 70 adolescents with gender dysphoria found that psychosocial impact in terms of global functioning (CGAS) and psychosocial functioning (CBCL and YSR) may be different in sex assigned at birth males compared with sex assigned at birth females, but no conclusions could be drawn.

 There was no statistically significant difference between sex assigned at birth males and sex assigned at birth females (at baseline or follow up) for the CBCL Total T score, the CBCL internalising T score, the YSR Total T score or the YSR internalising T score.

- Sex assigned at birth males had statistically higher mean [±SD] CGAS scores compared with sex assigned at birth females at baseline (n=54, 73.10 [±8.44] versus 67.25 [±11.06]) and follow up (n=54, 77.33 [±8.69] versus 70.30 [±9.44]), between sex difference p=0.021.
- Sex assigned at birth males had statistically lower mean [±SD] CBCL externalising T scores compared with sex assigned at birth females at baseline (n=54, 54.71 [±12.91] versus 60.70 [±12.64]) and follow up (n=54, 48.75 [±10.22] versus 57.87 [±11.66]), between sex difference p=0.015.
- Sex assigned at birth males had statistically lower mean [±SD] YSR externalising T scores compared with sex assigned at birth females at both baseline (n=54, 48.72 [±11.38] versus 57.24 [±10.59]) and follow up (n=54, 46.52 [±9.23] versus 52.97 [±8.51]), between sex difference p=0.004.

Bone density

The studies by <u>Joseph et al. 2019</u>, <u>Klink et al. 2015</u> and <u>Vlot et al. 2017</u> provided evidence on bone density in sex assigned at birth males (see above for details).

Cognitive development or functioning

The study by <u>Staphorsius et al. 2015</u> provided evidence on cognitive development or functioning in sex assigned at birth males (see above for details).

Other safety outcomes

The study by <u>Schagen et al. 2016</u> provided evidence on renal function in sex assigned at birth males (see above).

Sex assigned at birth females (transmales)

Impact on gender dysphoria

The studies by <u>de Vries et al. 2011</u> and <u>Costa et al. 2015</u> found that gender dysphoria (measured using the UGDS) in sex assigned at birth females is higher than in sex assigned at birth males at baseline and follow up (see above for details).

Impact on mental health

The study by <u>de Vries et al. 2011</u> found that the impact on mental health (depression, anger and anxiety) may be different in sex assigned at birth females compared with sex assigned at birth males. Over time there was no statistically significant difference between sex assigned at birth females and sex assigned at birth males for depression, but sex assigned at birth females had statistically significantly greater levels of anger and anxiety than sex assigned at birth males at both baseline and follow up (see above for details).

Impact on body image

The study by <u>de Vries et al. 2011</u> found that the impact on body image may be different in sex assigned at birth females compared with sex assigned at birth males. Sex assigned at birth females are more dissatisfied with their primary and secondary sex characteristics than sex assigned at birth males at both baseline and follow up, but the satisfaction with neutral body characteristics is not different (see above for details).

Psychosocial impact

The studies by <u>de Vries et al. 2011</u> and <u>Costa et al. 2015</u> found that psychosocial impact in terms of global functioning (CGAS) and psychosocial functioning (CBCL and YSR) may be different in sex assigned at birth females compared with sex assigned at birth males, but no conclusions could be drawn (see above for details).

Bone density

The studies by <u>Joseph et al. 2019</u>, <u>Klink et al. 2015</u> and <u>Vlot et al. 2017</u> provided evidence on bone density in sex assigned at birth females (see above for details).

Cognitive development or functioning

The study by <u>Staphorsius et al. 2015</u> provided evidence on cognitive development or functioning in sex assigned at birth females (see above for details).

Other safety outcomes

The study by <u>Schagen et al. 2016</u> provided evidence on renal function in sex assigned at birth females (see above for details).

From the evidence selected:

- (a) what are the criteria used by the research studies to define gender dysphoria, gender identity disorder and gender incongruence of childhood?
- (b) what were the ages at which participants commenced treatment with GnRH analogues?
- (c) what was the duration of treatment with GnRH analogues?

All studies that reported diagnostic criteria for gender dysphoria (6/9 studies) used the version of the Diagnostic and Statistical Manual of Mental Disorders (DSM) criteria that was in use at the time. In 5 studies (<u>Costa et al. 2015</u>, <u>Klink et al. 2015</u>, <u>Schagen et al. 2016</u>, <u>Staphorsius et al. 2015</u> and <u>Vlot et al. 2017</u>) the DSM-fourth edition, text revision (IV-TR) criteria were used. The study by <u>Brik et al. 2020</u> used DSM-V criteria. It was not reported how gender dysphoria was defined in the remaining 3 studies.

The studies show variation in the age (11 to 18 years old) at which children and adolescents with gender dysphoria started GnRH analogues.

Most studies did not report the duration of treatment with GnRH analogues (Joseph et al. 2019, Khatchadourian et al. 2014, Vlot et al. 2017, Costa et al. 2015, de Vries et al. 2011, Schagen et al. 2016), but where this was reported (Brik et al. 2020, Klink et al. 2015, Staphorsius et al. 2015) there was a wide variation ranging from a few months to about 5 years.

Discussion

A key limitation to identifying the effectiveness and safety of GnRH analogues for children and adolescents with gender dysphoria is the lack of reliable comparative studies. The lack of clear, expected outcomes from treatment with a GnRH analogue (the purpose of which is to suppress secondary sexual characteristics which may cause distress from unwanted pubertal changes) also makes interpreting the evidence difficult. The studies included in this evidence review are all small, uncontrolled observational studies, which are subject to bias and confounding, and all the results are of very low certainty using modified GRADE. They all reported physical and mental health comorbidities and concomitant treatments very poorly. All the studies are from a limited number of, mainly European, care facilities. They are described as either tertiary referral or expert services but the low number of services providing such care and publishing evidence may bias the results towards the outcomes in these services only and limit extrapolation.

Many of the studies did not report statistical significance or confidence intervals. Changes in outcome scores for clinical effectiveness and bone density were assessed with regards to statistical significance. However, there is relatively little interpretation of whether the changes in outcomes are clinically meaningful.

In the observational, retrospective studies providing evidence on bone density, participants acted as their own controls and change in bone density was determined between starting GnRH analogues and follow up. Observational studies such as these can only show an association with GnRH analogues and bone density; they cannot show that GnRH analogues caused any differences in bone density seen. Because there was no comparator group and participants acted as their own controls, it is not known whether the findings are associated with GnRH analogues or due to changes over time.

Conclusion

The results of the studies that reported impact on the critical outcomes of gender dysphoria and mental health (depression, anger and anxiety), and the important outcomes of body image and psychosocial impact (global and psychosocial functioning), in children and adolescents with gender dysphoria are of very low certainty using modified GRADE. They suggest little change with GnRH analogues from baseline to follow-up.

Studies that found differences in outcomes could represent changes that are either of questionable clinical value, or the studies themselves are not reliable and changes could be due to confounding, bias or chance. It is plausible, however, that a lack of difference in scores from baseline to follow-up is the effect of GnRH analogues in children and adolescents with gender dysphoria, in whom the development of secondary sexual characteristics might be expected to be associated with an increased impact on gender dysphoria, depression, anxiety, anger and distress over time without treatment. The study by <u>de Vries et al. 2011</u> reported statistically significant reductions in the Child Behaviour Checklist (CBCL) and Youth Self-Report (YSR) scores from baseline to follow up, which include measures of distress. As the aim of GnRH analogues is to reduce distress caused by the development of secondary sexual characteristics, this may be an important finding. However, as the studies all lack appropriate controls who were not receiving GnRH analogues, any positive changes could be a regression to mean.

The results of the studies that reported bone density outcomes suggest that GnRH analogues may reduce the expected increase in bone density (which is expected during puberty). However, as the studies themselves are not reliable, the results could be due to confounding, bias or chance. While controlled trials may not be possible, comparative studies are needed to understand this association and whether the effects of GnRH analogues on bone density are seen after they are stopped. All the studies that reported safety outcomes provided very low certainty evidence.

No cost-effectiveness evidence was found to determine whether or not GnRH analogues are cost-effective for children and adolescents with gender dysphoria.

The results of the studies that reported outcomes for subgroups of children and adolescents with gender dysphoria, suggest there may be differences between sex assigned at birth males (transfemales) and sex assigned at birth females (transmales).

3. Methodology

Review questions

The review question(s) for this evidence review are:

- 1. For children and adolescents with gender dysphoria, what is the clinical effectiveness of treatment with GnRH analogues compared with one or a combination of psychological support, social transitioning to the desired gender or no intervention?
- 2. For children and adolescents with gender dysphoria, what is the short-term and long-term safety of GnRH analogues compared with one or a combination of psychological support, social transitioning to the desired gender or no intervention?
- 3. For children and adolescents with gender dysphoria, what is the costeffectiveness of GnRH analogues compared to one or a combination of psychological support, social transitioning to the desired gender or no intervention?
- 4. From the evidence selected, are there any subgroups of children and adolescents with gender dysphoria that may derive more (or less) advantage from treatment with GnRH analogues than the wider population of children and adolescents with gender dysphoria?
- 5. From the evidence selected,
 - a) what are the criteria used by the research studies to define gender dysphoria, gender identity disorder and gender incongruence of childhood?
 - b) what were the ages at which participants commenced treatment with GnRH analogues?
 - c) what was the duration of treatment with GnRH analogues?

See <u>appendix A</u> for the full review protocol.

Review process

The methodology to undertake this review is specified by NHS England in their 'Guidance on conducting evidence reviews for Specialised Services Commissioning Products' (2020).

The searches for evidence were informed by the PICO document and were conducted on 23 July 2020.

See <u>appendix B</u> for details of the search strategy.

Results from the literature searches were screened using their titles and abstracts for relevance against the criteria in the PICO framework. Full text references of potentially

relevant evidence were obtained and reviewed to determine whether they met the inclusion criteria for this evidence review.

See <u>appendix C</u> for evidence selection details and <u>appendix D</u> for the list of studies excluded from the review and the reasons for their exclusion.

Relevant details and outcomes were extracted from the included studies and were critically appraised using a checklist appropriate to the study design. See appendices \underline{E} and \underline{F} for individual study and checklist details.

The available evidence was assessed by outcome for certainty using modified GRADE. See <u>appendix G</u> for GRADE Profiles.

4. Summary of included studies

Nine observational studies were identified for inclusion. Five studies were retrospective observational studies (Brik et al. 2020, Joseph et al. 2019, Khatchadourian et al. 2014, Klink et al. 2015, Vlot et al. 2017), 3 studies were prospective longitudinal observational studies (Costa et al. 2015, de Vries et al. 2011, Schagen et al. 2016) and 1 study was a cross-sectional study (Staphorsius et al. 2015).

The terminology used in this topic area is continually evolving and is different depending on stakeholder perspectives. In this evidence review we have used the phrase 'people's assigned sex at birth' rather than natal or biological sex, gonadotrophin releasing hormone (GnRH) analogues rather than 'puberty blockers' and gender-affirming hormones rather than 'cross sex hormones'. The research studies included in this evidence review may use historical terms which are no longer considered appropriate.

Table 1 provides a summary of these included studies and full details are given in <u>appendix E</u>.

Study	Population	Intervention and comparison	Outcomes reported
Brik et al. 2020 Retrospective observational single-centre study Netherlands	The study was conducted at the Curium-Leiden University Medical Centre gender clinic in Leiden, the Netherlands and involved adolescents with gender dysphoria. The sample size was 143 adolescents (median age at start of treatment was 15.0 years, range 11.1 to 18.6 years in transfemales; 16.1 years, range 10.1 to 17.9 years in transmales) from a sampling frame of 269 children and adolescents registered at the clinic between November 2010 and January 2018.	Intervention 143 children and adolescents receiving GnRH analogues (no specific treatment, dose, route or frequency of administration reported). The median duration was 2.1 years (range 1.6– 2.8 years). Comparison No comparator.	Critical Outcomes • No critical outcomes reported Important outcomes • Stopping treatment

Table 1 Summary of included studies

Study	Population	Intervention and comparison	Outcomes reported
	Participants were included in the study if they were diagnosed with gender dysphoria according to the DSM-5 criteria, registered at the clinic, were prepubertal and within the appropriate age range, and had started GnRH analogues. No concomitant treatments were reported.		
Costa et al. 2015 Prospective longitudinal observational single centre cohort study United Kingdom	The study was conducted at the Gender Identity Development Service in London and involved adolescents with gender dysphoria. The sample size was 201 adolescents (mean [±SD] age 15.52±1.41 years, range 12 to 17 years) from a sampling frame of 436 consecutive adolescents referred to the service between 2010 and 2014. The mean [±SD] age at the start of GnRH analogues was 16.48 [±1.26] years, range 13 to 17 years. Participants were invited to participate following a 6-month diagnostic process using DSM-IV- TR criteria. No concomitant treatments were reported.	Intervention 101 adolescents assessed as being immediately eligible for GnRH analogues (no specific treatment, dose or route of administration reported) plus psychological support. The average duration of treatment was approximately 12 months (no exact figure given). Comparison 100 adolescents assessed as not immediately eligible for GnRH analogues (more time needed to make the decision to start GnRH analogues) who had psychological support only. None received GnRH analogues throughout the study.	Critical Outcomes • No critical outcomes reported Important outcomes • Psychosocial impact
de Vries et al. 2011 Prospective longitudinal observational single centre before and after study Netherlands	The study was conducted at the Amsterdam gender identity clinic of the VU University Medical Centre and involved adolescents who were defined as "transsexual". The sample size was 70 adolescents receiving GnRH analogues (mean age [±SD] at assessment 13.6±1.8 years) from a sampling frame of 196 consecutive adolescents referred to the service between 2000 and 2008. Participants were invited to participate if they subsequently started gender-affirming hormones between 2003 and 2009. No diagnostic criteria or concomitant treatments were reported.	Intervention 70 individuals assessed at baseline (T0) before the start of GnRH analogues (no specific treatment, dose or route of administration reported). Comparison No comparator.	Critical Outcomes • Gender dysphoria • Mental health (depression, anger and anxiety) Important outcomes • Body image • Psychosocial impact

Study	Population	Intervention and comparison	Outcomes reported
Joseph et al. 2019 Retrospective longitudinal observational single centre study United Kingdom	This study was conducted at the Early intervention clinic at University College London Hospital (all participants had been seen at the Gender Identity Development Service in London) and involved adolescents with gender dysphoria. The sample size was 70 adolescents with gender dysphoria (no diagnostic criteria described) all offered GnRH analogues. The mean age at the start of treatment was 13.2 years (SD \pm 1.4) for transfemales and 12.6 years (SD \pm 1.0) for transmales. Details of the sampling frame were not reported. Further details of how the sample was drawn are not reported. No concomitant treatments were reported.	Intervention GnRH analogues. No specific treatment, duration, dose or route of administration reported. Comparison No comparator.	Critical Outcomes • No critical outcomes reported Important outcomes • Safety: bone density
Khatchadourian et al. 2014 Retrospective observational chart review single centre study Canada	This study was conducted at the Endocrinology and Diabetes Unit at British Columbia Children's Hospital, Canada and involved youths with gender dysphoria. The sample size was 27 young people with gender dysphoria who started GnRH analogues (at mean age 14.7 [SD ±1.9] years) out of 84 young people seen at the unit between 1998 and 2011. Diagnostic criteria and concomitant treatments were not reported.	Intervention 84 young people with gender dysphoria. For GnRH analogues no specific treatment, duration, dose or route of administration reported. Comparison No comparator.	Critical Outcomes • No critical outcomes reported Important outcomes • Stopping treatment • Safety: adverse effects
Klink et al. 2015 Retrospective longitudinal observational single centre study Netherlands	This study was conducted in the Netherlands at a tertiary referral centre. It is unclear which centre this was. The sample size was 34 adolescents (mean age 14.9 [SD ±1.9] years for transfemales and 15.0 [SD ±2.0] years for transmales at start of GnRH analogues). Details of the sampling frame are not reported. Participants were included if they met DSM-IV-TR criteria for gender identity disorder of adolescence and had been treated with GnRH analogues and gender-affirming hormones during their pubertal years. No concomitant treatments were reported.	Intervention The intervention was GnRH analogue monotherapy (triptorelin 3.75 mg subcutaneously every 4 weeks) followed by gender-affirming hormones with discontinuation of GnRH analogues after gonadectomy. Duration of GnRH analogues was 1.3 years (range 0.5 to 3.8 years) in transfemales and 1.5 years (0.25 to 5.2 years in transmales. Comparison No comparator.	Critical Outcomes • No critical outcomes reported Important outcomes • Safety: bone density

Study	Population	Intervention and comparison	Outcomes reported
Schagen et al. 2016 Prospective longitudinal study Netherlands	This study was conducted at the Centre of Expertise on Gender Dysphoria at the VU University Medical Centre (Amsterdam, Netherlands) and involved adolescents with gender dysphoria. The sample size was 116 adolescents (median age [range] 13.6 years [11.6 to 17.9] in transfemales and 14.2 years [11.1 to 18.6] in transmales during first year of GnRH analogues) out of 128 adolescents who started GnRH analogues. Participants were included if they met DSM-IV-TR criteria for gender dysphoria, had lifelong extreme gender dysphoria, were psychologically stable and were living in a supportive environment. No concomitant treatments were reported.	Intervention The intervention was GnRH analogue monotherapy (triptorelin 3.75 mg at 0, 2 and 4 weeks followed by intramuscular injections every 4 weeks, for at least 3 months). Comparison No comparator.	Critical Outcomes • No critical outcomes reported Important outcomes • Safety: liver and renal function.
Staphorsius et al. 2015 Cross-sectional (single time point) assessment single centre study Netherlands	This study was conducted at the VU University Medical Centre (Amsterdam, Netherlands) and involved adolescents with gender dysphoria. The sample size was 85, of whom 40 were adolescents with gender dysphoria (20 of whom were being treated with GnRH analogues) and 45 were controls without gender dysphoria (not further reported here). Mean (±SD) age 15.1 (±2.4) years in transfemales and 15.8 (±1.9) years in transmales. Details of the sampling frame are not reported. Participants were included if they were diagnosed with Gender Identity Disorder according to the DSM-IV-TR and at least 12 years old and Tanner stage of at least B2 or G2 to G3 with measurable oestradiol and testosterone levels in girls and boys, respectively. No concomitant treatments were reported.	Intervention The intervention was a GnRH analogue (triptorelin 3.75 mg every 4 weeks subcutaneously or intramuscularly). The mean duration of treatment was 1.6 years (SD ±1.0). Comparison Adolescents with gender dysphoria not treated with GnRH analogues.	Critical Outcomes • No critical outcomes reported Important outcomes • Psychosocial impact • Safety: cognitive functioning
Vlot et al. 2017 Retrospective observational data analysis study Netherlands	This study was conducted at the VU University Medical Centre (Amsterdam, Netherlands) and involved adolescents with gender dysphoria. The sample size was 70 adolescents (median age [range] 15.1 years [11.7 to 18.6] for transmales and 13.5 years [11.5 to	Intervention The intervention was a GnRH analogue (triptorelin 3.75 mg every 4 weeks subcutaneously). Comparison No comparator.	Critical Outcomes • No critical outcomes reported Important outcomes

Study	Population	Intervention and comparison	Outcomes reported
	18.3] for transfemales at start of GnRH analogues). Details of the sampling frame are not reported.		 Safety: bone density
	Participants were included if they had a diagnosis of gender dysphoria according to DSM-IV-TR criteria who were receiving GnRH analogues and then gender- affirming hormones. No concomitant treatments were reported.		
Abbreviations: DSM-IV-TR, Diagnostic and Statistical Manual of Mental Disorders, fourth edition, text revision; GnRH, Gonadotrophin releasing hormone; SD, Standard deviation.			

5. Results

In children and adolescents with gender dysphoria, what is the clinical effectiveness of treatment with GnRH analogues compared with one or a combination of psychological support, social transitioning to the desired gender or no intervention?

Outcome	Evidence statement
Clinical Effective	eness
Critical outcome	es
Impact on gender dysphoria	This is a critical outcome because gender dysphoria in children and adolescents is associated with significant distress and problems with functioning.
Certainty of evidence: very low	One uncontrolled, prospective observational longitudinal study (de <u>Vries et al. 2011</u>) provided evidence relating to the impact on gender dysphoria in adolescents, measured using the Utrecht Gender Dysphoria Scale (UGDS). The UGDS is a validated screening tool for both adolescents and adults to assess gender dysphoria. It consists of 12 items, to be answered on a 1- to 5-point scale, resulting in a sum score between 12 and 60. The higher the UGDS score the greater the gender dysphoria.
	 The study measured the impact on gender dysphoria at 2 time points: before starting a GnRH analogue (mean [±SD] age: 14.75 [±1.92] years), and shortly before starting gender-affirming hormones (mean [±SD] age: 16.64 [±1.90] years).
	The mean (\pm SD) UGDS score was not statistically significantly different at baseline compared with follow-up (n=41, 53.20 [\pm 7.91] versus 53.9 [\pm 17.42], p=0.333) (VERY LOW).
	This study provides very low certainty evidence that treatment with GnRH analogues, before starting gender-affirming hormones, does not affect gender dysphoria.

r	
Impact on mental health: depression	This is a critical outcome because self-harm and thoughts of suicide have the potential to result in significant physical harm and, for completed suicides, the death of the young person.
Certainty of evidence: very low	One uncontrolled, prospective observational longitudinal study (<u>de</u> <u>Vries et al. 2011</u>) provided evidence relating to the impact on depression in children and adolescents with gender dysphoria. Depression was measured using the Beck Depression Inventory-II (BDI-II). The BDI-II is a valid, reliable, and widely used tool for assessing depressive symptoms. There are no specific scores to categorise depression severity, but it is suggested that 0 to 13 is minimal symptoms, 14 to 19 is mild depression, 20 to 28 is moderate depression, and severe depression is 29 to 63.
	 The study provided evidence for depression measured at 2 time points: before starting a GnRH analogue (mean [±SD] age: 14.75 [±1.92] years), and shortly before starting gender-affirming hormones (mean [±SD] age: 16.64 [±1.90] years).
	The mean (\pm SD) depression (BDI) score was statistically significantly lower (improved) from baseline compared with follow-up (n=41, 8.31 [\pm 7.12] versus 4.95 [\pm 6.72], p=0.004) (VERY LOW).
	This study provides very low certainty evidence that treatment with GnRH analogues, before starting gender-affirming hormones, may reduce depression.
Impact on mental health: anger	This is a critical outcome because self-harm and thoughts of suicide have the potential to result in significant physical harm and, for completed suicides, the death of the young person.
Certainty of evidence: very low	One uncontrolled, prospective observational longitudinal study (<u>de</u> <u>Vries et al. 2011</u>) provided evidence relating to the impact on anger in children and adolescents with gender dysphoria. Anger was measured using the Trait Anger Scale of the State-Trait Personality Inventory (TPI). This is a validated 20-item inventory tool which measures the intensity of anger as the disposition to experience angry feelings as a personality trait. Higher scores indicate greater anger.
	 The study provided evidence for anger measured at 2 time points: before starting a GnRH analogue (mean [±SD] age: 14.75 [±1.92] years), and shortly before starting gender-affirming hormones (mean [±SD] age: 16.64 [±1.90] years).
	The mean (±SD) anger (TPI) score was not statistically significantly different at baseline compared with follow-up (n=41, 18.29 [±5.54] versus 17.88 [±5.24], p=0.503) (VERY LOW) .
	This study provides very low certainty evidence that treatment with GnRH analogues, before starting gender-affirming hormones, does not affect anger.
Impact on mental health: anxiety	This is a critical outcome because self-harm and thoughts of suicide have the potential to result in significant physical harm and, for completed suicides, the death of the young person.

Certainty of evidence: very low	One uncontrolled, prospective observational longitudinal study (<u>de</u> <u>Vries et al. 2011</u>) provided evidence relating to the impact on anxiety in children and adolescents with gender dysphoria. Anxiety was measured using the Trait Anxiety Scale of the State-Trait Personality Inventory (STAI). This is a validated and commonly used measure of trait and state anxiety. It has 20 items and can be used in clinical settings to diagnose anxiety and to distinguish it from depressive illness. Higher scores indicate greater anxiety.
	 The study provided evidence for anxiety at 2 time points: before starting a GnRH analogue (mean [±SD] age: 14.75 [±1.92] years), and shortly before starting gender-affirming hormones (mean [±SD] age: 16.64 [±1.90] years).
	The mean (±SD) anxiety (STAI) score was not statistically significantly different at baseline compared with follow-up (n=41, 39.43 [±10.07] versus 37.95 [±9.38], p=0.276) (VERY LOW) .
	This study provides very low certainty evidence that treatment with GnRH analogues, before starting gender-affirming hormones, does not affect levels of anxiety.
Quality of life	This is a critical outcome because gender dysphoria in children and adolescents may be associated with a significant reduction in health- related quality of life.
	No evidence was identified.
Important outco	
Impact on body image Certainty of	This is an important outcome because some children and adolescents with gender dysphoria may want to take steps to suppress features of their physical appearance associated with their sex assigned at birth or accentuate physical features of their desired gender.
evidence: very low	One uncontrolled, prospective observational longitudinal study provided evidence relating to the impact on body image (<u>de Vries et al. 2011</u>). Body image was measured using the Body Image Scale (BIS) which is a validated 30-item scale covering 3 aspects: primary, secondary and neutral body characteristics. Higher scores represent a higher degree of body dissatisfaction.
	 The study (<u>de Vries et al. 2011</u>) provided evidence for body image measured at 2 time points: before starting a GnRH analogue (mean [±SD] age: 14.75 [±1.92] years), and shortly before starting gender-affirming hormones (mean [±SD] age: 16.64 [±1.90] years).
	 The mean (±SD) body image (BIS) scores for were not statistically significantly different from baseline compared with follow-up for: primary sexual characteristics (n=57, 4.10 [±0.56] versus 3.98 [±0.71], p=0.145) secondary sexual characteristics (n=57, 2.74 [±0.65] versus 2.82 [±0.68], p=0.569)

	 neutral body characteristics (n=57, 2.41 [±0.63] versus 2.47 [±0.56], p=0.620) (VERY LOW).
	This study provides very low certainty evidence that treatment
	with GnRH analogues, before starting gender affirming hormones, does not affect body image.
Psychosocial impact: global functioning	This is an important outcome because gender dysphoria in children and adolescents is associated with internalising and externalising behaviours, and emotional and behavioural problems which may impact on social and occupational functioning.
Certainty of evidence: very low	One uncontrolled, observational, prospective cohort study (<u>de Vries et al 2011</u>) and one prospective cross-sectional cohort study (<u>Costa et al.</u> <u>2015</u>) provided evidence relating to psychosocial impact in terms of global functioning. Global functioning was measured using the Children's Global Assessment Scale (CGAS). The CGAS tool is a validated measure of global functioning on a single rating scale from 1 to 100. Lower scores indicate poorer functioning.
	 One study (<u>de Vries et al. 2011</u>) provided evidence for global functioning (CGAS) at 2 time points: before starting a GnRH analogue (mean [±SD] age: 14.75 [±1.92] years), and shortly before starting gender-affirming hormones (mean [±SD] age: 16.64 [±1.90] years).
	The mean (±SD) CGAS score was statistically significantly higher (improved) from baseline compared with follow-up (n=41, 70.24 [±10.12] versus 73.90 [±9.63], p=0.005) (VERY LOW).
	One study (<u>Costa et al. 2015</u>) in adolescents with gender dysphoria who had 6 months of psychological support followed by either GnRH analogues and continued psychological support (the immediately eligible group) or continued psychological support only (the delayed eligible group who did not receive GnRH analogues) provided evidence for global functioning (CGAS) measured at 4 time points: • at baseline (T0) in both groups,
	 after 6 months of psychological support in both groups (T1), after 6 months of GnRH analogues and 12 months of psychological support in the immediately eligible group and 12 months of psychological support only in the delayed eligible group (T2), and after 18 months of psychological support and 12 months of GnRH analogues in the immediately eligible group and after 18 months of psychological support only in the delayed eligible group (T3).
	The mean [±SD] CGAS score was statistically significantly higher (improved) for all adolescents (including those not receiving GnRH analogues) at T1, T2 or T3 compared with baseline (T0).
	For the immediately eligible group (who received GnRH analogues) versus the delayed eligible group (who did not receive GnRH analogues) there were no statistically significant differences in CGAS

	scores between the 2 groups at baseline T0 (n=201, p=0.23), T1 (n=201, p=0.73), T2 (n=121, p=0.49) or T3 (n=71, p=0.14) time points.
	For the immediately eligible group (who received GnRH analogues), the mean (±SD) CGAS score was not statistically significantly different at:
	T1 compared with T0
	T2 compared with T1
	T3 compared with T2.
	The mean (±SD) CGAS score was statistically significantly higher (improved) at:
	 T2 compared with T0 (n=60, 64.70 [±13.34] versus n=101, 58.72 [±11.38], p=0.003)
	• T3 compared with T0 (n=35, 67.40 [±13.39] versus n=101, 58.72 [±11.38], p<0.001)
	 T3 compared with T1 (n=35, 67.40 [±13.93] versus n=101, 60.89 [±12.17], p<0.001) (VERY LOW).
	These studies provide very low certainty evidence that during treatment with GnRH analogues, global functioning may improve over time. However, there was no statistically significant difference in global functioning between GnRH analogues plus psychological support compared with psychological support only at any time point.
Psychosocial	This is an important outcome because gender dysphoria in children and
impact:	adolescents is associated with internalising and externalising
psychosocial	behaviours, and emotional and behavioural problems which may impact
functioning	on social and occupational functioning.
Certainty of evidence: very low	Two studies provided evidence for this outcome. One uncontrolled, observational, prospective cohort study (de Vries et al, 2011) and 1 cross-sectional observational study (Staphorsius et al. 2015) assessed psychosocial functioning using the Child Behaviour Checklist (CBCL) and the self-administered Youth Self-Report (YSR). The CBCL is a checklist parents complete to detect emotional and behavioural problems in children and adolescents. YSR is similar but is self-completed by the child or adolescent. The scales consist of a Total problems score, which is the sum of the scores of all the problem items. An internalising problem scale sums the anxious/depressed, withdrawn-depressed, and somatic complaints scores while the externalising problem scale combines rule-breaking and aggressive behaviour. The standard scores are scaled so that 50 is average for the child or adolescent's age and gender, with a SD of 10 points. Higher scores indicate greater problems, with a T-score above 63 considered to be in the clinical range.
	 One study (<u>de Vries et al. 2011</u>) provided evidence for psychosocial functioning (CBCL and YSR scores) at 2 time points: before starting a GnRH analogue (mean [±SD] age: 14.75 [±1.92] years), and shortly before starting gender-affirming hormones (mean [±SD] age: 16.64 [±1.90] years).

low	In one retrospective study (<u>Brik et al. 2018</u>), 9 adolescents (9/214, 4.2%) who had stopped attending appointments were excluded from the study between November 2010 and July 2019 (VERY LOW).
Certainty of evidence: very	Two uncontrolled observational cohort studies provided evidence relating to loss to follow up, which could be a marker of engagement with health care services (Brik et al. 2018 and Costa et al. 2015).
Engagement with health care services	This is an important outcome because patient engagement with health care services will impact on their clinical outcomes.
	These studies provide very low certainty evidence that during treatment with GnRH analogues psychosocial functioning may improve, with the proportion of adolescents in the clinical range for some CBCL and YSR scores decreasing over time.
	 transmales (total) 60.4 [±10.2] transmales receiving GnRH analogues 57.5 [±9.4] transmales not receiving GnRH analogues 63.9 [±10.5] (VERY LOW).
	 The mean (±SD) CBCL scores for each group were (statistical analysis unclear): transfemales (total) 57.8 [±9.2] transfemales receiving GnRH analogues 57.4 [±9.8] transfemales not receiving GnRH analogues 58.2 [±9.3]
	One study (<u>Staphorsius et al. 2015</u>) assessed CBCL in a cohort of adolescents with gender dysphoria (transfemale: $n=18$, mean [±SD] age 15.1 [±2.4] years and transmale: $n=22$, mean [±SD] age 15.8 [±1.9] years) either receiving GnRH analogues (transfemale, $n=8$ and transmale, $n=12$), or not receiving GnRH analogues (transfemale, $n=10$ and transmale, $n=10$).
	The proportion of adolescents scoring in the clinical range decreased from baseline to follow up on the CBCL total problem scale (44.4% versus 22.2%, p=0.001) and the internalising scale of the YSR (29.6% versus 11.1%, p=0.017) (VERY LOW).
	 Internalising T score (n=54, 56.04 [±12.49] versus 49.78 [±11.63], p<0.001) Externalising T score (n=54, 53.30 [±11.87] versus 49.98 [±9.35], p=0.009).
	At follow up, the mean (±SD) YSR scores were statistically significantly lower (improved) compared with baseline for: • Total T score (n=54, 55.46 [±11.56] versus 50.00 [±10.56], p<0.001)
	 Internalising T score (n=54, 61.00 [±12.21] versus 52.17 [±9.81], p<0.001) Externalising T score (n=54, 58.04 [±12.99] versus 53.81 [±11.86], p=0.001).
	At follow up, the mean (±SD) CBCL scores were statistically significantly lower (improved) compared with baseline for: • Total T score (n=54, 60.70 [±12.76] versus 54.46 [±11.23], p<0.001

	One prospective study (<u>Costa et al. 2015</u>) had evidence for a large loss to follow-up over time. The sample size at baseline (T0) and 6 months (T1) was 201, which dropped by 39.8% to 121 after 12 months (T2) and by 64.7% to 71 at 18 months follow-up (T3). No explanation of the reasons for loss to follow-up are reported (VERY LOW).
	Due to their design there was no reported loss to follow-up in the other 3 effectiveness studies (<u>de Vries et al 2011</u> ; <u>Khatchadourian et al. 2014</u> ; <u>Staphorsius et al. 2015</u>).
	These studies provide very low certainty evidence about loss to follow up, which could be a marker of engagement with health care services, during treatment with GnRH analogues. Due to the large variation in rates between studies no conclusions could be drawn.
Impact on extent of and satisfaction with	This is an important outcome because some children and adolescents with gender dysphoria may proceed to transitioning surgery.
surgery	No evidence was identified.
Stopping treatment	This is an important outcome because there is uncertainty about the short- and long-term safety and adverse effects of GnRH analogues in children and adolescents with gender dysphoria.
Certainty of evidence: very low	Two uncontrolled, retrospective, observational cohort studies provided evidence relating to stopping GnRH analogues. One study had complete reporting of the cohort (<u>Brik et al. 2018</u>), the other (<u>Khatchadourian et al. 2014</u>) had incomplete reporting of its cohort, particularly for transfemales where outcomes for only 4/11 were reported.
	Brik et al. 2018 narratively reported the reasons for stopping GnRH analogues in a cohort of 143 adolescents (38 transfemales and 105 transmales). Median age at the start of GnRH analogues was 15.0 years (range, 11.1–18.6 years) in transfemales and 16.1 years (range, 10.1–17.9 years) in transmales. Of these adolescents, 125 (87%, 36 transfemales, 89 transmales) subsequently started gender-affirming hormones after 1.0 (0.5–3.8) and 0.8 (0.3–3.7) years of GnRH analogues. At the time of data collection, the median duration of GnRH analogue use was 2.1 years (1.6–2.8).
	 During the follow-up period 6.3% (9/143) of adolescents had discontinued GnRH analogues after a median duration of 0.8 years (range 0.1 to 3.0). The percentages and reasons for stopping were: 2.8% (4/143) stopped GnRH analogues although they wanted to continue endocrine treatments for gender dysphoria: 1 transmale stopped due to increase in mood problems, suicidal thoughts and confusion attributed to GnRH analogues 1 transmale had hot flushes, increased migraines, fear of injections, stress at school and unrelated medical issues, and temporarily stopped treatment (after 4)
	 on 1 transmale had mood swings 4 months after starting GnRH analogues. After 2.2 years had unexplained severe nausea and rapid weight loss and discontinued GnRH analogues after 2.4 years

 1 transmale stopped GnRH analogues because of inability to regularly collect medication and attend appointments for injections. 3.5% (5/143) stopped treatment because they no longer wished to receive gender-affirming treatment for various reasons (VERY LOW).
Khatchadourian et al. 2014 narratively reported the reasons for stopping GnRH analogues in a cohort of 26 adolescents (15 transmales and 11 transfemales), 42% (11/26) discontinued GnRH analogues during follow-up between 1998 and 2011.
 Of 15 transmales receiving GnRH analogues, 14 received testosterone during the observation period, of which: 7 continued GnRH analogues after starting testosterone 7 stopped GnRH analogues after a median of 3.0 years (range 0.2 to 9.2 years), of which: 5 stopped after hysterectomy and salpingo-oophorectomy 1 stopped after 2.2 years (transitioned to gender-affirming hormones) 1 stopped after <2 months due to mood and emotional lability (VERY LOW).
 Of 11 transfemales receiving GnRH analogues, 5 received oestrogen during the observation period, of which: 4 continued GnRH analogues after starting oestrogen 1 stopped GnRH analogues when taking oestrogen (no reason reported) (VERY LOW).
 Of the remaining 6 transfemales taking GnRH analogues: 1 stopped GnRH analogues after a few months due to emotional lability 1 stopped GnRH analogues before taking oestrogen (the following year delayed due to heavy smoking) 1 stopped GnRH analogues after 13 months due not to pursuing transition (VERY LOW).
These studies provide very low certainty evidence for the number of adolescents who stop GnRH analogues and the reasons for this.

Abbreviations: GnRH, gonadotrophin releasing hormone; SD, standard deviation.

In children and adolescents with gender dysphoria, what is the short-term and long-term safety of GnRH analogues compared with one or a combination of psychological support, social transitioning to the desired gender or no intervention?

Outcome	Evidence statement
Safety	
Change in bone	This is an important outcome because puberty is an important time for
density: lumbar	bone development and puberty suppression may affect bone
-	development, as shown by changes in lumbar bone density.

Containty of	
Certainty of evidence: very low	Three uncontrolled, observational, retrospective studies provided evidence relating to the effect of GnRH analogues on bone density (based on lumbar BMAD) between starting with a GnRH analogue and at 1 and 2 year intervals (<u>Joseph et al. 2019</u>), and between starting GnRH analogues and starting gender-affirming hormones (<u>Klink et al.</u> <u>2015</u> and <u>Vlot et al. 2017</u>). All outcomes were reported separately for transfemales and transmales; also see subgroups table below.
	BMAD is a size adjusted value of BMD incorporating body size measurements using UK norms in growing adolescents. It was reported as g/cm^3 and as z-scores. Z-scores report how many standard deviations from the mean a measurement sits. A z-score of 0 is equal to the mean, a z-score of -1 is equal to 1 standard deviation below the mean, and a z-score of +1 is equal to 1 standard deviation above the mean.
	 One retrospective observational study (Joseph et al. 2019, n=70) provided non-comparative evidence on change in lumbar BMAD increase using z-scores. The z-score for lumbar BMAD was statistically significantly lower at 2 years compared with baseline in transfemales (z-score [±SD]: baseline 0.486 [0.809], 2 years -0.279 [0.930], p=0.000) and transmales (baseline -0.361 [1.439], 2 years -0.913 [1.318], p=0.001) (VERY LOW). The z-score for lumbar BMAD was statistically significantly lower at 1 year compared with baseline in transfemales (baseline 0.859 [0.154], 1 year -0.228 [1.027], p=0.000) and transmales (baseline -0.186 [1.230], 1 year -0.541 [1.396], p=0.006) (VERY LOW). Actual lumbar BMAD values in g/cm³ were not statistically significantly different between baseline and 1 or 2 years in transfemales or transmales (VERY LOW).
	Two retrospective observational studies (<u>Klink et al. 2015</u> and <u>Vlot et al.</u> <u>2017</u> , n=104 in total) provided non-comparative evidence on change in lumbar BMAD between starting GnRH analogues and starting gender-affirming hormones. All outcomes were reported separately for transfemales and transmales; also see subgroups table below.
	In Klink et al. 2015 the z-score for lumbar BMAD was not statistically significantly different between starting GnRH analogues and starting gender-affirming hormones in transfemales but was statistically significantly lower when starting gender-affirming hormones in transmales (z-score mean [\pm SD]: GnRH analogue 0.28 (\pm 0.90], gender-affirming hormone -0.50 (\pm 0.81], p=0.004). Actual lumbar BMAD values in g/cm ³ were not statistically significantly different between starting GnRH analogues and starting gender-affirming hormones in transfemales or transmales (VERY LOW).
	 Vlot et al. 2017 reported change from starting GnRH analogues to starting gender-affirming hormones in lumbar BMAD by bone age. The z-score for lumbar BMAD in transfemales with a bone age of <15 years was statistically significantly lower at starting gender-affirming hormone treatment than at starting GnRH

 analogues (z-score median [range]: GnRH analogue -0.20 [-1.82 to 1.18], gender-affirming hormone -1.52 [-2.36 to 0.42], p=0.001) but was not statistically significantly different in transfemales with a bone age ≥15 years (VERY LOW). The z-score for lumbar BMAD in transmales with a bone age of <14 years was statistically significantly lower at starting gender-affirming hormone treatment than at starting GnRH analogues (z-score median [range]: GnRH analogue -0.05 [-0.78 to 2.94], gender-affirming hormone -0.84 [-2.20 to 0.87], p=0.003) and in transmales with a bone age ≥14 years (GnRH analogue 0.27 [-1.60 to 1.80], gender-affirming hormone -0.29 [-2.28 to 0.90], p≤0.0001) (VERY LOW). Actual lumbar BMAD values in g/cm³ were not statistically significantly different between starting GnRH analogues and starting gender-affirming hormones in transfemales or transmales with young or old bone age (VERY LOW).
Two uncontrolled, observational, retrospective studies provided evidence for the effect of GnRH analogues on bone density (based on lumbar BMD) between starting GnRH analogues and either at 1 or 2 year intervals (<u>Joseph et al. 2019</u>), or starting gender-affirming hormones (<u>Klink et al. 2015</u>). All outcomes were reported separately for transfemales and transmales; also see subgroups table below.
 One retrospective observational study (Joseph et al. 2019, n=70) provided non-comparative evidence on change in lumbar BMD increase using z-scores. The z-score for lumbar BMD was statistically significantly lower at 2 years compared with baseline in transfemales (z-score mean [±SD]: baseline 0.130 [0.972], 2 years -0.890 [±1.075], p=0.000) and transmales (baseline -0.715 [±1.406], 2 years -2.000 [1.384], p=0.000) (VERY LOW). The z-score for lumbar BMD was statistically significantly lower at 1 year compared with baseline in transfemales (z-score mean [±SD]: baseline -0.016 [±1.106], 1 year -0.461 [±1.121], p=0.003) and transmales (baseline -0.395 [±1.428], 1 year -1.276 [±1.410], p=0.000) (VERY LOW). With the exception of transmales, where lumbar BMD in kg/m² increased between baseline and 1 year (mean [±SD]: baseline 0.694 [±0.149], 1 year 0.718 [±0.124], p=0.006), actual lumbar BMD values were not statistically significantly different between baseline and 1 or 2 years in transfemales or between 0 and 2 years in transmales (VERY LOW).
 One retrospective observational study (<u>Klink et al. 2015</u>, n=34) provided non-comparative evidence on change in lumbar BMD between starting GnRH analogues and starting gender-affirming hormones. The z-score for lumbar BMD was not statistically significantly different between starting GnRH analogue and starting gender-affirming hormone treatment in transfemales, but was statistically significantly lower when starting gender-affirming hormones in transmales (z-score mean [±SD]: GnRH analogue 0.17 [±1.18], gender-affirming hormone -0.72 [±0.99], p<0.001) (VERY LOW).

	 Actual lumbar BMD in g/cm² was not statistically significantly different between starting GnRH analogues and starting gender-affirming hormones in transfemales but was statistically significantly lower when starting gender-affirming hormones in transmales (mean [±SD]: GnRH analogues 0.95 [±0.12], gender-affirming hormones 0.91 [±0.10], p=0.006) (VERY LOW).
	These studies provide very low certainty evidence that GnRH analogues reduce the expected increase in lumbar bone density (BMAD or BMD) compared with baseline (although some findings were not statistically significant). These studies also show that GnRH analogues do not statistically significantly decrease actual lumbar bone density (BMAD or BMD).
Change in bone density: femoral	This is an important outcome because puberty is an important time for bone development and puberty suppression may affect bone development, as shown by changes in femoral bone density.
Certainty of evidence: very low	Two uncontrolled, observational, retrospective studies provided evidence relating to the effect of GnRH analogues on bone density (based on femoral BMAD) between starting treatment with a GnRH analogue and starting gender-affirming hormones (<u>Klink et al. 2015</u> and <u>Vlot et al. 2017</u>). All outcomes were reported separately for transfemales and transmales; also see subgroups table below.
	 One retrospective observational study (<u>Klink et al. 2015</u>, n=34) provided non-comparative evidence on change in femoral area BMAD between starting GnRH analogues and starting gender-affirming hormones. All outcomes were reported separately for transfemales and transmales. The z-score for femoral area BMAD was not statistically significantly different between starting GnRH analogues and starting gender-affirming hormones in transfemales or transmales (VERY LOW). Actual femoral area BMAD values were not statistically significantly different between starting GnRH analogues and starting gender-affirming hormones in transfemales or transmales (VERY LOW).
	 One retrospective observational study (<u>Vlot et al. 2017</u>, n=70) provided non-comparative evidence on change in femoral neck (hip) BMAD between starting GnRH analogues and starting gender-affirming hormones. All outcomes were reported separately for transfemales and transmales; also see subgroups table below. The z-score for femoral neck BMAD in transfemales with a bone age of <15 years was not statistically significantly lower at starting gender-affirming hormones than at starting GnRH analogues (z-score median [range]: GnRH analogue -0.71 [-3.35 to 0.37], gender-affirming hormone -1.32 [-3.39 to 0.21], p≤0.1) or in transfemales with a bone age ≥15 years (GnRH analogue -0.44 [-1.37 to 0.93], gender-affirming hormone -0.36 [-1.50 to 0.46]) (VERY LOW).
	 The z-score for femoral neck BMAD in transmales with a bone age of <14 years was not statistically significantly lower at starting gender-affirming hormones than at starting GnRH analogues (z-score median [range]: GnRH analogue -0.01

 [-1.30 to 0.91], gender-affirming hormone -0.37 [-2.28 to 0.47]) but was statistically significantly lower in transmales with a bone age ≥14 years (GnRH analogue 0.27 [-1.39 to 1.32], gender-affirming hormone -0.27 [-1.91 to 1.29], p=0.002) (VERY LOW). Actual femoral neck BMAD values were not statistically significantly different between starting GnRH analogues and starting gender-affirming hormones in transfemales or in transmales with a young bone age, but were statistically significantly lower in transmales with a bone age ≥14 years (GnRH analogue 0.33 [0.25 to 0.39), gender-affirming hormone 0.30 [0.23 to 0.41], p≤0.01) (VERY LOW).
Two uncontrolled, observational, retrospective studies provided evidence for the effect of GnRH analogues on bone density (based on femoral BMD) between starting GnRH analogues and either at 1 or 2 year intervals (Joseph et al. 2019), or starting gender-affirming hormones (Klink et al. 2015). All outcomes were reported separately for transfemales and transmales; also see subgroups table below.
 One retrospective observational study (Joseph et al. 2019, n=70) provided non-comparative evidence on change in femoral neck BMD increase using z-scores. All outcomes were reported separately for transfemales and transmales. The z-score for femoral neck BMD was statistically significantly lower at 2 years compared with baseline in transfemales (z-score mean [±SD]: baseline 0.0450 [±0.781], 2 years -0.600 [±1.059], p=0.002) and transmales (baseline -1.075 [±1.145], 2 years -1.779 [±0.816], p=0.001) (VERY LOW). The z-score for femoral neck BMD was statistically significantly lower at 1 year compared with baseline in transfemales (z-score mean [±SD]: baseline 0.157 [±0.905], 1 year -0.340 [±0.816], p=0.002) and transmales (baseline -0.863 [±1.215], 1 year -1.440 [±1.075], p=0.000) (VERY LOW). Actual femoral neck BMD values in kg/m² were not statistically significantly different between baseline and 1 or 2 years in transmales or transfemales (VERY LOW).
 One retrospective observational study (Klink et al. 2015, n=34) provided non-comparative evidence on change in femoral area BMD between starting GnRH analogues and starting gender-affirming hormones. All outcomes were reported separately for transfemales and transmales. The z-score for femoral area BMD was not statistically significantly different between starting GnRH analogues and starting gender-affirming hormones in transfemales, but was statistically significantly lower in transmales (z-score mean [±SD]: GnRH analogue 0.36 [±0.88], gender-affirming hormone -0.35 [±0.79], p=0.001) (VERY LOW). Actual femoral area BMD values were not statistically significantly different between starting GnRH analogues and starting gender-affirming hormones in transfemales, but were statistically significantly lower in transmales (mean [±SD] GnRH analogue 0.36 [±0.88], gender-affirming hormone -0.35 [±0.79], p=0.001) (VERY LOW).

Cognitive development or functioning	These studies provide very low certainty evidence that GnRH analogues may reduce the expected increase in femoral bone density (femoral neck or area BMAD or BMD) compared with baseline (although some findings were not statistically significant). These studies also show that GnRH analogues do not statistically significantly decrease actual femoral bone density (femoral area BMAD or femoral neck BMD), apart from actual femoral area BMAD in transmales. This is an important outcome because puberty is an important time for cognitive development and puberty suppression may affect cognitive development or functioning.
Certainty of evidence: very low	 One cross-sectional observational study (<u>Staphorsius et al. 2015</u>, n=70) provided comparative evidence on cognitive development or functioning in adolescents with gender dysphoria on GnRH analogues compared with adolescents with gender dysphoria not on GnRH analogues. Cognitive functioning was measured using an IQ test. Reaction time (in seconds) and accuracy (percentage of correct trials) were measured using the Tower of London (ToL) task. All outcomes were reported separately for transfemales and transmales; also see subgroups table below. No statistical analyses or interpretation of the results in these groups were reported: IQ in transfemales (mean [±SD] GnRH analogue 94.0 [±10.3], control 109.4 [±21.2]). IQ transmales (GnRH analogue 95.8 [±15.6], control 98.5 [±15.9]. Reaction time in transfemales (mean [±SD] GnRH analogue 10.9 [±4.1], control: 9.9 [±3.1]). Reaction time transmales (GnRH analogue 9.9 [±3.1], control 10.0 [±2.0]). Accuracy score in transfemales (GnRH analogue 73.9 [±9.1], control 83.4 [±9.5]. Accuracy score in transmales (GnRH analogue 85.7 [±10.5], control 88.8 [±9.7].
Other safety outcomes: kidney function	This study provides very low certainty evidence (with no statistical analysis) on the effects of GnRH analogues on cognitive development or functioning. No conclusions could be drawn. This is an important outcome because if renal damage (raised serum creatinine is a marker of this) is suspected, GnRH analogues may need to be stopped.
Certainty of evidence: very low	One prospective observational study (<u>Schagen et al. 2016</u> , n=116) provided non-comparative evidence on change in serum creatinine between starting GnRH analogues and at 1 year. All outcomes were reported separately for transfemales and transmales; also see subgroups table below.
	 There was no statistically significant difference between baseline and 1 year for serum creatinine in transfemales (mean [±SD] baseline 70 [±12], 1 year 66 [±13], p=0.20). There was a statistically significant decrease between baseline and 1 year for serum creatinine in transmales (baseline 73 [±8], 1 year 68 [±13], p=0.01).
	This study provides very low certainty evidence that GnRH analogues do not affect renal function.

Other safety	This is an important outcome because if treatment-induced liver injury
outcomes: liver	(raised liver enzymes are a marker of this) is suspected, GnRH
function	analogues may need to be stopped.
Certainty of evidence: very low	 One prospective observational study (<u>Schagen et al. 2016</u>, n=116) provided non-comparative evidence on elevated liver enzymes between starting GnRH analogues and during use. No comparative values or statistical analyses were reported. Glutamyl transferase was not elevated at baseline or during use in any person. Mild elevations of AST and ALT above the reference range were present at baseline but were not more prevalent during use than at baseline. Glutamyl transferase, AST, and ALT levels did not significantly
	change from baseline to 12 months of use.
	This study provides very low certainty evidence (with no statistical
Other safety	analysis) that GnRH analogues do not affect liver function. This is an important outcome because if there are adverse effects,
outcomes:	GnRH analogues may need to be stopped.
adverse effects	en ar analoguee may nood to be etepped.
	One uncontrolled, retrospective, observational cohort study
Certainty of evidence: very low	(<u>Khatchadourian et al. 2014</u>) provided evidence relating to adverse effects from GnRH analogues. It had incomplete reporting of its cohort, particularly for transfemales where outcomes for only 4/11 were reported.
	Khatchadourian et al. 2014 reported adverse effects in a cohort of 26 adolescents (15 transmales and 11 transfemales) receiving GnRH analogues. Of these:
	 1 transmale developed sterile abscesses; they were switched from leuprolide acetate to triptorelin, and this was well tolerated. 1 transmale developed leg pains and headaches, which eventually resolved 1 participant gained 19 kg within 9 months of starting GnRH analogues.
	This study provides very low certainty evidence about potential adverse effects of GnRH analogues. No conclusions could be drawn.

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMAD, bone mineral apparent density; BMD, bone mineral density; GnRH, gonadotrophin releasing hormone; IQ, intelligence quotient; NS, not significant; SD, standard deviation.

In children and adolescents with gender dysphoria, what is the costeffectiveness of GnRH analogues compared to one or a combination of psychological support, social transitioning to the desired gender or no intervention?

Outcome	Evidence statement
Cost-effectiveness	No studies were identified to assess the cost-effectiveness of GnRH analogues for children and adolescents with gender dysphoria.

From the evidence selected, are there any subgroups of children and adolescents with gender dysphoria that may benefit from GnRH analogues more than the wider population of interest?

Subgroup	Evidence statement
Sex assigned at birth males (transfemales)	Some studies reported data separately for sex assigned at birth males (transfemales). This included some direct comparisons with sex assigned at birth females (transmales).
Certainty of evidence: Very low	Impact on gender dysphoria One uncontrolled prospective observational longitudinal study (de <u>Vries et al. 2011</u>) provided evidence for gender dysphoria in sex assigned at birth males. See the clinical effectiveness results table above for a full description of the study. The mean (±SD) UGDS score was statistically significantly lower (improved) in sex assigned at birth males compared with sex assigned at birth females at both baseline (T0) (n=not reported, mean UGDS score [±SD]: 47.95 [±9.70] versus 56.57 [±3.89]) and T1 (n=not reported, 49.67 [±9.47] versus 56.62 [±4.00]); between sex difference p<0.001 (VERY LOW).
	One further prospective observational longitudinal study (Costa et al. 2015) provided evidence for the impact on gender dysphoria in sex assigned at birth males. See the clinical effectiveness results table above for a full description of the study. Sex assigned at birth males had a statistically significantly lower (improved) mean (\pm SD) UGDS score of 51.6 [\pm 9.7] compared with sex assigned at birth females (56.1 [\pm 4.3], p<0.001). However, it was not reported if this was baseline or follow-up (VERY LOW).
	These studies provide very low certainty evidence that in sex assigned at birth males (transfemales), gender dysphoria is lower than in sex assigned at birth females (transmales).
	Impact on mental health One uncontrolled prospective observational longitudinal study (<u>de</u> <u>Vries et al. 2011</u>) provided evidence for the impact on mental health (depression, anger and anxiety) in sex assigned at birth males. See the clinical effectiveness results table above for a full description of the study.
	 The mean (±SD) depression (BDI-II) score was not statistically significantly different in sex assigned at birth males compared with sex assigned at birth females at both baseline (T0) (n=not reported, mean BDI score [±SD]: 5.71 [±4.31] versus 10.34 [±8.24]) and T1 (n=not reported, 3.50 [±4.58] versus 6.09 [±7.93]), between sex difference p=0.057
	 The mean (±SD) anger (TPI) score was statistically significantly lower (improved) in sex assigned at birth males compared with sex assigned at birth females at both baseline (T0) (n=not reported, mean TPI score [±SD]: 5.22 [±2.76] versus 6.43 [±2.78]) and T1 (n=not reported, 5.00 [±3.07] versus 6.39 [±2.59]), between sex difference p=0.022 The mean (±SD) anxiety (STAI) score was statistically significantly lower (improved) in sex assigned at birth males

compared with sex assigned at birth females at both baseline (T0) (n=not reported, mean STAI score [±SD]: 4.33 [±2.68] versus 7.00 [±2.36]) and T1 (n=not reported, 4.39 [±2.64] versus 6.17 [±2.69]), between sex difference p<0.001 (VERY LOW).
This study provides very low certainty evidence that the impact on mental health (depression, anger and anxiety) may be different in sex assigned at birth males (transfemales) compared with sex assigned at birth females (transmales). Over time there was no statistically significant difference between sex assigned at birth males and sex assigned at birth females for depression. However, sex assigned at birth males had statistically significantly lower levels of anger and anxiety than sex assigned at birth females at both baseline and follow up.
 Impact on body image One uncontrolled prospective observational longitudinal study (de Vries et al. 2011) provided evidence relating to the impact on body image in sex assigned at birth males. The mean (±SD) BIS score for primary sex characteristics was statistically significantly lower (improved) in sex assigned at birth males compared with sex assigned at birth females at both baseline (T0) (n=not reported, mean BIS score [±SD]: 4.02 [±0.61] versus 4.16 [±0.52]) and T1 (n=not reported, 3.74 [±0.78] versus 4.17 [±0.58]), between sex difference p=0.047 The mean (±SD) BIS score for secondary sex was statistically significantly lower (improved) in sex assigned at birth males compared with sex assigned at birth females at both baseline (T0) (n=not reported, mean BIS score [±SD]: 2.66 [±0.50] versus 2.81 [±0.76]) and T1 (n=not reported, 2.39 [±0.69] versus 3.18 [±0.42]), between sex difference p=0.001 The mean (±SD) BIS score for neutral body characteristics was not statistically significantly different in sex assigned at birth males compared with sex assigned at birth females at both baseline (T0) (n=not reported, mean BIS score [±SD]: 2.60 [±0.58] versus 2.24 [±0.62]) and T1 (n=not reported, 2.32 [±0.59] versus 2.61 [±0.50]), between sex difference p=0.777 (VERY LOW).
This study provides very low certainty evidence that the impact on body image may be different in sex assigned at birth males (transfemales) compared with sex assigned at birth females (transmales). Sex assigned at birth males are less dissatisfied with their primary and secondary sex characteristics than sex assigned at birth females at both baseline and follow up, but the satisfaction with neutral body characteristics is not different.
 Psychosocial impact One uncontrolled prospective observational longitudinal study (de <u>Vries et al. 2011</u>) provided evidence for psychosocial impact in terms of global functioning (CGAS) and psychosocial functioning (CBCL and YSR) in sex assigned at birth males. Sex assigned at birth males had statistically higher mean (±SD) CGAS scores compared with sex assigned at birth

	Three uncontrolled, observational, retrospective studies provided
	evidence for the effect of GnRH analogues on femoral bone density in
	sex assigned at birth males (<u>Joseph et al. 2019</u> , <u>Klink et al. 2015</u> and
	Vlot et al. 2017). See the safety results table above for a full
	description of the results.
	These studies provide very low certainty evidence that GnRH analogues may reduce the expected increase in femoral bone density (femoral neck or area BMAD or BMD) in sex assigned at birth males (transfemales; although some findings were not statistically significant). These studies also show that GnRH analogues do not statistically significantly decrease actual femoral bone density (femoral area BMAD or femoral neck BMD)
	in sex assigned at birth males (transfemales).
	Cognitive development or functioning One cross-sectional observational study (<u>Staphorsius et al. 2015</u>) provided comparative evidence on cognitive development or functioning in sex assigned at birth males. See the safety results table above for a full description of the results.
	This study provides very low certainty evidence (with no statistical analysis) on the effects of GnRH analogues on cognitive development or functioning in sex assigned at birth males (transfemales). No conclusions could be drawn.
	Other safety outcomes: kidney function
	One prospective observational study (<u>Schagen et al. 2016</u>) provided non-comparative evidence on change in serum creatinine in sex assigned at birth males. See the safety results table above for a full description of the results.
	This study provides very low certainty evidence that GnRH analogues do not affect renal function in sex assigned at birth males (transfemales).
Sex assigned at birth females (transmales)	Some studies reported data separately for sex assigned at birth females (transmales). This included some direct comparisons with sex assigned at birth males (transfemales).
Certainty of evidence: Very low	Impact on gender dysphoria One uncontrolled prospective observational longitudinal study (<u>de</u> <u>Vries et al. 2011</u>) and one prospective observational longitudinal study (<u>Costa et al. 2015</u>) provided evidence for gender dysphoria in sex assigned at birth females. See the sex assigned at birth males (transfemales) row above for a full description of the results.
	These studies provide very low certainty evidence that in sex assigned at birth females (transmales), gender dysphoria is higher than in sex assigned at birth males (transfemales) at both baseline and follow up.
	Impact on mental health One uncontrolled prospective observational longitudinal study (<u>de</u> <u>Vries et al. 2011</u>) provided evidence relating to the impact on mental health (depression, anger and anxiety) in sex assigned at birth

females. See the sex assigned at birth males (transfemales) row above for a full description of the results.
This study provides very low certainty evidence that the impact on mental health (depression, anger and anxiety) may be different in sex assigned at birth females (transmales) compared with sex assigned at birth males (transfemales). Over time there was no statistically significant difference between sex assigned at birth females and sex assigned at birth males for depression. However, sex assigned at birth females had statistically significantly greater levels of anger and anxiety than sex assigned at birth males at baseline and follow up.
Impact on body image One uncontrolled prospective observational longitudinal study (<u>de</u> <u>Vries et al. 2011</u>) provided evidence relating to the impact on body image in sex assigned at birth females. See the sex assigned at birth males (transfemales) row above for a full description of the results.
This study provides very low certainty evidence that the impact on body image may be different in sex assigned at birth females (transmales) compared with sex assigned at birth males (transfemales). Sex assigned at birth females are more dissatisfied with their primary and secondary sex characteristics than sex assigned at birth males at both baseline and follow up, but the satisfaction with neutral body characteristics is not different.
Psychosocial impact One uncontrolled prospective observational longitudinal study (de <u>Vries et al. 2011</u>) provided evidence for psychosocial impact in terms of global functioning (CGAS) and psychosocial functioning (CBCL and YSR) in sex assigned at birth females. One uncontrolled, observational, prospective cohort study (<u>Costa et al. 2015</u>) provided evidence for psychosocial impact in terms of global functioning (CGAS) in sex assigned at birth females. See the sex assigned at birth males (transfemales) row above for a full description of the results.
These studies provide very low certainty evidence that psychosocial impact may be different in sex assigned at birth females (transmales) compared with sex assigned at birth males (transfemales). However, no conclusions could be drawn.
Change in bone density: lumbar Three uncontrolled, observational, retrospective studies provided evidence relating to the effect of GnRH analogues on lumbar bone density in sex assigned at birth females (<u>Joseph et al. 2019</u> , <u>Klink et</u> <u>al. 2015</u> and <u>Vlot et al. 2017</u>). See the safety results table above for a full description of the results.
These studies provide very low certainty evidence that GnRH analogues reduce the expected increase in lumbar bone density (BMAD or BMD) in sex assigned at birth females (transmales; although some findings were not statistically significant). These studies also show that GnRH analogues do not statistically

significantly decrease actual lumbar bone density (BMAD or BMD) in sex assigned at birth females (transmales).
Change in bone density: femoral Three uncontrolled, observational, retrospective studies provided evidence relating to the effect of GnRH analogues on femoral bone density in sex assigned at birth females (<u>Joseph et al. 2019</u> , <u>Klink et</u> <u>al. 2015</u> and <u>Vlot et al. 2017</u>). See the safety results table above for a full description of the results.
These studies provide very low certainty evidence that GnRH analogues may reduce the expected increase in femoral bone density (femoral neck or area BMAD or BMD) in sex assigned at birth females (transmales; although some findings were not statistically significant). These studies also show that GnRH analogues do not statistically significantly decrease actual femoral bone density (femoral area BMAD or femoral neck BMD) in sex assigned at birth females (transmales), apart from actual femoral area.
Cognitive development or functioning One cross-sectional observational study (<u>Staphorsius et al. 2015</u>) provided comparative evidence on cognitive development or functioning in sex assigned at birth females. See the safety results table above for a full description of the results.
This study provides very low certainty evidence (with no statistical analysis) on the effects of GnRH analogues on cognitive development or functioning in sex assigned at birth females (transmales). No conclusions could be drawn.
Other safety outcomes: kidney function One prospective observational study (<u>Schagen et al. 2016</u>) provided non-comparative evidence on change in serum creatinine in sex assigned at birth females (transmales). See the safety results table above for a full description of the results.
This study provides very low certainty evidence that GnRH analogues do not affect renal function in sex assigned at birth females (transmales).
No evidence was identified.

Diagnosis of	No evidence was identified.
mental health	
condition	

Abbreviations: BDI-II, Beck Depression Inventory-II; BIS, Body Image Scale; CBCL, Child Behaviour Checklist; CGAS, Children's Global Assessment Scale; SD, standard deviation; STAI, Trait Anxiety Scale of the State-Trait Personality Inventory; TPI, Trait Anger Scale of the State-Trait Personality Inventory; UGDS, Utrecht Gender Dysphoria Scale; YSR, Youth Self-Report

From the evidence selected,

- (a) what are the criteria used by the research studies to define gender dysphoria, gender identity disorder and gender incongruence of childhood?
- (b) what were the ages at which participants commenced treatment with GnRH analogues?
- (c) what was the duration of treatment with GnRH analogues?

Outcome	Evidence statement	
Diagnostic		<u>15, Klink et al. 2015, Schagen et al. 2016,</u>
criteria	Staphorsius et al. 2015 and Vlot et al. 2017) the DSM-IV-TR criteria of	
	gender identity disorder was	s used.
	one overarching definition of criteria for children and for definition describes a com and/or problems functioning way they feel and the way t lasted at least 6 months. It was not reported how remaining 3 studies (VERY From the evidence selected	ed, all studies that reported diagnostic
	in use at the time the stud	oria (6/9 studies) used the DSM criteria
Age when GnRH		ge at which participants started GnRH
analogues started		an age (with SD) or median age (with the
	range):	
	Study	Mean age (±SD)
	Costa et al. 2015	16.5 years (±1.3)
	de Vries et al. 2011	13.6 years (±1.8)
	Joseph et al. 2019	13.2 years (±1.4) in transfemales
		12.6 years (±1.0) in transmales
	Khatchadourian et al. 2014	14.7 years (±1.9)
	Klink et al. 2015	14.9 years (±1.9) in transfemales
		15.0 years (±2.0) in transmales
		· / /
	Study	Median age (range)
	Brik et al. 2020	15.5 years (11.1–18.6) in transfemales
		16.1 years (10.1–17.9) in transmales

r		
	Schagen et al. 2016	13.6 years (11.6–17.9) in transfemales 14.2 years (11.1–18.6) in transmales
	Vlot et al. 2017	13.5 years (11.5–18.3) in transfemales 15.1 years (11.7–18.6) in transmales
	et al. 2015, but participant (VERY LOW) .	nalogues was not reported in Staphorsius s were required to be at least 12 years
		owed wide variation in the age (11 to 18 ildren and adolescents with gender inalogues.
Duration of	The duration of treatment with GnRH analogues was reported in 3/9	
treatment	studies. The median duration was:	
	, , ,	–2.8) in Brik et al. 2020.
	, , ,	–3.8) in transfemales and 1.5 years (range ales in Klink et al. 2015.
	In Staphorsius et al. 2015, th	ne mean duration was 1.6 years (SD ±1.0).
	-	e mean duration of time between starting er-affirming hormones was 1.88 years (SD
	treatment with GnRH anal this information. Treatme	owed wide variation in the duration of ogues, but most studies did not report nt duration ranged from a few months
Abbrevietienes DO	up to about 5 years.	Manual of Montal Disordora aritaria: SD

Abbreviations: DSM, Diagnostic and Statistical Manual of Mental Disorders criteria; SD, standard deviation.

6. Discussion

A key limitation to identifying the effectiveness and safety of GnRH analogues for children and adolescents with gender dysphoria is the lack of reliable comparative studies. The lack of clear, expected outcomes from treatment with a GnRH analogue (the purpose of which is to suppress secondary sexual characteristics which may cause distress from unwanted pubertal changes) also makes interpreting the evidence difficult. The size of the population with gender dysphoria means conducting a prospective trial may be unrealistic, at least on a single centre basis. There may also be ethical issues with a 'no treatment arm' in comparative trials of GnRH analogues, where there may be poor mental health outcomes if treatment is withheld. However, the use of an active comparator such as close psychological support may reduce ethical concerns in future trials.

The studies included in this evidence review are all small, uncontrolled observational studies, which are subject to bias and confounding, and are of very low certainty as assessed using modified GRADE. All the included studies reported physical and mental health comorbidities and concomitant treatments very poorly. For example, very little data are reported on how many children and adolescents needed additional mental health support, and for what reasons, or whether additional interventions, and what form and duration (for example drug treatment or counselling) that took. This is a possible confounder for the treatment outcomes in the studies because changes in critical and important

outcomes may be attributable to external care rather than the psychological support or GnRH analogues used in the studies.

The studies that reported diagnostic criteria for gender dysphoria (6/9 studies) used the Diagnostic and Statistical Manual of Mental Disorders (DSM) criteria in use at the time the study was conducted (either DSM-IV-TR or DSM-V). The definition was unclear in the remaining studies. There was wide variation in the ages at which participants started a GnRH analogue, typically ranging from about 11 to 18 years. Similarly, there was a wide variation in the duration of use, but few studies reported this.

Changes in outcome scores for clinical effectiveness were assessed for statistical significance in the 3 studies reporting these outcomes (<u>Costa et al. 2015</u>; <u>de Vries et al.</u> <u>2011; Staphorsius et al. 2015</u>). However, there is relatively little interpretation of whether the changes in outcome scores seen in these studies are clinically meaningful.

For some outcomes there was no statistically significant difference from before starting GnRH analogues until just before starting gender-affirming hormones. These were the Utrecht Gender Dysphoria Scale (UGDS) (which was assessed in 1 study <u>de Vries et al.</u> 2011), the Trait Anger (TPI) and Trait Anxiety (STAI) Scales (which were assessed in 1 study <u>de Vries et al. 2011</u>), and Body Image Scale (BIS) which was assessed in 1 study (<u>de Vries et al. 2011</u>).

The Beck Depression Inventory (BDI-II) was used in 1 study (de Vries et al. 2011) to assess change in depression from before starting GnRH analogues to just before starting genderaffirming hormones. The result is statistically significant, with the mean (\pm SD) BDI-II score decreasing from 8.31 (\pm 7.12) at baseline to 4.95 (\pm 6.27) at follow up (p=0.004). However, both scores fall into the minimal range using the general guidelines for interpretation of BDI-II (0 to 13 minimal, 14 to 19 mild depression, 20 to 28 moderate depression and 29 to 63 severe depression), suggesting that while statistically significant, it is unclear if this is a clinically meaningful change.

Psychosocial outcomes were assessed in 3 studies (<u>Costa et al. 2015</u>; <u>de Vries et al. 2011</u>; <u>Staphorsius et al. 2015</u>) using the Children's Global Assessment Scale (CGAS) and Child Behavior Checklist/Youth Self-Report (CBCL/YSR). The CGAS score was assessed in 2 studies (<u>Costa et al. 2015</u>; <u>de Vries et al. 2011</u>). In de Vries et al. 2011 the mean (±SD) CGAS score statistically significantly increased over time from 70.24 [±10.12] at baseline to 73.90 [±9.63] at follow up. CGAS scores are clinically categorised into 10 categories (10 to 1, 20 to 11 and so on until 100 to 91) and both scores reported were in a single category (71 to 80, no more than slight impairment) suggesting that while statistically significant, it is unclear if this is a clinically meaningful change. The Costa et al. 2015 study does highlight a larger change in CGAS scores from baseline to follow-up (mean [±SD] 58.72 [±11.38] compared with 67.40 [±13.39]), but whether this is clinically meaningful is unclear. The average score moved from the clinical category of 60 to 51 (variable functioning with sporadic difficulties) at baseline to 70 to 61 (some difficulty in a single area, but generally functioning pretty well) at follow up, but the large standard deviations suggest clinically significant overlaps between the scores from baseline to follow-up.

Psychosocial functioning using the CBCL/YSR was assessed in 2 studies (<u>de Vries et al.</u> <u>2011</u>; <u>Staphorsius et al. 2015</u>). In de Vries et al. 2011 there was a statistically significant reduction in both CBCL and YSR scores from before starting GnRH analogues to just before starting gender-affirming hormones. The study interpreted the CBCL/YSR with a proportion of adolescents who scored in the clinical range (a T-score above 63), which allows changes in clinically meaningful scores to be assessed, and proportions of adolescents in the clinical range for some CBCL and YSR scores decreased over time. One cross-sectional study (<u>Staphorsius et al. 2015</u>) assessed CBCL scores only, but it was unclear if this was the Total T score, or whether subscales of internalising or externalising scores were also assessed, and whether the results were statistically significant.

The 2 prospective observational studies (Costa et al. 2015; de Vries et al. 2011) are confounded by a number of common factors. Firstly, the single assessment of scores at baseline means it is unclear if scores were stable, already improving or declining before starting treatment. Secondly, in an uncontrolled study any changes in scores from baseline to follow-up could be attributed to a regression-to-mean, for example getting older has been positively associated with maturity and wellbeing. The studies use mean and standard deviations in the descriptive statistics and analyses; however, they do not report testing the normality of data which would support the use of parametric measures. The study by de Vries et al. 2011 used general linear models (regression) to examine between and within group variances (changes in outcomes). In using such models, the data is assumed to be balanced (measured at regular intervals and without missing data), but the large ranges in ages at which participants were assessed and started on various interventions suggests that ascertainment of outcome was unlikely to be regular and missing data was likely. Missing data was handled through listwise deletion (omits those cases with the missing data and analyses the remaining data) which is acceptable if data loss is completely random but for some outcomes where there was incomplete data for individual items this was not random (items were introduced by the authors after the first eligible adolescents had started GnRH analogues). The study provided no detail on whether these assumptions for the modeling were met, they also provided no adequate assessment of whether any regression diagnostics (analysis that seek to assess the validity of a model) or model fit (how much of the variance in outcome is explained by the between and within group variance) were undertaken.

The 2 retrospective observational studies (<u>Brik et al. 2020</u>; <u>Khatchadourian et al. 2014</u>) both only report absolute numbers for each trajectory along with reasons for stopping GnRH analogues. It is difficult to assess outcomes from such single centre studies because there is little comparative data for outcomes from other such services. A lack of any critical or other important outcomes also means the success of the treatment across all the participants is difficult to judge.

Three uncontrolled, observational, retrospective studies provided evidence relating to the effect of GnRH analogues on bone density (Joseph et al. 2019; Klink et al. 2015; Vlot et al. 2017). In all 3 studies, the participants acted as their own controls and change in bone density was determined between starting GnRH analogues and either after 1 and 2 year follow-up timepoints (Joseph et al. 2019) or when gender-affirming hormones were started (Klink et al. 2015 and Vlot et al. 2017). Observational studies such as these can only show an association with GnRH analogues and bone density; they cannot show that GnRH analogues caused any differences in bone density seen. Because there was no comparator group and participants acted as their own controls, it is unclear whether the findings are associated with GnRH analogues or due to changes over time. The authors reported z-scores which allows for comparison with the expected increase in bone density in the

general population. However, because no concomitant treatments or comorbidities were reported it is possible that the findings may not be because of GnRH analogues and there is another way in which the study population differs from the general population.

All the studies are from a limited number of, mainly European, care facilities. They are described as either tertiary referral or expert services but the low number of services providing such care and publishing evidence may bias the results towards the outcomes in these services only and limit extrapolation.

The first study (Brik et al. 2020) was an uncontrolled, retrospective, observational study that assessed the outcome trajectories of adolescents receiving GnRH analogues for gender dysphoria. This study followed-up 143 individuals who had received GnRH analogues (38 transfemales and 105 transmales) using clinical records to show outcomes for up to 9 years (continuing use of GnRH analogues, reasons for stopping GnRH analogues and onward care such as gender-affirming hormone use). The methods and results are well reported, but no analysis of data was undertaken. The views of adolescents and their parents are particularly difficult to interpret because no data on how many responded to each question and in what ways are reported.

The second study (Costa et al. 2015) was an uncontrolled, prospective observational study which assessed global functioning in adolescents with gender dysphoria using CGAS every 6 months, including during the first 6 months where statistically significant improvements were seen without GnRH analogues. The study is confounded by significant unexplained loss to follow-up (64.7%: from n=201 adolescents to n=71 after 18 months). Missing data for those lost to follow-up maybe more than sufficient to change the direction of effects seen in the study if the reasons for loss to follow-up are systematic (such as deriving little or no benefit from treatment). The study uses clustered data in its analysis, a single outcome (CGAS) measured in clusters (at different visits), and the analysis does not take account of the correlation of scores (data at different time points are not independent) as a significant change in scores early in the study means the successive changes measured against baseline were also significant. The study relies on multiple (>20) pairwise independent t-tests to examine change in CGAS between the 4 time points, increasing the possibility of type-I error (a false positive which occurs when a researcher incorrectly rejects a true null hypothesis) because the more tests performed the more likely a statistically significant result will be observed by chance alone.

The <u>Costa et al. 2015</u> study compares immediately eligible and delayed eligible cohorts, however, it is highly likely that they are non-comparable groups because the immediately eligible group were those able to start GnRH analogues straight away whilst those in the delayed eligible group were either not ready to make a decision about starting treatment (no age comparison was made between the 2 groups so it is unclear if they were a younger cohort than the immediately eligible group) or had comorbid mental health or psychological difficulties. The authors report that those with concomitant problems (such as mental health problems, substantial problems with peers, or conflicts with parents or siblings) were referred to local mental health services but no details are provided.

The third study (<u>de Vries et al. 2011</u>) was an uncontrolled, prospective observational study which assessed gender dysphoria and psychological functioning before and after puberty suppression in adolescents with gender dysphoria. Although the study mentions the DSM-IV-TR there is no explicit discussion of this, or any other criteria, being used as the

diagnostic criteria for study entry. There are no details reported for how the outcomes in the study were assessed, and by whom. The length of follow-up for the outcomes in the model are questionable in relation to whether there was sufficient time for GnRH analogues to have a measurable effect. The time points used are start of GnRH analogues and start of gender-affirming hormones. Overall, the mean time between starting GnRH analogues and gender-affirming hormones was 1.88 (±1.05) years, but the range is as low as just 5 months between the 2 time points, which may be insufficient for any difference in outcome to have occurred in some individuals.

The fourth study (Joseph et al. 2019) was a retrospective, longitudinal observational single centre study which assessed bone mineral density in adolescents with gender dysphoria in the UK. For inclusion in the study, participants had to have been assessed by the Gender Identity Development Service multi-disciplinary psychosocial health team for at least 4 assessments over a minimum of 6 months. No other diagnostic criteria, such as the DSM-IV-TR, are discussed. Bone density was assessed using dual energy X-ray absorptiometry (DAXA) scan of the lumbar spine (L1-L4) and the femoral neck at baseline (n=70), 1 year (n=70) and 2 years after starting GnRH analogues (n=39). The results suggest a possible association between GnRH analogues and bone mineral apparent density. However, the evidence is of poor quality, and the results could be due to bias or chance. No concomitant treatments or comorbidities were reported.

The fifth study (<u>Khatchadourian et al. 2014</u>) was an uncontrolled retrospective observational study which describes patient characteristics at presentation, treatment, and response to treatment in 84 adolescents with gender dysphoria, of whom 27 received GnRH analogues. The study used clinical records to show outcomes for up to 13 years (continuing use of GnRH analogues, reasons for stopping GnRH analogues and onward care such as gender-affirming hormone use). The methods are well reported but the results for those taking GnRH analogues are poorly and incompletely reported, particularly for transfemales, and no analysis of data was undertaken. It is difficult to assess the results for stopping GnRH analogues due to incomplete reporting of this outcome.

The sixth study (<u>Klink et al. 2015</u>) was a retrospective longitudinal observational single centre study which assessed bone mineral density in adolescents with gender dysphoria, diagnosed with the DSM-IV-TR criteria. Bone density was assessed when starting GnRH analogues and then when starting gender-affirming hormones. Results are reported for transmales and transfemales separately and no results for the whole cohort are given. Statistical analyses were reported for all outcomes of interest but, because there was no comparator group and participants acted as their own controls, it is not known whether the findings are associated with GnRH analogues or due to changes over time. The authors reported z-scores which allows for comparison with the expected increase in bone density in the general population. However, because no concomitant treatments or comorbidities were reported it is possible that the findings may not be because of GnRH analogues and there is another way in which the study population differs from the general population.

The seventh study (<u>Schagen et al. 2016</u>) was a prospective observational study of 116 adolescents which provided very low certainty non-comparative evidence on change in serum creatinine between starting GnRH analogues and 1 year, and liver function during treatment. Statistical analyses were reported for changes in serum creatinine but not for liver function. Because there was no comparator group and participants acted as their own

controls, it is not known whether the findings are associated with GnRH analogues or due to changes over time, or concomitant treatments.

The eighth study (<u>Staphorsius et al. 2015</u>) was a cross-sectional study of 85 adolescents, 40 with gender dysphoria (of whom 20 were receiving GnRH analogues) and 45 matched controls (not further reported in this evidence review). The study includes 1 outcome of interest for clinical effectiveness (CBCL) and 1 outcome of interest for safety (cognitive development or functioning). The mean (±SD) CBCL, IQ test, reaction time and accuracy scores were given for each group, but the statistical analysis is unclear. It is not reported what analysis was used or which of the groups were compared, therefore it is difficult to interpret the results.

The ninth study (<u>Vlot et al. 2017</u>) was a retrospective observational study which assessed bone mineral apparent density in adolescents with DSM-IV-TR gender dysphoria. Measurements were taken at the start of GnRH analogues and at the start of gender-affirming hormones. Results are reported for young bone age and old bone age in transmales and transfemales separately, and no results for the whole cohort are given. Statistical analyses were reported for all outcomes of interest but, because there was no comparator group and participants acted as their own controls, it is not known whether the findings are associated with GnRH analogues or due to changes over time. The authors reported z-scores which allows for comparison with the expected increase in bone density in the general population. However, because no concomitant treatments or comorbidities were reported it is possible that the findings may not be because of GnRH analogues and there is another way in which the study population differs from the general population.

7. Conclusion

The results of the studies that reported impact on the critical outcomes of gender dysphoria and mental health (depression, anger and anxiety), and the important outcomes of body image and psychosocial impact (global and psychosocial functioning) in children and adolescents with gender dysphoria are of very low certainty using modified GRADE. They suggest little change with GnRH analogues from baseline to follow-up.

Studies that found differences in outcomes could represent changes that are either of questionable clinical value, or the studies themselves are not reliable and changes could be due to confounding, bias or chance. It is plausible, however, that a lack of difference in scores from baseline to follow-up is the effect of GnRH analogues in children and adolescents with gender dysphoria, in whom the development of secondary sexual characteristics might be expected to be associated with an increased impact on gender dysphoria, depression, anxiety, anger and distress over time without treatment. One study reported statistically significant reductions in the Child Behaviour Checklist/Youth Self-Report (CBCL/YSR) scores from baseline to follow up, and given that the purpose of GnRH analogues is to reduce distress caused by the development of secondary sexual characteristics and the CBCL/YSR in part measures distress, this could be an important finding. However, as the studies all lack reasonable controls not receiving GnRH analogues, the natural history of the outcomes measured in the studies is not known and any positive changes could be a regression to mean.

The results of the studies that reported bone density outcomes suggest that GnRH analogues may reduce the increase in bone density which is expected during puberty. However, as the studies themselves are not reliable, the results could be due to confounding, bias or chance. While controlled trials may not be possible, comparative studies are needed to understand this association and whether the effects of GnRH analogues on bone density are seen after treatment is stopped. All the studies that reported safety outcomes provided very low certainty evidence.

No cost-effectiveness evidence was found to determine whether or not GnRH analogues are cost-effective for children and adolescents with gender dysphoria.

The results of the studies that reported outcomes for subgroups of children and adolescents with gender dysphoria, suggest there may be differences between sex assigned at birth males (transfemales) and sex assigned at birth females (transmales).

Appendix A PICO document

The review questions for this evidence review are:

- 1. For children and adolescents with gender dysphoria, what is the clinical effectiveness of treatment with GnRH analogues compared with one or a combination of psychological support, social transitioning to the desired gender or no intervention?
- 2. For children and adolescents with gender dysphoria, what is the short-term and longterm safety of GnRH analogues compared with one or a combination of psychological support, social transitioning to the desired gender or no intervention?
- 3. For children and adolescents with gender dysphoria, what is the cost-effectiveness of GnRH analogues compared to one or a combination of psychological support, social transitioning to the desired gender or no intervention?
- 4. From the evidence selected, are there any subgroups of children and adolescents with gender dysphoria that may derive more (or less) advantage from treatment with GnRH analogues than the wider population of children and adolescents with gender dysphoria?
- 5. From the evidence selected,
 - a) what are the criteria used by the research studies to define gender dysphoria, gender identity disorder and gender incongruence of childhood?
 - b) what were the ages at which participants commenced treatment with GnRH analogues?
 - c) what was the duration of treatment with GnRH analogues?

PICO table

	* Triptorelin (brand names Gonapeptyl and Decapeptyl) are used in Leeds Hospital, England. The search should include brand names as well as generic names.	
	One or a combination of:	
	Psychological support.	
C – Comparator(s)	• Social transitioning to the gender with which the individual identifies.	
	No intervention.	
	There are no known minimal clinically important differences and there are no preferred timepoints for the outcome measures selected.	
	All outcomes should be stratified by:	
	The age at which treatment with GnRH analogues was initiated.The length of treatment with GnRH analogues where possible.	
	A: Clinical Effectiveness	
	Critical to decision making	
O – Outcomes	• Impact on Gender Dysphoria This outcome is critical because gender dysphoria in adolescents and children is associated with significant distress and problems functioning. Impact on gender dysphoria may be measured by the Utrecht Gender Dysphoria Scale. Other measures as reported in studies may be used as an alternative to the stated measure.	
	• Impact on mental health Examples of mental health problems include self-harm, thoughts of suicide, suicide attempts, eating disorders, depression/low mood and anxiety. These outcomes are critical because self- harm and thoughts of suicide have the potential to result in significant physical harm and for completed suicides the death of the young person. Disordered eating habits may cause significant morbidity in young people. Depression and anxiety are also critical outcomes because they may impact on social, occupational, or other areas of functioning of children and adolescents. The Child and Adolescent Psychiatric Assessment (CAPA) may be used to measure depression and anxiety. The impact on self-harm and suicidality (ideation and behaviour) may be measured using the Suicide Ideation Questionnaire Junior. Other measures may be used as an alternative to the stated measures.	
	• Impact on Quality of Life This outcome is critical because gender dysphoria in children and adolescents may be associated with a significant reduction in health-related quality of life. Quality of Life may be measured by the KINDL questionnaire, Kidscreen 52. Other measures as reported in studies may be used as an alternative to the stated measure.	
	Important to decision making	
	• Impact on body Image This outcome is important because some transgender young people may desire to take steps to suppress features of their physical appearance associated with their sex assigned at birth or accentuate physical features of their desired gender. The Body Image Scale could be used as a measure. Other measures	

Study design	Systematic reviews, randomised controlled trials, controlled clinical trials, cohort studies. If no higher level quality evidence is found, case series can be considered.	
Inclusion criteria		
	Cost effectiveness studies should be reported.	
	<u>C: Cost effectiveness</u>	
	system, and any others as reported.	
	 Impact of withdrawing the drug such as, slipped upper femoral epiphysis, reversibility on the reproductive 	
	density, arterial hypertension, cognitive development/functioning	
	gender dysphoria. Aspects to be reported on should include: o Impact of the drug use such as its impact on bone	
	 Short and long-term safety and adverse effects of taking GnRH analogues are important because GnRH analogues are not licensed for the treatment of adolescents and children with 	
	B: Safety	
	• Stopping treatment The proportion of patients who stop treatment with GnRH analogues and the reasons why. This outcome is important to patients because there is uncertainty about the short- and long- term safety and adverse effects of GnRH analogues in children and adolescents being treated for gender dysphoria.	
	Transitioning surgery – Impact on extent of and satisfaction with surgery This outcome is important because some children and adolescents with gender dysphoria may proceed to transitioning surgery. Stated measures of the extent of transitioning surgery and satisfaction with surgery in studies may be reported.	
	Engagement with health care services may be measured using the Youth Health Care measure-satisfaction, utilization, and needs (YHC-SUN) questionnaire. Loss to follow up should also be ascertained as part of this outcome. Alternative measures to the YHC-SUN questionnaire may be used as reported in studies.	
	• Engagement with health care services This outcome is important because patient engagement with healthcare services will impact on their clinical outcomes.	
	relationships. This outcome is important because gender dysphoria in adolescents and children is associated with internalising and externalising behaviours and emotional and behavioural problems which may impact on social and occupational functioning. The child behavioural check list (CBCL) may be used to measure the impact on psychosocial functioning. Other measures as reported in studies may be used as an alternative to the stated measure.	
	Psychosocial Impact Examples of psychosocial impact are: coping mechanisms which may impact on substance misuse; family relationships; peer	
	as reported in studies may also be used as an alternative to the stated measure.	

Language	English only
Patients	Human studies only
Age	18 years or less
Date limits	2000-2020
Exclusion criteria	
Publication type	Conference abstracts, non-systematic reviews, narrative reviews, commentaries, letters, editorials, guidelines and pre-publication prints
Study design	Case reports, resource utilisation studies

Appendix B Search strategy

Medline, Embase, the Cochrane Library, HTA and APA PsycInfo were searched on 23 July 2020, limiting the search to papers published in English language in the last 20 years. Conference abstracts and letters were excluded.

Database: Medline

Platform: Ovid Version: Ovid MEDLINE(R) <1946 to July 21, 2020> Search date: 23/7/2020 Number of results retrieved: 144 Search strategy:

- 1 Gender Dysphoria/ (485)
- 2 Gender Identity/ (18452)
- 3 "Sexual and Gender Disorders"/ (75)
- 4 Transsexualism/ (3758)
- 5 Transgender Persons/ (3143)
- 6 Health Services for Transgender Persons/ (136)
- 7 exp Sex Reassignment Procedures/ (836)

8 (gender* adj3 (dysphori* or affirm* or incongruen* or identi* or disorder* or confus* or minorit* or queer*)).tw. (7435)

9 (transgend* or transex* or transsex* or transfem* or transwom* or transma* or transmen* or transperson* or transpeopl*).tw. (12678)

10 (trans or crossgender* or cross-gender* or crossex* or cross-sex* or genderqueer*).tw. (102343)

- 11 ((sex or gender*) adj3 (reassign* or chang* or transform* or transition*)).tw. (6974)
- 12 (male-to-female or m2f or female-to-male or f2m).tw. (114841)
- 13 or/1-12 (252702)
- 14 exp Infant/ or Infant Health/ or Infant Welfare/ (1137479)

15 (prematur* or pre-matur* or preterm* or pre-term* or infan* or newborn* or new-born* or perinat* or peri-nat* or neo-nat* or baby* or babies or toddler*).ti,ab,in,jn. (852400)
16 exp Child/ or exp Child Behavior/ or Child Health/ or Child Welfare/ (1913257)

17 Minors/ (2574)

18 (child* or minor or minors or boy* or girl* or kid or kids or young*).ti,ab,in,jn. (2361686)

- 19 exp pediatrics/ (58118)
- 20 (pediatric* or paediatric* or peadiatric*).ti,ab,in,jn. (836269)
- 21 Adolescent/ or Adolescent Behavior/ or Adolescent Health/ (2024207)
- 22 Puberty/ (13278)
- 23 (adolescen* or pubescen* or prepubescen* or pre-pubescen* or pubert* or prepubert* or pre-pubert* or teen* or preteen* or pre-teen* or juvenil* or youth* or under*age*).ti,ab,in,jn. (424246)
- 24 Schools/ (38104)
- 25 Child Day Care Centers/ or exp Nurseries/ or Schools, Nursery/ (7199)

26 (pre-school* or preschool* or kindergar* or daycare or day-care or nurser* or school* or pupil* or student*).ti,ab,jn. (468992)

27 (("eight" or "nine" or "ten" or "eleven" or "twelve" or "thirteen" or "fourteen" or "fifteen" or "sixteen" or "seventeen" or "eighteen" or "nineteen") adj2 (year or years or age or ages or aged)).ti,ab. (89353)

28 (("8" or "9" or "10" or "11" or "12" or "13" or "14" or "15" or "16" or "17" or "18" or "19") adj2 (year or years or age or ages or aged)).ti,ab. (887838)

- 29 or/14-28 (5534171)
- 30 13 and 29 (79263)
- 31 (transchild* or transyouth* or transteen* or transadoles* or transgirl* or transboy*).tw. (7)
- 32 30 or 31 (79263)
- 33 Gonadotropin-Releasing Hormone/ (27588)
- 34 (pubert* adj3 block*).ti,ab. (78)
- 35 ((gonadotrophin or gonadotropin) and releasing).ti,ab. (17299)
- 36 (GnRH adj2 analog*).ti,ab. (2541)
- 37 GnRH*.ti,ab. (20991)
- 38 "GnRH agonist*".ti,ab. (4040)
- 39 Triptorelin Pamoate/ (1906)
- 40 triptorelin.ti,ab. (677)
- 41 arvekap.ti,ab. (1)
- 42 ("AY 25650" or AY25650).ti,ab. (1)
- 43 ("BIM 21003" or BIM21003).ti,ab. (0)
- 44 ("BN 52014" or BN52014).ti,ab. (0)
- 45 ("CL 118532" or CL118532).ti,ab. (0)
- 46 Debio.ti,ab. (83)
- 47 diphereline.ti,ab. (17)
- 48 moapar.ti,ab. (0)
- 49 pamorelin.ti,ab. (0)
- 50 trelstar.ti,ab. (3)
- 51 triptodur.ti,ab. (1)
- 52 ("WY 42422" or WY42422).ti,ab. (0)
- 53 ("WY 42462" or WY42462).ti,ab. (0)
- 54 gonapeptyl.ti,ab. (0)
- 55 decapeptyl.ti,ab. (210)
- 56 salvacyl.ti,ab. (0)
- 57 Buserelin/ (2119)
- 58 buserelin.ti,ab. (1304)

```
59
     bigonist.ti,ab. (0)
60
     ("hoe 766" or hoe-766 or hoe766).ti,ab. (69)
61
     profact.ti,ab. (2)
62
     receptal.ti,ab. (30)
63
     suprecur.ti,ab. (4)
64
     suprefact.ti,ab. (22)
65
     tiloryth.ti,ab. (0)
66
     histrelin.ti,ab. (55)
67
     "LHRH-hydrogel implant".ti,ab. (1)
68
     ("RL 0903" or RL0903).ti,ab. (1)
69
     ("SPD 424" or SPD424).ti,ab. (1)
70
     goserelin.ti,ab. (875)
71
     Goserelin/ (1612)
72
     ("ici 118630" or ici118630).ti,ab. (51)
73
     ("ZD-9393" or ZD9393).ti,ab. (0)
74
     zoladex.ti,ab. (379)
75
     leuprorelin.ti,ab. (413)
76
     carcinil.ti,ab. (0)
77
     enanton*.ti,ab. (23)
78
     ginecrin.ti,ab. (0)
79
     leuplin.ti,ab. (13)
80
     Leuprolide/ (2900)
81
     leuprolide.ti,ab. (1743)
82
     lucrin.ti,ab. (11)
83
     lupron.ti,ab. (162)
84
     provren.ti,ab. (0)
85
     procrin.ti,ab. (3)
86
     ("tap 144" or tap144).ti,ab. (40)
87
     (a-43818 or a43818).ti,ab. (3)
88
     Trenantone.ti,ab. (1)
89
     staladex.ti,ab. (0)
90
     prostap.ti,ab. (6)
91
     Nafarelin/ (327)
92
     nafarelin.ti,ab. (251)
93
     ("76932-56-4" or "76932564").ti,ab. (0)
94
     ("76932-60-0" or "76932600").ti,ab. (0)
95
     ("86220-42-0" or "86220420").ti,ab. (0)
96
     ("rs 94991 298" or rs94991298).ti,ab. (0)
97
     synarel.ti,ab. (12)
98
     deslorelin.ti,ab. (263)
     gonadorelin.ti,ab. (201)
99
100
       ("33515-09-2" or "33515092").ti,ab. (0)
101
       ("51952-41-1" or "51952411").ti,ab. (0)
102
       ("52699-48-6" or "52699486").ti,ab. (0)
103
       cetrorelix.ti,ab. (463)
104
       cetrotide.ti,ab. (41)
105
       ("NS 75A" or NS75A).ti,ab. (0)
106
       ("NS 75B" or NS75B).ti,ab. (0)
```

107 ("SB 075" or SB075).ti,ab. (0) 108 ("SB 75" or SB75).ti,ab. (63) 109 gonadoliberin.ti,ab. (143) 110 kryptocur.ti,ab. (6) 111 cetrorelix.ti,ab. (463) 112 cetrotide.ti,ab. (41) 113 antagon.ti,ab. (17) 114 ganirelix.ti,ab. (138) 115 ("ORG 37462" or ORG37462).ti,ab. (3) 116 orgalutran.ti,ab. (20) 117 ("RS 26306" or RS26306).ti,ab. (5) 118 ("AY 24031" or AY24031).ti,ab. (0) 119 factrel.ti,ab. (11) 120 fertagyl.ti,ab. (11) 121 lutrelef.ti,ab. (5) 122 lutrepulse.ti,ab. (3) 123 relefact.ti,ab. (10) 124 fertiral.ti,ab. (0) 125 (hoe471 or "hoe 471").ti,ab. (6) 126 relisorm.ti,ab. (4) 127 cystorelin.ti,ab. (18) 128 dirigestran.ti,ab. (5) 129 or/33-128 (42216) 130 32 and 129 (416) 131 limit 130 to english language (393) 132 limit 131 to (letter or historical article or comment or editorial or news or case reports) (36) 133 131 not 132 (357) 134 animals/ not humans/ (4686361)

- 135 133 not 134 (181)
- 136 limit 135 to yr="2000 -Current" (144)

Database: Medline in-process

Platform: Ovid Version: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations <1946 to July 21, 2020> Search date: 23/7/2020 Number of results retrieved: Search strategy: 42

- 1 Gender Dysphoria/ (0)
- 2 Gender Identity/ (0)
- 3 "Sexual and Gender Disorders"/ (0)
- 4 Transsexualism/ (0)
- 5 Transgender Persons/ (0)
- 6 Health Services for Transgender Persons/ (0)
- 7 exp Sex Reassignment Procedures/ (0)

8 (gender* adj3 (dysphori* or affirm* or incongruen* or identi* or disorder* or confus* or minorit* or queer*)).tw. (1645)

9 (transgend* or transex* or transsex* or transfem* or transwom* or transma* or transmen* or transperson* or transpeopl*).tw. (2333)

10 (trans or crossgender* or cross-gender* or crossex* or cross-sex* or genderqueer*).tw. (20884)

11 ((sex or gender*) adj3 (reassign* or chang* or transform* or transition*)).tw. (968)

12 (male-to-female or m2f or female-to-male or f2m).tw. (15513)

13 or/1-12 (39905)

14 exp Infant/ or Infant Health/ or Infant Welfare/ (0)

15 (prematur* or pre-matur* or preterm* or pre-term* or infan* or newborn* or new-born* or perinat* or perinat* or neonat* or neo-nat* or baby* or babies or toddler*).ti,ab,in,jn. (80723)

16 exp Child/ or exp Child Behavior/ or Child Health/ or Child Welfare/ (0)

17 Minors/ (0)

18 (child* or minor or minors or boy* or girl* or kid or kids or young*).ti,ab,in,jn. (321871)

19 exp pediatrics/ (0)

20 (pediatric* or paediatric* or peadiatric*).ti,ab,in,jn. (119783)

21 Adolescent/ or Adolescent Behavior/ or Adolescent Health/ (0)

22 Puberty/ (0)

23 (adolescen* or pubescen* or prepubescen* or pre-pubescen* or pubert* or prepubert* or pre-pubert* or teen* or pre-teen* or juvenil* or youth* or under*age*).ti,ab,in,jn. (60264)

24 Schools/ (0)

25 Child Day Care Centers/ or exp Nurseries/ or Schools, Nursery/ (0)

26 (pre-school* or preschool* or kindergar* or daycare or day-care or nurser* or school* or pupil* or student*).ti,ab,jn. (69233)

27 (("eight" or "nine" or "ten" or "eleven" or "twelve" or "thirteen" or "fourteen" or "fifteen" or "sixteen" or "seventeen" or "eighteen" or "nineteen") adj2 (year or years or age or ages or aged)).ti,ab. (10319)

28 (("8" or "9" or "10" or "11" or "12" or "13" or "14" or "15" or "16" or "17" or "18" or "19") adj2 (year or years or age or ages or aged)).ti,ab. (112800)

29 or/14-28 (525529)

30 13 and 29 (9196)

31 (transchild* or transyouth* or transteen* or transadoles* or transgirl* or transboy*).tw. (3)

- 32 30 or 31 (9197)
- 33 Gonadotropin-Releasing Hormone/ (0)
- 34 (pubert* adj3 block*).ti,ab. (19)
- 35 ((gonadotrophin or gonadotropin) and releasing).ti,ab. (1425)
- 36 (GnRH adj2 analog*).ti,ab. (183)
- 37 GnRH*.ti,ab. (1695)
- 38 "GnRH agonist*".ti,ab. (379)
- 39 Triptorelin Pamoate/ (0)
- 40 triptorelin.ti,ab. (72)
- 41 arvekap.ti,ab. (0)
- 42 ("AY 25650" or AY25650).ti,ab. (0)
- 43 ("BIM 21003" or BIM21003).ti,ab. (0)
- 44 ("BN 52014" or BN52014).ti,ab. (0)
- 45 ("CL 118532" or CL118532).ti,ab. (0)

```
46
      Debio.ti,ab. (11)
47
      diphereline.ti,ab. (6)
      moapar.ti,ab. (0)
48
49
      pamorelin.ti,ab. (0)
50
      trelstar.ti,ab. (0)
51
      triptodur.ti,ab. (0)
52
      ("WY 42422" or WY42422).ti,ab. (0)
53
      ("WY 42462" or WY42462).ti,ab. (0)
54
      gonapeptyl.ti,ab. (0)
55
      decapeptyl.ti,ab. (8)
56
      salvacyl.ti,ab. (0)
57
      Buserelin/(0)
58
      buserelin.ti,ab. (59)
59
      bigonist.ti,ab. (0)
60
      ("hoe 766" or hoe-766 or hoe766).ti,ab. (3)
61
      profact.ti,ab. (0)
62
      receptal.ti,ab. (0)
63
      suprecur.ti,ab. (1)
64
      suprefact.ti,ab. (2)
65
      tiloryth.ti,ab. (0)
66
      histrelin.ti,ab. (9)
      "LHRH-hydrogel implant".ti,ab. (0)
67
68
      ("RL 0903" or RL0903).ti,ab. (0)
69
      ("SPD 424" or SPD424).ti,ab. (0)
70
      goserelin.ti,ab. (68)
71
      Goserelin/(0)
72
      ("ici 118630" or ici118630).ti,ab. (0)
73
      ("ZD-9393" or ZD9393).ti,ab. (0)
74
      zoladex.ti,ab. (6)
75
      leuprorelin.ti,ab. (47)
76
      carcinil.ti,ab. (0)
77
      enanton*.ti,ab. (1)
78
      ginecrin.ti,ab. (0)
79
      leuplin.ti,ab. (1)
80
      Leuprolide/ (0)
81
      leuprolide.ti,ab. (121)
82
      lucrin.ti,ab. (4)
83
      lupron.ti,ab. (10)
84
      provren.ti,ab. (0)
85
      procrin.ti,ab. (0)
86
      ("tap 144" or tap144).ti,ab. (0)
87
      (a-43818 or a43818).ti,ab. (0)
88
      Trenantone.ti,ab. (1)
89
      staladex.ti,ab. (0)
90
      prostap.ti,ab. (0)
91
      Nafarelin/ (0)
92
      nafarelin.ti,ab. (5)
93
      ("76932-56-4" or "76932564").ti,ab. (0)
```

```
94
     ("76932-60-0" or "76932600").ti,ab. (0)
95
     ("86220-42-0" or "86220420").ti,ab. (0)
96
     ("rs 94991 298" or rs94991298).ti,ab. (0)
97
     synarel.ti,ab. (0)
98
     deslorelin.ti,ab. (14)
99
     gonadorelin.ti,ab. (13)
100
      ("33515-09-2" or "33515092").ti,ab. (0)
101
      ("51952-41-1" or "51952411").ti,ab. (0)
102
      ("52699-48-6" or "52699486").ti,ab. (0)
103
      cetrorelix.ti,ab. (31)
104
      cetrotide.ti,ab. (5)
105
       ("NS 75A" or NS75A).ti,ab. (0)
106
      ("NS 75B" or NS75B).ti,ab. (0)
107
       ("SB 075" or SB075).ti,ab. (0)
108
      ("SB 75" or SB75).ti,ab. (2)
109
      gonadoliberin.ti,ab. (4)
110
      kryptocur.ti,ab. (1)
111
      cetrorelix.ti,ab. (31)
112
      cetrotide.ti,ab. (5)
113
      antagon.ti,ab. (0)
114
      ganirelix.ti,ab. (8)
115
      ("ORG 37462" or ORG37462).ti,ab. (0)
116
      orgalutran.ti,ab. (3)
117
       ("RS 26306" or RS26306).ti,ab. (0)
118
      ("AY 24031" or AY24031).ti,ab. (0)
119
      factrel.ti,ab. (2)
120
      fertagyl.ti,ab. (1)
121
      lutrelef.ti,ab. (0)
122
      lutrepulse.ti,ab. (0)
123
      relefact.ti,ab. (0)
124
      fertiral.ti,ab. (0)
125
       (hoe471 or "hoe 471").ti,ab. (0)
126
      relisorm.ti,ab. (0)
127
      cystorelin.ti,ab. (1)
128
      dirigestran.ti,ab. (0)
129
      or/33-128 (2332)
130
      32 and 129 (45)
131
       limit 130 to english language (45)
132
       limit 131 to yr="2000 -Current" (42)
```

Database: Medline epubs ahead of print

Platform: Ovid Version: Ovid MEDLINE(R) Epub Ahead of Print <July 21, 2020> Search date: 23/7/2020 Number of results retrieved: 8 Search strategy:

1 Gender Dysphoria/ (0)

- 2 Gender Identity/ (0)
- 3 "Sexual and Gender Disorders"/ (0)
- 4 Transsexualism/ (0)
- 5 Transgender Persons/ (0)
- 6 Health Services for Transgender Persons/ (0)
- 7 exp Sex Reassignment Procedures/ (0)

8 (gender* adj3 (dysphori* or affirm* or incongruen* or identi* or disorder* or confus* or minorit* or queer*)).tw. (486)

9 (transgend* or transex* or transsex* or transfem* or transwom* or transma* or transmen* or transperson* or transpeopl*).tw. (640)

10 (trans or crossgender* or cross-gender* or crossex* or cross-sex* or genderqueer*).tw. (1505)

- 11 ((sex or gender*) adj3 (reassign* or chang* or transform* or transition*)).tw. (178)
- 12 (male-to-female or m2f or female-to-male or f2m).tw. (2480)
- 13 or/1-12 (4929)
- 14 exp Infant/ or Infant Health/ or Infant Welfare/ (0)

15 (prematur* or pre-matur* or preterm* or pre-term* or infan* or newborn* or new-born* or perinat* or peri-nat* or neo-nat* or baby* or babies or toddler*).ti,ab,in,jn. (15496)

16 exp Child/ or exp Child Behavior/ or Child Health/ or Child Welfare/ (0)

- 17 Minors/ (0)
- 18 (child* or minor or minors or boy* or girl* or kid or kids or young*).ti,ab,in,jn. (53563)
- 19 exp pediatrics/ (0)
- 20 (pediatric* or paediatric* or peadiatric*).ti,ab,in,jn. (22796)
- 21 Adolescent/ or Adolescent Behavior/ or Adolescent Health/ (0)
- 22 Puberty/ (0)

23 (adolescen* or pubescen* or prepubescen* or pre-pubescen* or pubert* or prepubert* or pre-pubert* or pre-teen* or juvenil* or youth* or under*age*).ti,ab,in,jn. (13087)

- 24 Schools/ (0)
- 25 Child Day Care Centers/ or exp Nurseries/ or Schools, Nursery/ (0)

26 (pre-school* or preschool* or kindergar* or daycare or day-care or nurser* or school* or pupil* or student*).ti,ab,jn. (12443)

27 (("eight" or "nine" or "ten" or "eleven" or "twelve" or "thirteen" or "fourteen" or "fifteen" or "sixteen" or "seventeen" or "eighteen" or "nineteen") adj2 (year or years or age or ages or aged)).ti,ab. (1416)

28 (("8" or "9" or "10" or "11" or "12" or "13" or "14" or "15" or "16" or "17" or "18" or "19") adj2 (year or years or age or ages or aged)).ti,ab. (20166)

- 29 or/14-28 (88366)
- 30 13 and 29 (1638)
- 31 (transchild* or transyouth* or transteen* or transadoles* or transgirl* or transboy*).tw. (1)
- 32 30 or 31 (1638)
- 33 Gonadotropin-Releasing Hormone/ (0)
- 34 (pubert* adj3 block*).ti,ab. (2)
- 35 ((gonadotrophin or gonadotropin) and releasing).ti,ab. (176)
- 36 (GnRH adj2 analog*).ti,ab. (30)
- 37 GnRH*.ti,ab. (223)
- 38 "GnRH agonist*".ti,ab. (49)
- 39 Triptorelin Pamoate/ (0)

This document was prepared in October 2020

```
40
     triptorelin.ti,ab. (12)
41
     arvekap.ti,ab. (0)
42
     ("AY 25650" or AY25650).ti,ab. (0)
43
     ("BIM 21003" or BIM21003).ti,ab. (0)
44
     ("BN 52014" or BN52014).ti,ab. (0)
45
     ("CL 118532" or CL118532).ti,ab. (0)
46
     Debio.ti,ab. (2)
47
     diphereline.ti,ab. (1)
48
     moapar.ti,ab. (0)
49
     pamorelin.ti,ab. (0)
50
     trelstar.ti,ab. (0)
51
     triptodur.ti,ab. (0)
52
     ("WY 42422" or WY42422).ti,ab. (0)
53
     ("WY 42462" or WY42462).ti,ab. (0)
54
     gonapeptyl.ti,ab. (0)
55
     decapeptyl.ti,ab. (0)
56
     salvacyl.ti,ab. (0)
57
     Buserelin/(0)
58
     buserelin.ti,ab. (7)
59
     bigonist.ti,ab. (0)
60
     ("hoe 766" or hoe-766 or hoe766).ti,ab. (0)
61
     profact.ti,ab. (0)
62
     receptal.ti,ab. (0)
63
     suprecur.ti,ab. (0)
64
     suprefact.ti,ab. (1)
65
     tiloryth.ti,ab. (0)
66
     histrelin.ti,ab. (2)
67
     "LHRH-hydrogel implant".ti,ab. (0)
68
     ("RL 0903" or RL0903).ti,ab. (0)
69
     ("SPD 424" or SPD424).ti,ab. (0)
70
     goserelin.ti,ab. (11)
71
     Goserelin/ (0)
72
     ("ici 118630" or ici118630).ti,ab. (0)
73
     ("ZD-9393" or ZD9393).ti,ab. (0)
74
     zoladex.ti,ab. (1)
75
     leuprorelin.ti,ab. (13)
76
     carcinil.ti,ab. (0)
77
     enanton*.ti,ab. (1)
78
     ginecrin.ti,ab. (0)
79
     leuplin.ti,ab. (0)
80
     Leuprolide/ (0)
     leuprolide.ti,ab. (22)
81
82
     lucrin.ti,ab. (0)
83
     lupron.ti,ab. (2)
84
     provren.ti,ab. (0)
85
     procrin.ti,ab. (0)
86
     ("tap 144" or tap144).ti,ab. (1)
87
     (a-43818 or a43818).ti,ab. (0)
```

```
88
     Trenantone.ti,ab. (0)
89
     staladex.ti,ab. (0)
90
     prostap.ti,ab. (0)
91
     Nafarelin/ (0)
92
     nafarelin.ti,ab. (4)
93
     ("76932-56-4" or "76932564").ti,ab. (0)
94
     ("76932-60-0" or "76932600").ti,ab. (0)
95
     ("86220-42-0" or "86220420").ti,ab. (0)
96
     ("rs 94991 298" or rs94991298).ti,ab. (0)
97
     synarel.ti,ab. (0)
98
     deslorelin.ti,ab. (3)
99
     gonadorelin.ti,ab. (3)
100
       ("33515-09-2" or "33515092").ti,ab. (0)
101
       ("51952-41-1" or "51952411").ti,ab. (0)
102
       ("52699-48-6" or "52699486").ti,ab. (0)
103
       cetrorelix.ti,ab. (6)
104
       cetrotide.ti,ab. (2)
105
       ("NS 75A" or NS75A).ti,ab. (0)
106
       ("NS 75B" or NS75B).ti,ab. (0)
107
       ("SB 075" or SB075).ti,ab. (0)
108
       ("SB 75" or SB75).ti,ab. (0)
109
       gonadoliberin.ti,ab. (0)
110
       kryptocur.ti,ab. (0)
111
       cetrorelix.ti,ab. (6)
112
       cetrotide.ti,ab. (2)
113
       antagon.ti,ab. (1)
114
       ganirelix.ti,ab. (1)
115
       ("ORG 37462" or ORG37462).ti,ab. (0)
116
       orgalutran.ti,ab. (0)
117
       ("RS 26306" or RS26306).ti,ab. (0)
118
       ("AY 24031" or AY24031).ti,ab. (0)
119
       factrel.ti,ab. (0)
120
       fertagyl.ti,ab. (0)
121
       lutrelef.ti,ab. (0)
122
       lutrepulse.ti,ab. (0)
123
       relefact.ti,ab. (0)
124
       fertiral.ti,ab. (0)
       (hoe471 or "hoe 471").ti,ab. (0)
125
126
       relisorm.ti,ab. (0)
127
       cystorelin.ti,ab. (0)
128
       dirigestran.ti,ab. (0)
129
       or/33-128 (310)
130
       32 and 129 (8)
131
       limit 130 to english language (8)
132
       limit 131 to yr="2000 -Current" (8)
```

Database: Medline daily update

Platform: Ovid

Version: Ovid MEDLINE(R) Daily Update <July 21, 2020> Search date: 23/7/2020 Number of results retrieved: 1 Search strategy

- 1 Gender Dysphoria/ (4)
- 2 Gender Identity/ (38)
- 3 "Sexual and Gender Disorders"/ (0)
- 4 Transsexualism/ (2)
- 5 Transgender Persons/ (26)
- 6 Health Services for Transgender Persons/ (1)
- 7 exp Sex Reassignment Procedures/ (3)

8 (gender* adj3 (dysphori* or affirm* or incongruen* or identi* or disorder* or confus* or minorit* or queer*)).tw. (24)

9 (transgend* or transex* or transsex* or transfem* or transwom* or transma* or transmen* or transperson* or transpeopl*).tw. (39)

10 (trans or crossgender* or cross-gender* or crossex* or cross-sex* or genderqueer*).tw.
(87)

11 ((sex or gender*) adj3 (reassign* or chang* or transform* or transition*)).tw. (15)

12 (male-to-female or m2f or female-to-male or f2m).tw. (181)

13 or/1-12 (358)

14 exp Infant/ or Infant Health/ or Infant Welfare/ (932)

15 (prematur* or pre-matur* or preterm* or pre-term* or infan* or newborn* or new-born* or perinat* or perinat* or neo-nat* or baby* or babies or toddler*).ti,ab,in,jn. (981)

16 exp Child/ or exp Child Behavior/ or Child Health/ or Child Welfare/ (1756)

17 Minors/ (3)

- 18 (child* or minor or minors or boy* or girl* or kid or kids or young*).ti,ab,in,jn. (3672)
- 19 exp pediatrics/ (75)

20 (pediatric* or paediatric* or peadiatric*).ti,ab,in,jn. (1658)

21 Adolescent/ or Adolescent Behavior/ or Adolescent Health/ (2006)

22 Puberty/ (8)

(adolescen* or pubescen* or prepubescen* or pre-pubescen* or pubert* or prepubert* or pre-pubert* or pre-teen* or juvenil* or youth* or under*age*).ti,ab,in,jn.
 (732)

24 Schools/ (56)

25 Child Day Care Centers/ or exp Nurseries/ or Schools, Nursery/ (5)

26 (pre-school* or preschool* or kindergar* or daycare or day-care or nurser* or school* or pupil* or student*).ti,ab,jn. (622)

27 (("eight" or "nine" or "ten" or "eleven" or "twelve" or "thirteen" or "fourteen" or "fifteen" or "sixteen" or "seventeen" or "eighteen" or "nineteen") adj2 (year or years or age or ages or aged)).ti,ab. (98)

28 (("8" or "9" or "10" or "11" or "12" or "13" or "14" or "15" or "16" or "17" or "18" or "19") adj2 (year or years or age or ages or aged)).ti,ab. (1301)

29 or/14-28 (6705)

- 30 13 and 29 (130)
- 31 (transchild* or transyouth* or transteen* or transadoles* or transgirl* or transboy*).tw. (0)
- 32 30 or 31 (130)
- 33 Gonadotropin-Releasing Hormone/ (11)

```
34
     (pubert* adj3 block*).ti,ab. (0)
35
     ((gonadotrophin or gonadotropin) and releasing).ti,ab. (10)
36
     (GnRH adj2 analog*).ti,ab. (2)
37
     GnRH*.ti,ab. (14)
     "GnRH agonist*".ti,ab. (4)
38
39
     Triptorelin Pamoate/ (1)
40
     triptorelin.ti,ab. (1)
41
     arvekap.ti,ab. (0)
42
     ("AY 25650" or AY25650).ti,ab. (0)
43
     ("BIM 21003" or BIM21003).ti,ab. (0)
44
     ("BN 52014" or BN52014).ti,ab. (0)
45
     ("CL 118532" or CL118532).ti,ab. (0)
46
     Debio.ti,ab. (1)
47
     diphereline.ti,ab. (0)
48
     moapar.ti,ab. (0)
49
     pamorelin.ti,ab. (0)
50
     trelstar.ti,ab. (0)
51
     triptodur.ti,ab. (0)
52
     ("WY 42422" or WY42422).ti,ab. (0)
53
     ("WY 42462" or WY42462).ti,ab. (0)
54
     gonapeptyl.ti,ab. (0)
55
     decapeptyl.ti,ab. (0)
56
     salvacyl.ti,ab. (0)
57
     Buserelin/(0)
58
     buserelin.ti,ab. (0)
59
     bigonist.ti,ab. (0)
60
     ("hoe 766" or hoe-766 or hoe766).ti,ab. (0)
61
     profact.ti,ab. (0)
62
     receptal.ti,ab. (0)
     suprecur.ti,ab. (0)
63
64
     suprefact.ti,ab. (0)
65
     tiloryth.ti,ab. (0)
66
     histrelin.ti,ab. (0)
67
     "LHRH-hydrogel implant".ti,ab. (0)
68
     ("RL 0903" or RL0903).ti,ab. (0)
69
     ("SPD 424" or SPD424).ti,ab. (0)
70
     goserelin.ti,ab. (1)
71
     Goserelin/ (2)
72
     ("ici 118630" or ici118630).ti,ab. (0)
73
     ("ZD-9393" or ZD9393).ti,ab. (0)
74
     zoladex.ti,ab. (0)
75
     leuprorelin.ti,ab. (0)
76
     carcinil.ti,ab. (0)
77
     enanton*.ti,ab. (0)
78
     ginecrin.ti,ab. (0)
79
     leuplin.ti,ab. (0)
80
     Leuprolide/ (0)
81
     leuprolide.ti,ab. (0)
```

```
82
      lucrin.ti,ab. (0)
83
      lupron.ti,ab. (0)
84
      provren.ti,ab. (0)
85
      procrin.ti,ab. (0)
86
      ("tap 144" or tap144).ti,ab. (0)
87
      (a-43818 or a43818).ti,ab. (0)
88
      Trenantone.ti,ab. (0)
89
      staladex.ti,ab. (0)
90
      prostap.ti,ab. (0)
91
      Nafarelin/ (0)
92
      nafarelin.ti,ab. (0)
93
      ("76932-56-4" or "76932564").ti,ab. (0)
94
      ("76932-60-0" or "76932600").ti,ab. (0)
95
      ("86220-42-0" or "86220420").ti,ab. (0)
96
      ("rs 94991 298" or rs94991298).ti,ab. (0)
97
      synarel.ti,ab. (0)
98
      deslorelin.ti,ab. (0)
99
      gonadorelin.ti,ab. (0)
100
       ("33515-09-2" or "33515092").ti,ab. (0)
101
       ("51952-41-1" or "51952411").ti,ab. (0)
102
       ("52699-48-6" or "52699486").ti,ab. (0)
103
       cetrorelix.ti,ab. (0)
104
       cetrotide.ti,ab. (0)
105
       ("NS 75A" or NS75A).ti,ab. (0)
106
       ("NS 75B" or NS75B).ti,ab. (0)
       ("SB 075" or SB075).ti,ab. (0)
107
108
       ("SB 75" or SB75).ti,ab. (0)
109
       gonadoliberin.ti,ab. (0)
110
       kryptocur.ti,ab. (0)
111
       cetrorelix.ti,ab. (0)
112
       cetrotide.ti,ab. (0)
113
       antagon.ti,ab. (0)
114
       ganirelix.ti,ab. (0)
115
       ("ORG 37462" or ORG37462).ti,ab. (0)
116
       orgalutran.ti,ab. (0)
117
       ("RS 26306" or RS26306).ti,ab. (0)
118
       ("AY 24031" or AY24031).ti,ab. (0)
119
       factrel.ti,ab. (0)
120
       fertagyl.ti,ab. (0)
121
       lutrelef.ti,ab. (0)
122
       lutrepulse.ti,ab. (0)
123
       relefact.ti,ab. (0)
124
       fertiral.ti,ab. (0)
125
       (hoe471 or "hoe 471").ti,ab. (0)
126
       relisorm.ti,ab. (0)
127
       cystorelin.ti,ab. (0)
128
       dirigestran.ti,ab. (0)
129
       or/33-128 (23)
```

130 32 and 129 (1)

131 limit 130 to english language (1)132 limit 131 to yr="2000 -Current" (1)

Database: Embase

Platform: Ovid Version: Embase <1974 to 2020 July 22> Search date: 23/7/2020 Number of results retrieved: 367 Search strategy:

- 1 exp Gender Dysphoria/ (5399)
- 2 Gender Identity/ (16820)
- 3 "Sexual and Gender Disorders"/ (24689)
- 4 Transsexualism/ (3869)
- 5 exp Transgender/ (6597)
- 6 Health Services for Transgender Persons/ (158848)
- 7 exp Sex Reassignment Procedures/ or sex transformation/ (3058)

8 (gender* adj3 (dysphori* or affirm* or incongru* or identi* or disorder* or confus* or minorit* or queer*)).tw. (13005)

9 (transgend* or transex* or transsex* or transfem* or transwom* or transma* or transmen* or transperson* or transpeopl*).tw. (22509)

10 (trans or crossgender* or cross-gender* or crossex* or cross-sex* or genderqueer*).tw. (154446)

11 ((sex or gender*) adj3 (reassign* or chang* or transform* or transition*)).tw. (10327)

12 (male-to-female or m2f or female-to-male or f2m).tw. (200166)

13 or/1-12 (582812)

14 exp juvenile/ or Child Behavior/ or Child Welfare/ or Child Health/ or infant welfare/ or "minor (person)"/ or elementary student/ (3437324)

15 (prematur* or pre-matur* or preterm* or pre-term* or infan* or newborn* or new-born* or perinat* or peri-nat* or neo-nat* or baby* or babies or toddler*).ti,ab,in,jn. (1186161)
16 (child* or minor or minors or boy* or girl* or kid or kids or young*).ti,ab,in,jn. (3586795)

17 exp pediatrics/ (106214)

18 (pediatric* or paediatric* or peadiatric*).ti,ab,in,jn. (1491597)

19 exp adolescence/ or exp adolescent behavior/ or adolescent health/ or high school student/ or middle school student/ (105108)

20 (adolescen* or pubescen* or prepubescen* or pre-pubescen* or pubert* or prepubert* or pre-pubert* or teen* or pre-teen* or juvenil* or youth* or under*age*).ti,ab,in,jn. (641660)

school/ or high school/ or kindergarten/ or middle school/ or primary school/ or nursery school/ or day care/ (103791)

22 (pre-school* or preschool* or kindergar* or daycare or day-care or nurser* or school* or pupil* or student*).ti,ab,jn. (687437)

23 (("eight" or "nine" or "ten" or "eleven" or "twelve" or "thirteen" or "fourteen" or "fifteen" or "sixteen" or "seventeen" or "eighteen" or "nineteen") adj2 (year or years or age or ages or aged)).ti,ab. (138908)

24 (("8" or "9" or "10" or "11" or "12" or "13" or "14" or "15" or "16" or "17" or "18" or "19") adj2 (year or years or age or ages or aged)).ti,ab. (1562903)

```
25 or/14-24 (7130881)
```

- 26 13 and 25 (182161)
- (transchild* or transyouth* or transteen* or transadoles* or transgirl* or transboy*).tw.
- (17)
- 28 26 or 27 (182161)
- 29 gonadorelin/ (37580)
- 30 (pubert* adj3 block*).ti,ab. (142)
- 31 ((gonadotrophin or gonadotropin) and releasing).ti,ab. (21450)
- 32 (GnRH adj2 analog*).ti,ab. (4013)
- 33 GnRH*.ti,ab. (29862)
- 34 "GnRH agonist*".ti,ab. (6719)
- 35 exp gonadorelin agonist/ or gonadorelin derivative/ or gonadorelin acetate/ (23304)
- 36 Triptorelin/ (5427)
- 37 triptorelin.ti,ab. (1182)
- 38 arvekap.ti,ab. (3)
- 39 ("AY 25650" or AY25650).ti,ab. (1)
- 40 ("BIM 21003" or BIM21003).ti,ab. (0)
- 41 ("BN 52014" or BN52014).ti,ab. (0)
- 42 ("CL 118532" or CL118532).ti,ab. (0)
- 43 Debio.ti,ab. (185)
- 44 diphereline.ti,ab. (51)
- 45 moapar.ti,ab. (0)
- 46 pamorelin.ti,ab. (0)
- 47 trelstar.ti,ab. (5)
- 48 triptodur.ti,ab. (1)
- 49 ("WY 42422" or WY42422).ti,ab. (0)
- 50 ("WY 42462" or WY42462).ti,ab. (0)
- 51 gonapeptyl.ti,ab. (10)
- 52 decapeptyl.ti,ab. (307)
- 53 salvacyl.ti,ab. (1)
- 54 buserelin acetate/ or buserelin/ (5164)
- 55 buserelin.ti,ab. (1604)
- 56 bigonist.ti,ab. (1)
- 57 ("hoe 766" or hoe-766 or hoe766).ti,ab. (89)
- 58 profact.ti,ab. (4)
- 59 receptal.ti,ab. (37)
- 60 suprecur.ti,ab. (8)
- 61 suprefact.ti,ab. (30)
- 62 tiloryth.ti,ab. (0)
- 63 histrelin/ (446)
- 64 histrelin.ti,ab. (107)
- 65 "LHRH-hydrogel implant".ti,ab. (1)
- 66 ("RL 0903" or RL0903).ti,ab. (1)
- 67 ("SPD 424" or SPD424).ti,ab. (1)
- 68 goserelin.ti,ab. (1487)
- 69 Goserelin/ (7128)
- 70 ("ici 118630" or ici118630).ti,ab. (49)
- 71 ("ZD-9393" or ZD9393).ti,ab. (0)

```
72
     zoladex.ti,ab. (501)
73
     leuprorelin/ (11312)
74
     leuprorelin.ti,ab. (727)
75
     carcinil.ti,ab. (0)
76
     enanton*.ti,ab. (38)
77
     ginecrin.ti,ab. (1)
78
     leuplin.ti,ab. (26)
79
     leuprolide.ti,ab. (2788)
80
     lucrin.ti,ab. (47)
81
     lupron.ti,ab. (361)
82
     provren.ti,ab. (0)
83
     procrin.ti,ab. (11)
84
     ("tap 144" or tap144).ti,ab. (63)
85
     (a-43818 or a43818).ti,ab. (3)
86
     Trenantone.ti,ab. (7)
87
     staladex.ti,ab. (0)
88
     prostap.ti,ab. (11)
89
     nafarelin acetate/ or nafarelin/ (1441)
90
     nafarelin.ti,ab. (324)
91
     ("76932-56-4" or "76932564").ti,ab. (0)
92
     ("76932-60-0" or "76932600").ti,ab. (0)
93
     ("86220-42-0" or "86220420").ti,ab. (0)
94
     ("rs 94991 298" or rs94991298).ti,ab. (0)
95
     synarel.ti,ab. (28)
96
     deslorelin/ (452)
97
     deslorelin.ti,ab. (324)
98
     gonadorelin.ti,ab. (338)
99
     ("33515-09-2" or "33515092").ti,ab. (0)
100
       ("51952-41-1" or "51952411").ti,ab. (0)
101
       ("52699-48-6" or "52699486").ti,ab. (0)
102
       cetrorelix/ (2278)
103
       cetrorelix.ti,ab. (717)
104
       cetrotide.ti,ab. (113)
105
       ("NS 75A" or NS75A).ti,ab. (0)
106
       ("NS 75B" or NS75B).ti,ab. (0)
107
       ("SB 075" or SB075).ti,ab. (1)
108
       ("SB 75" or SB75).ti,ab. (76)
109
       gonadoliberin.ti,ab. (152)
110
       kryptocur.ti,ab. (6)
111
       cetrorelix.ti,ab. (717)
112
       cetrotide.ti,ab. (113)
113
       antagon.ti,ab. (32)
114
       ganirelix/ (1284)
115
       ganirelix.ti,ab. (293)
116
       ("ORG 37462" or ORG37462).ti,ab. (4)
117
       orgalutran/ (1284)
118
       orgalutran.ti,ab. (68)
119
       ("RS 26306" or RS26306).ti,ab. (6)
```

- 120 ("AY 24031" or AY24031).ti,ab. (0)
- 121 factrel.ti,ab. (14)
- 122 fertagyl.ti,ab. (20)
- 123 lutrelef.ti,ab. (7)
- 124 lutrepulse.ti,ab. (6)
- 125 relefact.ti,ab. (10)
- 126 fertiral.ti,ab. (0)
- 127 (hoe471 or "hoe 471").ti,ab. (4)
- 128 relisorm.ti,ab. (6)
- 129 cystorelin.ti,ab. (26)
- 130 dirigestran.ti,ab. (5)
- 131 or/29-130 (80790)
- 132 28 and 131 (988)
- 133 limit 132 to english language (940)
- 134 133 not (letter or editorial).pt. (924)

135 134 not (conference abstract or conference paper or conference proceeding or "conference review").pt. (683)

- 136 nonhuman/ not (human/ and nonhuman/) (4649157)
- 137 135 not 136 (506)
- 138 limit 137 to yr="2000 -Current" (420)
- 139 elsevier.cr. (25912990)
- 140 138 and 139 (372)
- 141 remove duplicates from 140 (367)

Database: Cochrane Library – incorporating Cochrane Database of Systematic Reviews (CDSR); CENTRAL

Platform: Wiley

Version: CDSR – Issue 7 of 12, July 2020

CENTRAL – Issue 7 of 12, July 2020

Search date: 23/7/2020

Number of results retrieved: CDSR – 1; CENTRAL - 8.

- #1 [mh ^"Gender Dysphoria"] 3
- #2 [mh ^"gender identity"] 227
- #3 [mh ^"sexual and gender disorders"] 2
- #4 [mh ^transsexualism] 27
- #5 [mh ^"transgender persons"] 36
- #6 [mh ^"health services for transgender persons"] 0
- #7 [mh "sex reassignment procedures"] 4
- #8 (gender* NEAR/3 (dysphori* or affirm* or incongruen* or identi* or disorder* or confus* or minorit* or queer*)):ti,ab 308

#9 (transgend* or transex* or transsex* or transfem* or transwom* or transma* or transmen* or transperson* or transpeopl*):ti,ab 929

#10 (trans or crossgender* or cross-gender* or crossex* or cross-sex* or genderqueer*):ti,ab 3915

#11 ((sex or gender*) NEAR/3 (reassign* or chang* or transform* or transition*)):ti,ab 493

#12 (male-to-female or m2f or female-to-male or f2m):ti,ab 489

- #13 {or #1-#12} 6142
- #14 [mh infant] or [mh ^"infant health"] or [mh ^"infant welfare"] 27769

#15 (prematur* or pre-matur* or preterm* or pre-term* or infan* or newborn* or new-born* or perinat* or perinat* or neonat* or neo-nat* or baby* or babies or toddler*):ti,ab 69476

- #16 [mh child] or [mh "child behavior"] or [mh ^"child health"] or [mh ^"child welfare"] 42703
- #17 [mh ^minors] 8
- #18 (child* or minor or minors or boy* or girl* or kid or kids or young*):ti,ab 175826
- #19 [mh pediatrics]661
- #20 (pediatric* or paediatric* or peadiatric*):ti,ab 30663
- #21 [mh ^adolescent] or [mh ^"adolescent behavior"] or [mh ^"adolescent health"] 102154
- #22 [mh ^puberty] 295
- #23 (adolescen* or pubescen* or prepubescen* or pre-pubescen* or pubert* or prepubert* or pre-pubert* or teen* or pre-teen* or juvenil* or youth* or under*age*):ti,ab 34139
- #24 [mh ^schools] 1914
- #25 [mh ^"Child Day Care Centers"] or [mh nurseries] or [mh ^"schools, nursery"] 277

#26 (pre-school* or preschool* or kindergar* or daycare or day-care or nurser* or school* or pupil* or student*):ti,ab 54723

#27 (("eight" or "nine" or "ten" or "eleven" or "twelve" or "thirteen" or "fourteen" or "fifteen" or "sixteen" or "seventeen" or "eighteen" or "nineteen") NEAR/2 (year or years or age or ages or aged)):ti,ab 6710

#28(("8" or "9" or "10" or "11" or "12" or "13" or "14" or "15" or "16" or "17" or "18" or "19")NEAR/2 (year or years or age or ages or aged)):ti,ab196881

- #29 {or #14-#28} 469351
- #30 #13 and #29 2146
- #31 (transchild* or transyouth* or transteen* or transadoles* or transgirl* or transboy*):ti,ab
 0

0

0

- #32 #30 or #31 2146
- #33 [mh ^"Gonadotropin-Releasing Hormone"] 1311
- #34 (pubert* NEAR/3 block*):ti,ab1
- #35 ((gonadotrophin or gonadotropin) and releasing):ti,ab 2095
- #36 (GnRH NEAR/2 analog*):ti,ab 493
- #37 GnRH*:ti,ab 3764
- #38 "GnRH agonist*":ti,ab 1399
- #39 [mh ^"Triptorelin Pamoate"] 451
- #40 triptorelin:ti,ab 451
- #41 arvekap:ti,ab 4
- #42 ("AY 25650" or AY25650):ti,ab
- #43 ("BIM 21003" or BIM21003):ti,ab 0

#44 ("BN 52014" or BN52014):ti,ab

- #45 ("CL 118532" or CL118532):ti,ab 0
- #46 Debio:ti,ab 301
- #47 diphereline:ti,ab 25
- #48 moapar:ti,ab 0
- #49 pamorelin:ti,ab
- #50 trelstar:ti,ab 3

5

#51 triptodur:ti,ab 0 #52 ("WY 42422" or WY42422):ti,ab 0 #53 ("WY 42462" or WY42462):ti,ab 0 #54 gonapeptyl:ti,ab 11 #55 135 decapeptyl:ti,ab #56 salvacyl:ti,ab 0 #57 [mh ^Buserelin] 290 #58 Buserelin:ti,ab 339 #59 bigonist:ti,ab 0 #60 ("hoe 766" or hoe-766 or hoe766):ti,ab #61 profact:ti,ab 1 #62 receptal:ti,ab 4 #63 suprecur:ti,ab 0 #64 suprefact:ti,ab 28 #65 tiloryth:ti,ab 0 #66 histrelin:ti,ab 5 #67 0 "LHRH-hydrogel implant":ti,ab #68 ("RL 0903" or RL0903):ti,ab 0 #69 ("SPD 424" or SPD424):ti,ab 0 #70 goserelin:ti,ab 761 #71 [mh ^goserelin] 568 #72 ("ici 118630" or ici118630):ti,ab 7 #73 ("ZD-9393" or ZD9393):ti,ab 1 #74 zoladex:ti,ab 318 #75 leuprorelin:ti,ab 248 #76 carcinil:ti,ab 0 #77 enanton*:ti,ab 21 #78 ginecrin:ti,ab 1 #79 leuplin:ti,ab 7 686 #80 [mh ^Leuprolide] #81 leuprolide:ti,ab696 #82 lucrin:ti.ab 21 #83 lupron:ti,ab 77 #84 provren:ti,ab 0 #85 procrin:ti,ab 2 #86 ("tap 144" or tap144):ti,ab 24 #87 0 (a-43818 or a43818):ti,ab #88 Trenantone:ti.ab 3 #89 staladex:ti,ab 0 #90 prostap:ti,ab 9 #91 [mh ^Nafarelin] 77 #92 nafarelin:ti,ab 114 #93 ("76932-56-4" or "76932564"):ti,ab 0 #94 2 ("76932-60-0" or "76932600"):ti,ab #95 ("86220-42-0" or "86220420"):ti,ab 0 #96 ("rs 94991 298" or rs94991298):ti,ab 0 #97 synarel:ti,ab 10 #98 deslorelin:ti,ab16

11

```
#99
      gonadorelin:ti,ab
                           11
#100 ("33515-09-2" or "33515092"):ti,ab
                                         0
#101 ("51952-41-1" or "51952411"):ti,ab
                                         0
#102 ("52699-48-6" or "52699486"):ti,ab
                                         0
#103 cetrorelix:ti,ab 221
#104 cetrotide:ti,ab 111
#105 ("NS 75A" or NS75A):ti,ab
                                  0
#106 ("NS 75B" or NS75B):ti,ab
                                  0
                                  0
#107 ("SB 075" or SB075):ti,ab
#108 ("SB 75" or SB75):ti,ab
                                  10
#109 gonadoliberin:ti,ab
                           5
#110 kryptocur:ti,ab 0
#111 cetrorelix:ti,ab 221
#112 cetrotide:ti,ab 111
#113 antagon:ti,ab 12
#114 ganirelix:ti,ab 142
#115 ("ORG 37462" or ORG37462):ti,ab 4
#116 orgalutran:ti,ab
                           45
#117 ("RS 26306" or RS26306):ti,ab
                                         0
                                         0
#118 ("AY 24031" or AY24031):ti,ab
#119 factrel:ti,ab
                    1
#120 fertagyl:ti,ab
                    0
#121 lutrelef:ti,ab
                    0
#122 lutrepulse:ti,ab1
#123 relefact:ti,ab
                    1
#124 fertiral:ti,ab
                    0
#125 (hoe471 or "hoe 471"):ti,ab
                                  3
#126 relisorm:ti,ab 0
#127 cystorelin:ti,ab0
#128 dirigestran:ti,ab
                           0
#129 {or #33-#128} 6844
#130 #32 and #129 27
#131 #130 with Cochrane Library publication date Between Jan 2000 and Jul 2020, in
Cochrane Reviews
                    1
#132 #130 27
#133 "conference":pt or (clinicaltrials or trialsearch):so
                                                       492465
#134 #132 not #1339
#135 #134 with Publication Year from 2000 to 2020, in Trials
                                                              8
Database: HTA
Platform: CRD
```

Platform: CRD Version: HTA Search date: 23/7/2020 Number of results retrieved: 26 Search strategy:

- 1 MeSH DESCRIPTOR Gender Dysphoria EXPLODE ALL TREES 0
- 2 MeSH DESCRIPTOR Gender Identity EXPLODE ALL TREES 14

3 MeSH DESCRIPTOR Sexual and Gender Disorders EXPLODE ALL TREES 2

4 MeSH DESCRIPTOR Transsexualism EXPLODE ALL TREES 12

5 MeSH DESCRIPTOR Transgender Persons EXPLODE ALL TREES

6 MeSH DESCRIPTOR Health Services for Transgender Persons EXPLODE ALL TREES 0

7 MeSH DESCRIPTOR Sex Reassignment Procedures EXPLODE ALL TREES

8 ((gender* adj3 (dysphori* or affirm* or incongruen* or identi* or disorder* or confus* or minorit* or queer*))) 28

9 ((transgend* or transex* or transsex* or transfem* or transwom* or transma* or transmen* or transperson* or transpeopl*)) 76

10 ((trans or crossgender* or cross-gender* or crossex* or cross-sex* or genderqueer*)) 83

11 (((sex or gender*) adj3 (reassign* or chang* or transform* or transition*))) 24

- 12 (male-to-female or m2f or female-to-male or f2m) 86
- 13 ((transchild* or transyouth* or transteen* or transadoles* or transgirl* or transboy*))
 0

14 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 262

15 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13) IN HTA 30

*26 results are from 200 onwards. Downloaded as a set to sift for drug terms rather than continuing with search strategy.

Database: APA PsycInfo

Search date: July 2020 (Week 2) Search Strategy:

1 Gender Dysphoria/ (936)

2 Gender Identity/ (8648)

- 3 Transsexualism/ (2825)
- 4 Transgender/ (5257)
- 5 exp Gender Reassignment/ (568)

6 (gender* adj3 (dysphori* or affirm* or incongruen* or identi* or disorder* or confus* or minorit* or queer*)).tw. (15471)

7 (transgend* or transex* or transsex* or transfem* or transwom* or transma* or transmen* or transperson* or transpeopl*).tw. (13028)

8 (trans or crossgender* or cross-gender* or crossex* or cross-sex* or genderqueer*).tw. (7679)

9 ((sex or gender*) adj3 (reassign* or chang* or transform* or transition*)).tw. (5796)

- 10 (male-to-female or m2f or female-to-male or f2m).tw. (63688)
- 11 or/1-10 (99560)

12 exp Infant Development/ (21841)

13 (prematur* or pre-matur* or preterm* or pre-term* or infan* or newborn* or new-born* or perinat* or peri-nat* or neo-nat* or baby* or babies or toddler*).ti,ab,in,jn. (150219)

3

1

14 Child Characteristics/ or exp Child Behavior/ or Child Psychology/ or exp Child Welfare/ or Child Psychiatry/ (23423)

15 (child* or minor or minors or boy* or girl* or kid or kids or young*).ti,ab,in,jn. (984230)

16 (pediatric* or paediatric* or peadiatric*).ti,ab,in,jn. (78962)

17 Adolescent Psychiatry/ or Adolescent Behavior/ or Adolescent Development/ or Adolescent Psychology/ or Adolescent Characteristics/ or Adolescent Health/ (62142)

18 Puberty/ (2753)

19 (adolescen* or pubescen* or prepubescen* or pre-pubescen* or pubert* or prepubert* or pre-pubert* or teen* or pre-teen* or juvenil* or youth* or under*age*).ti,ab,in,jn. (347604)

20 Schools/ or exp elementary school students/ or high school students/ or junior high school students/ or middle school students/ (113053)

21 Child Day Care/ or Nursery Schools/ (2836)

22 (pre-school* or preschool* or kindergar* or daycare or day-care or nurser* or school* or pupil* or student*).ti,ab,jn. (772814)

23 (("eight" or "nine" or "ten" or "eleven" or "twelve" or "thirteen" or "fourteen" or "fifteen" or "sixteen" or "seventeen" or "eighteen" or "nineteen") adj2 (year or years or age or ages or aged)).ti,ab. (21475)

24 (("8" or "9" or "10" or "11" or "12" or "13" or "14" or "15" or "16" or "17" or "18" or "19") adj2 (year or years or age or ages or aged)).ti,ab. (285697)

- 25 or/12-24 (1772959)
- 26 11 and 25 (49612)

(transchild* or transyouth* or transteen* or transadoles* or transgirl* or transboy*).tw.

- 28 26 or 27 (49613)
- 29 exp Gonadotropic Hormones/ (4226)
- 30 (pubert* adj3 block*).ti,ab. (29)
- 31 ((gonadotrophin or gonadotropin) and releasing).ti,ab. (1060)
- 32 (GnRH adj2 analog*).ti,ab. (49)
- 33 GnRH*.ti,ab. (998)
- 34 "GnRH agonist*".ti,ab. (72)
- 35 triptorelin.ti,ab. (25)
- 36 arvekap.ti,ab. (0)
- 37 ("AY 25650" or AY25650).ti,ab. (0)
- 38 ("BIM 21003" or BIM21003).ti,ab. (0)
- 39 ("BN 52014" or BN52014).ti,ab. (0)
- 40 ("CL 118532" or CL118532).ti,ab. (0)
- 41 Debio.ti,ab. (7)
- 42 diphereline.ti,ab. (0)
- 43 moapar.ti,ab. (0)
- 44 pamorelin.ti,ab. (0)
- 45 trelstar.ti,ab. (0)
- 46 triptodur.ti,ab. (0)
- 47 ("WY 42422" or WY42422).ti,ab. (0)
- 48 ("WY 42462" or WY42462).ti,ab. (0)
- 49 gonapeptyl.ti,ab. (0)
- 50 decapeptyl.ti,ab. (3)
- 51 salvacyl.ti,ab. (1)

```
58
      suprefact.ti,ab. (0)
59
      tiloryth.ti,ab. (0)
60
      histrelin.ti,ab. (1)
61
      "LHRH-hydrogel implant".ti,ab. (0)
62
      ("RL 0903" or RL0903).ti,ab. (0)
63
      ("SPD 424" or SPD424).ti,ab. (0)
64
      goserelin.ti,ab. (30)
65
      ("ici 118630" or ici118630).ti,ab. (0)
66
      ("ZD-9393" or ZD9393).ti,ab. (0)
67
      zoladex.ti,ab. (3)
68
      leuprorelin.ti,ab. (12)
69
      carcinil.ti,ab. (0)
70
      enanton*.ti,ab. (1)
71
      ginecrin.ti,ab. (0)
72
      leuplin.ti,ab. (0)
73
      leuprolide.ti,ab. (79)
74
      lucrin.ti,ab. (1)
75
      lupron.ti,ab. (18)
76
      provren.ti,ab. (0)
77
      procrin.ti,ab. (0)
78
      ("tap 144" or tap144).ti,ab. (1)
79
      (a-43818 or a43818).ti,ab. (0)
80
      Trenantone.ti,ab. (0)
81
      staladex.ti,ab. (0)
82
      prostap.ti,ab. (0)
83
      nafarelin.ti,ab. (1)
84
      ("76932-56-4" or "76932564").ti,ab. (0)
85
      ("76932-60-0" or "76932600").ti,ab. (0)
86
      ("86220-42-0" or "86220420").ti,ab. (0)
87
      ("rs 94991 298" or rs94991298).ti,ab. (0)
88
      synarel.ti,ab. (0)
89
      deslorelin.ti,ab. (8)
90
      gonadorelin.ti,ab. (3)
91
      ("33515-09-2" or "33515092").ti,ab. (0)
92
      ("51952-41-1" or "51952411").ti,ab. (0)
93
      ("52699-48-6" or "52699486").ti,ab. (0)
94
      cetrorelix.ti,ab. (9)
95
      cetrotide.ti,ab. (0)
96
      ("NS 75A" or NS75A).ti,ab. (0)
97
      ("NS 75B" or NS75B).ti,ab. (0)
98
      ("SB 075" or SB075).ti,ab. (0)
99
      ("SB 75" or SB75).ti,ab. (1)
```

52

53

54

55

56

57

buserelin.ti,ab. (6)

("hoe 766" or hoe-766 or hoe766).ti,ab. (0)

bigonist.ti,ab. (0)

profact.ti,ab. (0)

receptal.ti,ab. (0)


suprecur.ti,ab. (0)

- 100 gonadoliberin.ti,ab. (1) 101 kryptocur.ti,ab. (0) 102 cetrorelix.ti,ab. (9) 103 cetrotide.ti,ab. (0) 104 antagon.ti,ab. (0) 105 ganirelix.ti,ab. (0) 106 ("ORG 37462" or ORG37462).ti,ab. (0) 107 orgalutran.ti,ab. (0) 108 ("RS 26306" or RS26306).ti,ab. (0) 109 ("AY 24031" or AY24031).ti,ab. (0) 110 factrel.ti,ab. (0) 111 fertagyl.ti,ab. (0) 112 lutrelef.ti,ab. (0) 113 lutrepulse.ti,ab. (0) 114 relefact.ti,ab. (0) 115 fertiral.ti,ab. (0) 116 (hoe471 or "hoe 471").ti,ab. (0) 117 relisorm.ti,ab. (0) 118 cystorelin.ti,ab. (0) 119 dirigestran.ti,ab. (0) 120 or/29-119 (4869) 121 28 and 120 (130)
- 122 limit 121 to english language (120)
- 123 limit 122 to yr="2000 -Current" (93)

Appendix C Evidence selection

The literature searches identified 525 references. These were screened using their titles and abstracts and 25 references were obtained and assessed for relevance. Of these, 9 references are included in the evidence review. The remaining 16 references were excluded and are listed in <u>appendix D</u>.





References submitted with Preliminary Policy Proposal

There is no preliminary policy proposal for this policy.

Appendix D Excluded studies table

Study reference	Reason for exclusion
Achille, C., Taggart, T., Eaton, N.R. et al. (2020)	Intervention – data for
Longitudinal impact of gender-affirming endocrine	GnRH analogues not
intervention on the mental health and well-being of	reported separately from
transgender youths: Preliminary results. International	other interventions
Journal of Pediatric Endocrinology 2020(1): 8	
Bechard, Melanie, Vanderlaan, Doug P, Wood, Hayley et al.	Population – no GnRH
(2017) Psychosocial and Psychological Vulnerability in	analogues at time of study
Adolescents with Gender Dysphoria: A "Proof of Principle"	
Study. Journal of sex & marital therapy 43(7): 678-688	
Chew, Denise, Anderson, Jemma, Williams, Katrina et al.	All primary studies included
(2018) Hormonal Treatment in Young People With Gender	apart from 1 conference
Dysphoria: A Systematic Review. Pediatrics 141(4)	abstract
de Vries, Annelou L C, McGuire, Jenifer K et al. (2014)	Population – relevant
Young adult psychological outcome after puberty	population included in de
suppression and gender reassignment. Pediatrics 134(4):	Vries et al. 2011
696-704	
Ghelani, Rahul, Lim, Cheryl, Brain, Caroline et al. (2020)	Outcomes – not in the
Sudden sex hormone withdrawal and the effects on body	PICO
composition in late pubertal adolescents with gender	
dysphoria. Journal of pediatric endocrinology & metabolism:	
JPEM 33(1): 107-112	

Appendix E Evidence tables

Study details	Population	Interventions	Study outcomes	Appraisal and Funding
Brik T, Vrouenraets L, de Vries	Inclusion criteria were	The study only	Critical outcomes	This study was appraised using the
M, et al. (2020) <u>Trajectories of</u>	adolescents with gender	reports that GnRH	No critical outcomes assessed.	Newcastle-Ottawa tool for cohort
adolescents treated with	dysphoria, according to	analogues were		studies.
gonadotropin-releasing	the DSM-5 criteria, seen	given, no specific	Important outcomes	
hormone analogues for gender	at the single centre and	drug, dose, route, or	Psychosocial impact	Domain 1: Selection
dysphoria. Archives of Sexual	treated with GnRH	frequency of	Not assessed.	1. somewhat representative
Behaviour	analogues between	administration are		2. no-non exposed cohort
https://doi.org/10.1007/s10508-	November 2010 and	reported.	Engagement with health care services	3. secure record
020-01660-8	January 1, 2018.		Not formally assessed but the study	4. yes
		No comparator	reported that out of 214 age and	Domain 2: Comparability
Netherlands	The study excluded	cohort was used in	developmentally appropriate adolescents	1. no comparator
	adolescents without a	the study.	for potential inclusion in the study, 9	Domain 3: Outcome
Retrospective observational	diagnosis of gender		were excluded as they stopped attending	1. record linkage
single-centre study	dysphoria, those who had	Follow-up was at (up	appointments (4.2%).	2. yes
	coexisting problems that	to) 9 years (last		3. complete follow-up
To document trajectories after	interfered with the	follow-up July 2019).	Stopping treatment	
the initiation of GnRH	diagnostic process and/or		Of the 143 adolescents, 9 (6.2%,	Overall quality is assessed as
analogue and explore reasons	might interfere with		1 transfemale and 8 transmales) stopped	poor.
for extended use and	successful treatment (not		taking GnRH analogues after a median	
discontinuation of GnRH	further defined), those		duration of 0.8 years (range 0.1 to 3.0).	Other comments: Physical and
analogues.	adolescents not wanting		Four adolescents (2.8%) discontinued	psychological comorbidity was
	hormones, those with		GnRH analogues although they wanted	poorly reported, concomitant use of
Includes participants seen	ongoing diagnostic		to continue endocrine treatments for	other medicines was not reported.
between November 2010 and	evaluation and those who		gender dysphoria:	
January 1, 2018.	did not attend		• 1 transmale stopped due to increase	Source of funding: not reported.
	appointments.		in mood problems, suicidal thoughts	
	The complete service of the		and confusion attributed to GnRH	
	The sample consisted of		analogues (later had gender-	
	143 adolescents meeting		affirming hormones at an adult	
	the inclusion/exclusion		gender clinic) ¹	
	criteria, 38 transfemales,		• 1 transmale experienced hot flushes,	
	105 transmales, with		increased migraines, had a fear of	
	median ages of 15.0		injections, stress at school and	
	years (range 11.1 to 18.6		unrelated medical issues, and	
	years) and 16.1 years		temporarily discontinued treatment	
	(range 10.1 to 17.9		(after 4 months) ²	

Study details	Population	Interventions	Study outcomes	Appraisal and Funding
	years), respectively at commencement of GnRH analogues. Of the 143 adolescents in the study, 125 (87%, 36 transfemales and 89 transmales) subsequently started treatment with gender-affirming hormones after median 1.0 (range 0.5 to 3.8) years and 0.8 (0.3 to 3.7) years, respectively. Median age at the start of gender-affirming hormones was 16.2 years (range 14.5 to 18.6 years) in transfemales and 17.1 years (range 14.9 to 18.8 years) in transmales. Five adolescents who used GnRH analogues had not started gender- affirming hormones at the time of data collection as they were not yet eligible for this treatment due to age. At the time of data collection, they had used GnRH analogues for a median duration of 2.1 years (range 1.6 to 2.8). Tanner stage was not reported. Six adolescents had been referred to a gender clinic elsewhere for further		 1 transmale experienced mood swings 4 months after commencing GnRH analogues. After 2.2 years he developed unexplained severe nausea and rapid weight loss and due to his general condition discontinued GnRH analogues after 2.4 years³ 1 transmale stopped GnRH analogues as his parents were unable to regularly collect medication from the pharmacy and take him to appointments for the injections⁴ Five adolescents (3.5%) stopped treatment as they no longer wished to continue with gender-affirming treatment. 1 adolescent had been very distressed about breast development at the start of GnRH analogues and later thought that she might want to live as a woman without breasts. She did not want to live as a boy and discontinued GnRH analogues, although dreaded breast development and menstruation. 1 adolescent experienced concurrent psychosocial problems interfering with the exploration of gender identity and did not currently want treatment.⁵ 1 adolescent felt more in between male and female and therefore did not want to continue with GnRH analogues.⁶ 1 adolescent made a social transition while using GnRH analogues and shortly after decided to discontinue treatment.⁷ 	

Study details	Population	Interventions	Study outcomes	Appraisal and Funding
	treatment, including 1 who had prolonged use.		 1 adolescent discontinued after using GnRH analogues as the treatment allowed them to feel who they were.⁸ 	

¹ The adolescent later indicated "I was already fully matured when I started GnRH analogues, menstruations were already suppressed by contraceptives. For me, it had no added value" (transmale, age 19 years).

² The adolescent restarted endocrine treatment (testosterone) 5 months later.

³ The adolescent recovered over the next 2 years and subsequently started lynestrenol and testosterone treatment.

⁴ The adolescent subsequently started lynestrenol to suppress menses, he was not yet eligible for testosterone treatment.

⁵ The adolescent later reflected that "The decision to stop GnRH analogues to my mind was made by the gender team, because they did not think gender dysphoria was the right diagnosis. I do still feel like a man, but for me it is okay to be just me instead of a he or a she, so for now I do not want any further treatment" (adolescent assigned female sex at birth, age 16 years).

⁶ The adolescent stated "At the moment, I feel more like 'I am' instead of 'I am a woman' or 'I am a man'" (adolescent assigned female sex at birth, age 16 years).

⁷ The adolescent stated that "he had fallen in love with a girl and had never had such feelings, which made him question his gender identity. At subsequent visits, he indicated that he was happy living as a man.

⁸ The adolescent stated "After using GnRH analogues for the first time, I could feel who I was without the female hormones, this gave me peace of mind to think about my future. It was an inner feeling that said I am a woman" (adolescent assigned female sex at birth, age 18 years).

Study details	Population	Interventions	Study outcomes	Appraisal and Funding
Costa R, Dunsford M,	Adolescents with gender	Intervention	Critical outcomes	This study was appraised using the
Skagerberg E, et al. (2015)	dysphoria who completed a 6-	101 individuals were	Impact on gender dysphoria	Newcastle-Ottawa tool for cohort
Psychological support, puberty	month diagnostic process using	assessed as being	The Utrecht gender dysphoria scale	studies.
suppression, and psychosocial	DSM-IV-TR criteria for gender	immediately eligible	(UGDS) was used to assess	
functioning in adolescents with	dysphoria (comprising the	for use of GnRH	adolescents' gender dysphoria related	Domain 1: Selection
gender dysphoria. Journal of	gender dysphoria assessment	analogues (no	discomfort. The Cronbach's alpha (α) for	1. somewhat representative
Sexual Medicine 12(11):2206-	and psychological interventions)	specific treatment,	the study was reported as 0.76 to 0.88,	2. drawn from the same
14.	either immediately eligible for	dose or route, or	suggesting good internal consistency.	community as the exposed
	treatment with GnRH analogues	frequency of	UGDS was only reported once, for 160	cohort.
United Kingdom	or delayed eligible for treatment	administration	adolescents (50 sex assigned at birth	3. secure record
	with GnRH analogues (received	reported but all	males and 110 sex assigned at birth	4. no
Prospective longitudinal	psychological support without	received	females). The assessment time point is	Domain 2: Comparability
observational single centre	any physical intervention).	psychological	not reported (baseline or follow-up) and	1. partial comparator
cohort study		support).	the comparison for gender related	Domain 3: Outcome
	No exclusion criteria were		discomfort was between sex assigned at	 independent assessment
Includes participants referred	reported.	Comparison	birth males and sex assigned at birth	(unclear if blinded)
to the service between 2010		The analyses were	females. Sex assigned at birth males	2. yes
and 2014.	The sample consisted of 201	between the	had a mean (±SD) UGDS score of 51.6	3. incomplete follow-up
	adolescents (sex assigned at	immediately eligible	[±9.7] versus sex assigned at birth	
	birth male to female ratio 1:1.6)	and delayed eligible	females score of 56.1 [±4.3], <i>t</i> -test 4.07;	Overall quality is assessed as
	mean (±SD) age 15.52±1.41	(n=100) adolescents,	p<0.001.	poor.
	years) from a sampling frame of			

This document was prepared in October 2020

Study details	Population	Interventions	Study outcomes	Appraisal and Funding
Study details	Population		Study outcomes eligible adolescents and delayed eligible adolescents: • T1, n=201, 60.89 [±12.17] versus 60.29 [±12.81]; <i>t</i> -test 0.34; p=0.73 • T2, n=121, 64.70 [±13.34] versus 62.97 [±14.10]; <i>t</i> -test 0.69; p=0.49 • T3, n=71, 67.40 [±13.93] versus 62.53 [±13.54]; <i>t</i> -test 1.49; p=0.14. All participants There was a statistically significant increase in mean (±SD) CGAS scores at any follow-up time point (T1, T2 or T3) compared with baseline (T0) for the all adolescents group: • T0 (n=201) versus T1 (n=201), 57.73 [±12.27] versus 60.68 [±12.47]; <i>t</i> -test 4.87; p<0.001 • T0 (n=201) versus T2 (n=121), 57.73 [±12.27] versus 63.31 [±14.41]; <i>t</i> -test 3.70; p<0.001 • T0 (n=201) versus T3 (n=71), 57.73 [±12.27] versus 64.93 [±13.85]; <i>t</i> -test 4.11; p<0.001 There was a statistically significant increase in mean (±SD) CGAS scores when comparing the follow-up period T1 to T3 but not for the periods T1 to T2 and T2 to T3, for all adolescents: • T1 (n=201) versus T2 (n=121), 60.68 [±12.47] versus 63.31 [±14.41]; <i>t</i> -test 1.73; p<0.08 • T1 (n=201) versus T3 (n=71), 60.68 [±12.47] versus 64.93 [±13.85], <i>t</i> -test 2.40; p<0.02 • T2 (n=121) versus T3 (n=71), 63.31 [±14.41] versus 64.93 [±13.85], <i>t</i> -test 0.76; p=0.45 There were no statistically significant differences in CGAS scores between sex assigned at birth males and sex	Appraisal and Funding
			assigned at birth males and sex	<u> </u>

Study details	Population	Interventions	Study outcomes	Appraisal and Funding
			 assigned at birth females with gender dysphoria in all the follow-up evaluations (all p>0.1). Delayed eligible and immediately eligible adolescents with gender dysphoria were not statistically significantly different for demographic variables (all p>0.1). Immediately eligible participants There was a statistically significant increase in mean (±SD) CGAS scores at follow-up times T2 and T3 compared with baseline (T0) but not for T0 versus T1, for the immediately eligible adolescents: T0 (n=101) versus T1 (n=101), 58.72 [±11.38] versus 60.89 [±12.17]; <i>t</i>-test 1.31; p=0.19 T0 (n=101) versus T2 (n=60), 58.72 [±11.38] versus 64.70 [±13.34]; <i>t</i>-test 3.02; p=0.003 T0 (n=101) versus T3 (n=35), 58.72 [±11.38] versus 67.40 [±13.93]; <i>t</i>-test 3.66; p<0.001 There was a statistically significant increase in mean (±SD) CGAS scores when comparing the follow-up period T1 to T3 with each other but not for the periods T1 to T2 and T2 to T3, for the immediately eligible adolescents: T1 (n=101) versus T3 (n=35), 60.89 [±12.17] versus 67.40 [±13.93]; <i>t</i>-test 1.85; p=0.07 T1 (n=101) versus T3 (n=35), 60.89 [±12.17] versus 67.40 [±13.93], <i>t</i>-test 2.63; p<0.001 T2 (n=60) versus T3 (n=35), 64.70 [±13.34] versus 67.40 [±13.93], <i>t</i>-test 0.94; p=0.35 The immediately eligible adolescents had a CGAS score which was not 	

Study details	Population	Interventions	Study outcomes	Appraisal and Funding
			statistically significantly different compared to the sample of children/ adolescents without observed psychological /psychiatric symptoms after 12 months of puberty suppression (T3, <i>t</i> =0.01, <i>p</i> =0.99).	

Study details	Population	Interventions	Study outcomes	Appraisal and Funding
de Vries A, Steensma T, Doreleijers T, et al. (2011) <u>Puberty suppression in</u> <u>adolescents with gender</u> <u>identity disorder: a prospective</u> <u>follow-up study</u> . The Journal of Sexual Medicine 8 (8):2276- 83. Netherlands Prospective longitudinal observational single centre before and after study.	The sample size was 70 adolescents receiving GnRH analogues (mean age [±SD] at assessment 13.6±1.8 years) from a sampling frame of 196 consecutive adolescents referred to the service between 2000 and 2008. Inclusion criteria were if they subsequently started gender- affirming hormones between 2003 and 2009 (mean [±SD] age at start of GnRH analogues was 14.75 [±1.92] years) ¹ . No specific exclusion criteria were described. No diagnostic criteria or concomitant treatments were reported. Tanner stage of the included adolescents was not reported.	Intervention 70 adolescents were assessed at baseline (T0) before the start of GnRH analogues (no specific treatment, dose or route of administration reported). Comparison The same 70 adolescents were assessed again at follow-up (T1), shortly before starting gender- affirming hormones. Not all adolescents completed all assessments for all items ² .	 Critical outcomes Impact on gender dysphoria Impact on gender dysphoria was assessed using the Utrecht Gender Dysphoria Scale (UGDS). There was no statistically significant difference in UGDS scores between T0 and T1 (n=41). There was a statistically significant difference between sex assigned at birth males and sex assigned at birth females, with sex assigned at birth females reporting more gender dysphoria, <i>F</i> (<i>df, errdf</i>), <i>P</i>: 15.98 (1,39), p<0.001. Impact on mental health Depressive symptoms were assessed using the Beck Depression Inventory (BDI-II). There was a statistically significant reduction in BDI score between T0 and T1, n=41, 8.31 [±7.12] versus 4.95 [±6.72], <i>F (df, errdf)</i>, <i>P</i>: 9.28 (1,39), p=0.004. There was no statistically significant difference between sex assigned at birth males and sex assigned at birth females, <i>F (df, errdf)</i>, <i>P</i>: 3.85 (1,39), p=0.057. 	 This study was appraised using the Newcastle-Ottawa tool for cohort studies. Domain 1: Selection somewhat representative of children and adolescents who have gender dysphoria no non-exposed cohort no description no Domain 2: Comparability study controls for age, age at start of treatment, IQ, and parental factors Domain 3: Outcome no/unclear complete Overall quality is assessed as poor. Other comments: Physical and psychological comorbidity was not reported, concomitant use of other medicines was not reported.

Study details	Population	Interventions	Study outcomes	Appraisal and Funding
			 Anger and anxiety were assessed using Trait Anger and Anxiety (TPI and STAI, respectively) Scales of the State-Trait Personality Inventory. There was no statistically significant difference in anger (TPI) scale scores between T0 and T1 (n=41). There was a statistically significant difference between sex assigned at birth females and sex assigned at birth females, with sex assigned at birth females reporting increased anger compared with sex assigned at birth males, <i>F</i> (<i>df, errdf</i>), <i>P</i>: 5.70 (1,39), p=0.022. Similarly, there was no statistically significant difference in anxiety (STAI) scale scores between T0 and T1 (n=41). There was a statistically significant difference between sex assigned at birth males and sex assigned at birth males and sex assigned at birth females, with sex assigned at birth males and sex assigned at birth males and sex assigned at birth males and sex assigned at birth females, with sex assigned at birth females, <i>F</i> (<i>df, errdf</i>), <i>P</i>: 16.07 (1,39), p<0.001. 	grant awarded to the first author by the Netherlands Organization for Health Research and Development.
			Important outcomes Impact on body image Impact on body image was assessed using the Body Image Scale to measure body satisfaction (BIS). There was no statistically significant difference between T0 and T1 for any of the 3 BIS scores (primary sex characteristics, secondary sex characteristics or neutral characteristics,	

Study details	Population	Interventions	Study outcomes	Appraisal and Funding
			 n=57). There were statistically significant differences between sex assigned at birth females, with sex assigned at birth females reporting more dissatisfaction, for: primary sexual characteristics, <i>F</i> (<i>df</i>, <i>errdf</i>), <i>P</i>: 4.11 (1,55), p=0.047. secondary sexual characteristics, <i>F</i> (<i>df</i>, <i>errdf</i>), <i>P</i>: 11.57 (1,55), p=0.001. But no statistically significant difference between sex assigned at birth males and sex assigned at birth females was found for neutral characteristics. However, there was a significant interaction effect between sex assigned at birth sex and the changes of gender dysphoria between T0 and T1; sex assigned at birth females (<i>ff</i>, <i>errdf</i>), <i>P</i>: 14.59 (1,55), p=0.001) and neutral characteristics, <i>F</i> (<i>df</i>, <i>errdf</i>), <i>P</i>: 15.26 (1,55), p<0.001). 	
			 Psychosocial impact Psychosocial impact was assessed using both the Child Behaviour Checklist (CBCL) and the Youth Self-Report (YSR) to parents and adolescents, respectively. The Children's Global Assessment Scale was also reported. There was a statistically significant decrease in mean (±SD) total, internalising, and externalising³ parental CBCL scores between T0 and T1⁴ for all adolescents (n=54): Total score (T0 – T1) 60.70 [±12.76] versus 54.46 [±11.23], <i>F (df, errdf), P</i>: 26.17 (1,52), p<0.001. 	

Study details	Population	Interventions	Study outcomes	Appraisal and Funding
			 Internalising score (T0 – T1) 61.00 [±12.21] versus 54.56 [±10.22], <i>F</i> (<i>df</i>, <i>errdf</i>), <i>P</i>: 22.93 (1,52), p<0.001. Externalising score (T0 – T1) 58.04 [±12.99] versus 53.81 [±11.86], <i>F</i> (<i>df</i>, <i>errdf</i>), <i>P</i>: 12.04 (1,52), p=0.001. There was no statistically significant difference between sex assigned at birth males and sex assigned at birth females for total and internalising CBCL score but there was a significant difference for the externalising score: Externalising score: Externalising score: Externalising score: Externalising score: Externalising, and externalising³ YSR scores between T0 and T1 for all adolescents (n=54): Total score (T0 – T1) 55.46 [±11.56] versus 50.00 [±10.56], <i>F</i> (<i>df</i>, <i>errdf</i>), <i>P</i>: 16.24 (1,52), p<0.001. Internalising score (T0 – T1) 56.04 [±12.49] versus 49.78 [±11.63], <i>F</i> (<i>df</i>, <i>errdf</i>), <i>P</i>: 15.05 (1,52), p<0.001. Externalising score (T0 – T1) 53.30 [±11.87] versus 49.98 [±9.35], <i>F</i> (<i>df</i>, <i>errdf</i>), <i>P</i>: 7.26 (1,52), p=0.009. There was no statistically significant difference between sex assigned at birth males and sex assigned at birth females for total and internalising YSR score but there was a significant difference for the externalising score: Externalising score: Exte	

Study details	Population	Interventions	Study outcomes	Appraisal and Funding
			(1,39), p=0.005. There was a statistically	
			significant difference between sex	
			assigned at birth males and sex assigned	
			at birth females, with sex assigned at birth	
			females reporting lower score for global	
			functioning compared with sex assigned	
			at birth males, <i>F</i> (<i>df, errdf</i>), <i>P</i> : 5.77 (1,52),	
			p=0.021.	
			The proportion of adolescents scoring in	
			the clinical range significantly decreased	
			between T0 and T1, on the CBCL total	
			problem scale (44.4% versus 22.2%, X^{2} [1]	
			= 6.00, $p=0.001$), and the internalising	
			scale (29.6% versus 11.1%, X^2 [1] = 5.71,	
			p=0.017) of the YSR.	

¹ There were statistically significant mean age [\pm SD] differences between sex assigned at birth males and sex assigned at birth females for age at assessment (13.14 [\pm 1.55] versus 14.10 [\pm 1.99] years, p=0.028), age at start of GnRH analogues (14.25 [\pm 1.79] versus 15.21 [\pm 1.95] years, p=0.036) and age at the start of gender-affirming hormones (16.24 [\pm 1.21] versus 16.99 [\pm 1.09] years, p=0.008). No statistically significant differences were seen for other baseline characteristics, time between GnRH analogue and gender-affirming hormones, full scale IQ, parental marital status, education, and sexual attraction to own, other or both sexes.

² Independent t-tests between mean scores on the CBCL, YSR, BDI, TPI, STAI, CGAS, UGS, and BIS of adolescents who completed both assessments and mean scores of adolescents who completed only one of the assessments revealed no significant differences on all used measures, at neither T0 or at T1.

³ The CBCL/YSR has 2 components: Internalising score which sums the anxious/depressed, withdrawn-depressed, and somatic complaints scores; externalising score which sums rule-breaking and aggressive behaviour. The total problems score is the sum of the scores of all the problem items. The YSR is a child self-report version of the CBCL.

⁴ A repeated measures ANOVA (analysis of variance) was used.

Study details	Population	Interventions	Study outcomes	Appraisal and Funding
Joseph T, Ting J, Butler G. (2019)	Adolescents (12 to 14 years)	Treatment with a	Critical outcomes	This study was appraised using
The effect of GnRH analogue	with gender dysphoria (no	GnRH analogue for	No critical outcomes assessed.	the Newcastle-Ottawa quality
treatment on bone mineral density	diagnostic criteria described),	at least 1 year or		assessment checklist for cohort
in young adolescents with gender	n=70.	ongoing until they	Important outcomes	studies.
dysphoria: findings from a large	including 31 transfemales and	reached 16 years.	Bone density: lumbar ¹	
national cohort. Journal of pediatric endocrinology & metabolism 32(10): 1077-1081 United Kingdom	39 transmales. All had been seen and assessed by a Gender Identity Development Service multi- disciplinary psychosocial health team for at least 4 assessments over a minimum of 6 months. All participants had entered puberty	No specific treatment, dose or route of administration reported. No concomitant treatments were reported.	Lumbar spine bone mineral apparent density (BMAD) ² 0 to 1 year Transfemales (mean [±SD]): 0.235 (0.030) g/cm3 at baseline, 0.233 g/cm3 (0.029) at 1 year (p=0.459); z-score 0.859 (0.154) at baseline, -0.228 (1.027) at 1 year (p=0.000) Transmales (mean [±SD]):	 Domain 1: Selection 1. Somewhat representative of children and adolescents who have gender dysphoria 2. Not applicable 3. Via routine clinical records 4. No

This document was prepared in October 2020

Page 86 of 131

Retrospective longitudinal observational single centre studyand all but 2 of the transmales were postmenarchal.To investigate whether there is any significant loss of bone mineral density (BMD) and bone mineral apparent density (BMAD)and all but 2 of the transmales were postmenarchal.To investigate whether there is any significant loss of bone mineral apparent density (BMAD)and all but 2 of the transmales were postmenarchal.	No comparator.	0.196 (0.035) g/cm3 at baseline, 0.201 (0.033) g/cm3 at 1 year (p=0.074); z-score -0.186 (1.230) at baseline, -0.541 (1.396) at 1 year (p=0.006) Lumbar spine BMAD 0 to 2 years Transfemales (mean [±SD]): 0.240 (0.027) g/cm3 at baseline, 0.240 (0.030) g/cm3 at 2 years (p=0.865); z-score 0.486 (0.809) at baseline, -0.279	 Domain 2: Comparability 1. No control group Domain 3: Outcome 1. Via routine clinical records 2. Yes 3. No statement
for up to 3 years of GnRH analogues. To investigate whether there was a significant drop after 1 year of treatment following abrupt withdrawal. 2011 to 2016		(0.930) at 2 years (p=0.000) Transmales (mean [\pm SD]): 0.195 (0.058) g/cm3 at baseline, 0.198 (0.055) at 2 years (p=0.433); z-score -0.361 (1.439) at baseline, -0.913 (1.318) at 2 years (p=0.001) Lumbar spine bone mineral density (BMD) 0 to 1 year Transfemales (mean [\pm SD]): 0.860 (0.154) kg/m2 at baseline, 0.859 (0.129) kg/m2 at 1 year (p=0.962); z-score -0.016 (1.106) at baseline, -0.461 (1.121) at 1 year (p=0.003) Transmales (mean [\pm SD]): 0.694 (0.149) kg/m2 at baseline, 0.718 (0.124) kg/m2 at 1 year (p=0.006); z-score -0.395 (1.428) at baseline, -1.276 (1.410) at 1 year (p=0.000) Lumbar spine BMD 0 to 2 years Transfemales (mean [\pm SD]): 0.867 (0.141) kg/m2 at baseline, 0.878 (0.130) kg/m2 at 2 years (p=0.395); z-score 0.130 (0.972) at baseline, -0.890 (1.075) at 2 years (p=0.000) Transmales (mean [\pm SD]): 0.695 (0.220) kg/m2 at 2 years (p=0.058); z-score -0.715 (1.406) at baseline, -2.000 (1.384) at 2 years (p=0.000) Bone density: femoral	Overall quality is assessed as poor. Other comments: although the evidence is of poor quality, the results suggest a possible association between GnRH analogues and BMAD. However, the results are not reliable and could be due to bias or chance. Further details of how the sample was drawn are not reported. No concomitant treatments were reported. Source of funding: None disclosed

Study details	Population	Interventions	Study outcomes	Appraisal and Funding
			Femoral neck (hip) BMD 0 to 1 year Transfemales (mean [±SD]): 0.894 (0.118) kg/m2 at baseline, 0.905	
			(0.104) kg/m2 at 1 year (p=0.571); z-score 0.157 (0.905) at baseline, -0.340 (0.816) at 1 year (p=0.002)	
			Transmales (mean [±SD]): 0.772 (0.137) kg/m2 at baseline, 0.785 (0.120) kg/m2 at 1 year (p=0.797);	
			z-score -0.863 (1.215) at baseline, -1.440 (1.075) at 1 year (p=0.000) Femoral neck (hip) BMD 0 to 2 years	
			Transfemales (mean [±SD]): 0.920 (0.116) kg/m2 at baseline, 0.910 (0.125) kg/m2 at 2 years (p=0.402);	
			z-score 0.450 (0.781) at baseline, −0.600 (1.059) at 2 years (p=0.002) Transmales (mean [±SD]):	
			0.766 (0.215) kg/m2 at baseline, 0.773 (0.197) at 2 years (p=0.604);	
			z-score −1.075 (1.145) at baseline, −1.779 (0.816) at 2 years (p=0.001)	

¹Lumbar spine (L1-L4) BMD was measured by yearly dual energy X-ray absorptiometry (DXA) scans at baseline (n=70), 1 year (n=70), and 2 years (n=31). ²BMAD is a size adjusted value of BMD incorporating body size measurements using UK norms in growing adolescents. Reported as g/cm3 and z-scores. Hip BMAD z-scores were not calculated as there were no available reference ranges.

Study details	Population	Interventions	Study outcomes	Appraisal and Funding
Khatchadourian K, Shazhan A,	27 young people with gender	Intervention	Critical Outcomes	This study was appraised using
Metzger D. (2014) <u>Clinical</u>	dysphoria who started GnRH	84 young people with	No critical outcomes assessed.	the Newcastle-Ottawa tool for
management of youth with	analogues (at mean age [±SD]	gender dysphoria		cohort studies.
gender dysphoria in	14.7±1.9 years) out of 84 young	were included. For	Important outcomes	
Vancouver. The Journal of	people seen at the unit between	GnRH analogues no	Stopping treatment	Domain 1: Selection
Pediatrics 164 (4): 906-11.	1998 and 2011.	specific treatment,	The authors report that of 15 transmales	1. not reported
	Note: the transmale and	dose or route of	taking GnRH analogues:	2. no non-exposed cohort
Canada	transfemale subgroups reported	administration	 14 transitioned to testosterone 	3. secure record
	in the paper is discrepant, 15	reported.	treatment during the observation	4. no
Retrospective observational	transmales and 11 transfemales	Comparison	period	Domain 2: Comparability
chart review single centre	(n=26) reported in the outcomes	No comparator.	• 7 continued taking GnRH analogues	1. not applicable
study	section rather than the n=27		after starting testosterone	Domain 3: Outcome

This document was prepared in October 2020

Page 88 of 131

Study details	Population	Interventions	Study outcomes	Appraisal and Funding
	stated in the paper; complete outcome reporting is also incomplete for the transfemale group. Inclusion criteria were at least Tanner stage 2 pubertal development, previous assessment by a mental health professional and a confirmed diagnostic criteria not specified). No exclusion criteria are specified.		 7 discontinued GnRH analogues after a median of 3.0 years (range 0.2 to 9.2 years), of which: 5 discontinued after hysterectomy and salpingo-oophorectomy 1 discontinued after 2.2 years (transitioned to gender-affirming hormone) 1 discontinued after <2 months due to mood and emotional lability The authors report that of 11 transfemales taking GnRH analogues: 5 received oestrogen treatment during the observation period 4 continued taking GnRH analogues during oestrogen treatment 1 discontinued GnRH analogues during oestrogen treatment (no reason reported) 1 stopped GnRH analogues after a few months due to emotional lability 1 stopped GnRH analogues before oestrogen treatment (the following year delayed due to heavy smoking) 1 discontinued GnRH analogues after a few months due to choosing not to pursue transition Safety Of the 27 patients treated with GnRH analogues: 1 transmale participant developed sterile abscesses; they were switched from leuprolide acetate to triptorelin, and this was well tolerated. 1 transmale participant developed leg pains and headaches on GnRH 	 record linkage yes in complete missing data Overall quality is assessed as poor. Other comments: mental health comorbidity was reported for all participants but not for the GnRH analogue cohort separately. Concomitant use of other medicines was not reported. Source of funding: No source of funding identified.
			analogues, which eventually resolved without treatment.	

Study details	Population	Interventions	Study outcomes	Appraisal and Funding
			 1 participant gained 19 kg within 9 months of initiating GnRH analogues, although their body mass index was >85 percentile before GnRH analogues. 	

Study details	Population	Interventions	Study outcomes	Appraisal and Funding
Klink D, Caris M, Heijboer A et al. (2015) <u>Bone mass in young</u> <u>adulthood following gonadotropin- releasing hormone analog</u> <u>treatment and cross-sex hormone</u> <u>treatment in adolescents with</u> <u>gender dysphoria</u> . The Journal of clinical endocrinology and metabolism 100(2): e270-5 Netherlands Retrospective longitudinal observational single centre study To assess BMD development during GnRH analogues and at age 22 years in adolescents with gender dysphoria who started treatment for gender dysphoria during adolescence. 1998 to 2012	34 adolescents (mean age ±SD 14.9±1.9 for transfemales and 15.0±2.0 for transmales at start of GnRH analogues). Participants were included if they met DSM-IV-TR criteria for gender identity disorder of adolescence and had been treated with GnRH analogues and gender-affirming hormones during their pubertal years. No concomitant treatments were reported.	The intervention was GnRH analogue monotherapy (triptorelin pamoate 3.75 mg subcutaneously every 4 weeks) followed by gender- affirming hormones from 16 years with discontinuation of GnRH analogue after gonadectomy. Median duration of GnRH analogue monotherapy in transfemales was 1.3 years (range, 0.5 to 3.8 years), and in transmales was 1.5 years (range, 0.25 to 5.2 years).	Critical outcomes No critical outcomes assessed. Important outcomes Bone density: lumbar Lumbar spine bone mineral apparent density (BMAD) ¹ Change from starting GnRH analogue (mean age 14.9±1.9) to starting gender- affirming hormones (mean age 16.6±1.4) in transfemales (mean [±SD]): GnRH analogue: 0.22 (0.03) g/cm3, gender-affirming hormones: 0.22 (0.02) g/cm3 (NS); z-score GnRH analogue: −0.44 (1.10), gender-affirming hormones: −0.90 (0.80) (p=NS) Change from starting GnRH analogue (mean age 15.0±2.0) to starting gender- affirming hormones (mean age 16.4±2.3) in transmales (mean [±SD]: GnRH analogue: 0.25 (0.03) g/cm3, gender-affirming hormones: 0.24 (0.02) g/cm3 (NS); z-score GnRH analogue: 0.28 (0.90), gender-affirming hormones: −0.50 (0.81) (p=0.004) Lumbar spine bone mineral density (BMD) ¹ Change from starting GnRH analogue (mean age 14.9±1.9) to starting gender- affirming hormones (mean age	This study was appraised using the Newcastle-Ottawa quality assessment checklist for cohort studies. Domain 1: Selection 1. somewhat representative of children and adolescents who have gender dysphoria 2. not applicable 3. via routine clinical records 4. no Domain 2: Comparability 1. no control group Domain 3: Outcome 1. via routine clinical records 2. yes 3. follow-up rate variable across timepoints and no description of those lost Overall quality is assessed as poor . Other comments: Within person comparison. Small numbers of participants in each subgroup. No concomitant treatments or comorbidities were reported. Source of funding: None disclosed

Page 90 of 131

Study details	Population	Interventions	Study outcomes	Appraisal and Funding
			16.6±1.4) in transfemales (mean [±SD]): GnRH analogue: 0.84 (0.13) g/m2, gender-affirming hormones: 0.84 (0.11) g/m2 (NS); z-score GnRH analogue: -0.77 (0.89), gender-affirming hormones: -1.01 (0.98) (NS) Change from starting GnRH analogue (mean age 15.0±2.0) to starting gender- affirming hormones (mean age 16.4±2.3) in transmales (mean [±SD]): GnRH analogue: 0.95 (0.12) g/m2, gender-affirming hormones: 0.91 (0.10) g/m2 (p=0.006); z-score GnRH analogue: 0.17 (1.18), gender-affirming hormones: -0.72 (0.99) (p<0.001)	
			Bone density; femoral Femoral area BMAD ¹ Change from starting GnRH analogue (mean age 14.9±1.9) to starting gender- affirming hormones (mean age 16.6±1.4) in transfemales (mean [±SD]), GnRH analogue: 0.28 (0.04) g/cm3, gender-affirming hormones: 0.26 (0.04) g/cm3 (NS); z-score GnRH analogue: -0.93 (1.22), gender-affirming hormones: -1.57 (1.74) (p=NS) Change from starting GnRH analogue (mean age 15.0±2.0) to starting gender- affirming hormones (mean age 16.4±2.3) in transmales (mean [±SD]), GnRH analogue: 0.32 (0.04) g/cm3, gender-affirming hormones: 0.31 (0.04) (NS); z-score GnRH analogue: 0.01 (0.70), gender-affirming hormones: -0.28 (0.74) (NS)	

Study details	Population	Interventions	Study outcomes	Appraisal and Funding
			Femoral area BMD ¹	
			Change from starting GnRH analogue	
			(mean age 14.9±1.9) to starting gender-	
			affirming hormones (mean age	
			16.6±1.4) in transfemales (mean [±SD]),	
			GnRH analogue: 0.88 (0.12) g/m2,	
			gender-affirming hormones: 0.87 (0.08) (NS);	
			z-score GnRH analogue: −0.66 (0.77),	
			gender-affirming hormones: -0.95 (0.63)	
			(NS)	
			Change from starting GnRH analogue	
			(mean age 15.0±2.0) to starting gender-	
			affirming hormones (mean age	
			16.4±2.3) in transmales (mean [±SD]),	
			GnRH analogue: 0.92 (0.10) g/m2,	
			gender-affirming hormones: 0.88 (0.09)	
			(p=0.005);	
			z-score GnRH analogue: 0.36 (0.88),	
			gender-affirming hormones: $-0.35(0.79)$	
			(p=0.001)	

¹BMD and BMAD of the lumbar spine and femoral region (nondominant side) measured by DXA scans at start of GnRH analogues, (n=32), start of gender-affirming hormones (n=34), and at 22 years (n=34).

Study details	Population	Interventions	Study outcomes	Appraisal and Funding
Schagen SEE, Cohen- Kettenis PT, Delemarre- van de Waal HA et al. (2016) <u>Efficacy and Safety of Gonadotropin-Releasing</u> <u>Hormone Agonist</u> <u>Treatment to Suppress</u> <u>Puberty in Gender</u> <u>Dysphoric Adolescents</u> . The journal of sexual medicine 13(7): 1125-32	Adolescents with gender dysphoria (n=116), median age (range) 13.6 years (11.6 to 17.9) in transfemales and 14.2 years (11.1 to 18.6) in transmales during first year of GnRH analogues. Participants were included if they met DSM-IV-TR criteria for gender dysphoria, had lifelong extreme gender dysphoria, were psychologically stable and were living in a supportive environment. No concomitant treatments were	GnRH analogue monotherapy (triptorelin pamoate 3.75 mg at 0, 2 and 4 weeks followed by injections every 4 weeks, route of administration not described) for at least 3 months.	Critical outcomes No critical outcomes assessed. Important outcomes Other safety outcomes: liver function Glutamyl transferase was not elevated at baseline or during treatment in any subject. Mild elevations of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) above the reference range were present at baseline but were not more prevalent during treatment than at baseline. Glutamyl transferase, AST, and ALT	This study was appraised using the Newcastle-Ottawa quality assessment checklist for cohort studies. Domain 1: Selection 1. somewhat representative of children and adolescents who have gender dysphoria 2. not applicable 3. via routine clinical records 4. no Domain 2: Comparability 1. no control group

This document was prepared in October 2020

Page 92 of 131

Study details	Population	Interventions	Study outcomes	Appraisal and Funding
Netherlands Prospective longitudinal study	reported.		levels did not significantly change from baseline to 12 months of treatment. No values or statistical analyses were reported.	Domain 3: Outcome 1. via routine clinical records 2. yes 3. no statement
To describe the changes in Tanner stage, testicular volume, gonadotropins, and sex steroids during GnRH analogues of adolescents with gender dysphoria to evaluate the efficacy. To report on liver enzymes, renal function and changes in body composition.			Other safety outcomes: kidney function Change in serum creatinine between 0 and 1 year Transfemales (mean [±SD]): 70 (12) micromol/I at baseline, 66 (13) micromol/I at 1 year (p=0.20) Transmales (mean [±SD]): 73 (8) micromol/I at baseline, 68 (13) micromol/I at 1 year (p=0.01)	Overall quality is assessed as poor. Other comments: Within person comparison. No concomitant treatments or comorbidities were reported. Source of funding: Ferring pharmaceuticals (triptorelin manufacturer)
1998 to 2009				

Study details	Population	Interventions	Study outcomes	Appraisal and Funding
Staphorsius A,	The inclusion criteria were diagnosed	Intervention	Critical Outcomes	This study was appraised using
Baudewijntje P, Kreukels	with Gender Identity Disorder	GnRH analogues	No critical outcomes assessed.	the Newcastle-Ottawa tool for
P, et al. (2015) <u>Puberty</u>	according to the DSM-IV-TR and at	(triptorelin pamoate		cohort studies.
suppression and executive	least 12 years old and Tanner stage	3.75 mg every 4	Important outcomes	
functioning: an fMRI-study	of at least B2 or G2 to G3 with	weeks	Psychosocial impact	Domain 1: Selection domain
in adolescents with gender	measurable oestradiol and	subcutaneously or	The Child Behaviour Checklist (CBCL)	1. somewhat representative of
<u>dysphoria.</u>	testosterone levels in girls and boys,	intramuscularly).	was used to assess psychosocial impact.	children and adolescents
Psychoneuroendocrinology	respectively.		The CBCL was administered once during	who have gender dysphoria
565:190-9.		Comparison	the study. The reported outcomes for	2. drawn from the same
	For all group's exclusion criteria were	The comparison was	each group were (n, mean [±SD]):	community as the exposed
Netherlands	an insufficient command of the Dutch	between	 Transfemales (all, n=18) 57.8 	cohort
rienenands	language (how assessed not	adolescents with	[±9.2]	3. via routine clinical records
	reported), unadjusted endocrine	gender dysphoria	 Transfemales on GnRH 	4. no
Cross-sectional (single	disorders, neurological or psychiatric	receiving GnRH	analogues (n=8) 57.4 [±9.8]	Domain 2: Comparability
time point) assessment	disorders that could lead to deviant	analogues and those	 Transfemales without GnRH 	 study controls for age and
single centre study	test results (details not reported) use	without GnRH	analogues (n=10) 58.2 [±9.3]	diagnosis

This document was prepared in October 2020

Page 93 of 131

Study details F	Population	Interventions	Study outcomes	Appraisal and Funding
A P fr C C C C C C C C C C C C C C C C C C	 Transfemales on GnRH analogues 4.1 [±1.0] Transfemales without GnRH analogues 3.8 [±1.1] Transmales 4.5 [±0.9] 	analogues.	 Transmales (all, n=22) 60.4 [±10.2] Transmales on GnRH analogues (n=12) 57.5 [±9.4] Transmales without GnRH analogues (n=10) 63.9 [±10.5] The analysis of the CBCL data is not discussed, and statistical analysis is unclear. Cognitive development or functioning IQ¹ Transfemales (mean [±SD]) on GnRH analogues: 94.0 (10.3) Transfemales (mean [±SD]) without GnRH analogues: 109.4 (21.2) Transmales (mean [±SD]) on GnRH analogues: 95.8 (15.6) Transmales (mean [±SD]) without GnRH analogues: 98.5 (15.9) Reaction time² Transfemales (mean [±SD]) on GnRH analogues: 10.9 (4.1) Transfemales (mean [±SD]) on GnRH analogues: 9.9 (3.1) Transmales (mean [±SD]) on GnRH analogues: 9.9 (3.1) Transmales (mean [±SD]) on GnRH analogues: 10.0 (2.0) Accuracy³ Transfemales (mean [±SD]) on GnRH analogues: 73.9 (9.1) Transfemales (mean [±SD]) on GnRH analogues: 73.9 (9.1) Transfemales (mean [±SD]) on GnRH analogues: 83.4 (9.5) Transmales (mean [±SD]) on GnRH analogues: 85.7 (10.5) Transmales (mean [±SD]) on GnRH analogues: 85.7 (10.5) 	 Domain 3: Outcome via clinical assessment yes unclear Overall quality is assessed as poor. Other comments: Physical and psychological comorbidity was not reported, concomitant use of other medicines was not reported. Source of funding: This work was supported by an educational grant from the pharmaceutical firm Ferring BV, and by a VICI grant (453-08-003) from the Dutch Science Foundation. The authors state that funding sources did not play a role in any component of this study.

This document was prepared in October 2020

Page 94 of 131

Study details	Population	Interventions	Study outcomes	Appraisal and Funding
			GnRH analogues: 88.8 (9.7)	
¹ Estimated with 4 subscales (arit	i hmetic, vocabulary, picture arrangement, and	l block design) of the Wec	hsler Intelligence Scale for Children, third edition (WISC-III®, Wechsler 1991) or the

Wechsler Adult Intelligence Scale, third edition (WAIS-III®, Wechsler 1997), depending on the participant's age. ² Reaction time in seconds in the Tower of London task ³ Percentage of correct trials in the Tower of London task

Study details	Population	Interventions	Study outcomes	Appraisal and Funding
Vlot, Mariska C, Klink, Daniel T, den Heijer, Martin et al. (2017) Effect of pubertal suppression and cross-sex hormone therapy on bone turnover markers and bone mineral apparent density (BMAD) in transgender adolescents. Bone 95: 11-19 Netherlands Retrospective observational data analysis study To investigate the course of 3 bone turnover markers in relation to bonemineral density, in adolescents with gender dysphoria during GnRH analogue and gender- affirming hormones. 2001 to 2011	Adolescents with gender dysphoria, n=70. Median age (range) 15.1 years (11.7 to 18.6) for transmales and 13.5 years (11.5 to 18.3) for transfemales at start of GnRH analogues. Participants were included if they had a diagnosis of gender dysphoria according to DSM-IV- TR criteria who were treated with GnRH analogues and then gender-affirming hormones. No concomitant treatments were reported. The study categorised participants into a young and old pubertal group, based on their bone age. The young transmales had a bone age of <14 years and the old transmales had a bone age of ≥14 years. The young transfemales group had a bone age of <15 years and the old transfemales group ≥15 years.	GnRH analogues (triptorelin pamoate 3.75 mg every 4 weeks subcutaneously).	Critical outcomes No critical outcomes reported Important outcomes Bone density: lumbar Lumbar spine bone mineral apparent density (BMAD) Change from starting GnRH analogue to starting gender-affirming hormones in transfemales (bone age of <15 years; median [range]), GnRH analogue: 0.21 (0.17 to 0.25) g/cm3, gender-affirming hormones: 0.20 (0.18 to 0.24) g/cm3 (NS); z-score GnRH analogue: -0.20 (-1.82 to 1.18), gender-affirming hormones: -1.52 (-2.36 to 0.42) (p=0.001) Change from starting GnRH analogue to starting gender-affirming hormones in transfemales (bone age of ≥15; median [range]), GnRH analogue: 0.22 (0.18 to 0.25) g/cm3, gender-affirming hormones: 0.22 (0.19 to 0.24) g/cm3 (NS); z-score GnRH analogue: -1.18 (-1.78 to 1.09), gender-affirming hormones: -1.15 (-2.21 to 0.08) (p≤0.1) Change from starting GnRH analogue to starting gender-affirming hormones in transmales (bone age of <15 years; median [range]), GnRH analogue: 0.23 (0.20 to 0.29) g/cm3, gender-affirming	This study was appraised using the Newcastle-Ottawa quality assessment checklist for cohort studies. Domain 1: Selection 1. Somewhat representative of children and adolescents who have gender dysphoria 2. Not applicable 3. Via routine clinical records 4. No Domain 2: Comparability 1. No control group Domain 3: Outcome 1. Via routine clinical records 2. Yes 3. Follow-up rate variable across outcomes and no description of those lost Overall quality is assessed as poor . Other comments: Within person comparison. No concomitant treatments were reported. Source of funding: grant from Abbott diagnostics

	hormones: 0.23 (0.19 to 0.28) g/cm3 (NS); z-score GnRH analogue: -0.05 (-0.78 to 2.94), gender-affirming hormones: -0.84 (-2.20 to 0.87) (p=0.003) Change from starting GnRH analogue to starting gender-affirming hormones in transmales (bone age of \geq 15; median [range]), GnRH analogue: 0.26 (0.21 to 0.29) g/cm3, gender-affirming hormones: 0.24 (0.20 to 0.28) g/cm3 (p \leq 0.01); z-score GnRH analogue: 0.27 (-1.60 to 1.80), gender-affirming hormones: -0.29 (-2.28 to 0.90) (p \leq 0.0001)	
	Bone density; femoral Femoral neck BMAD Change from starting GnRH analogue to starting gender-affirming hormones in transfemales (bone age of <15 years; median [range]), GnRH analogue: 0.29 (0.20 to 0.33) g/cm3, gender-affirming hormones: 0.27 (0.20 to 0.33) g/cm3 (p \leq 0.1); z-score GnRH analogue: -0.71 (-3.35 to 0.37), gender-affirming hormones: -1.32 (-3.39 to 0.21) (p \leq 0.1) Change from starting GnRH analogue to starting gender-affirming hormones in transfemales (bone age of \geq 15; median [range]), GnRH analogue: 0.30 (0.26 to 0.36) g/cm3, gender-affirming hormones: 0.30 (0.26 to 0.34) g/cm3 (NS); z-score GnRH analogue: -0.44 (-1.37 to 0.93), gender-affirming hormones: -0.36 (-1.50 to 0.46) (NS) Change from starting GnRH analogue to starting gender-affirming hormones in transmales (bone age of <15 years;	

Study details	Population	Interventions	Study outcomes	Appraisal and Funding
			GnRH analogue: 0.31 (0.26 to 0.36)	
			g/cm3, gender-affirming hormones: 0.30	
			(0.22 to 0.35) g/cm3 (NS);	
			z-score GnRH analogue: −0.01 (−1.30 to	
			0.91), gender-affirming hormones: -0.37	
			(-2.28 to 0.47) (NS)	
			Change from starting GnRH analogue to	
			starting gender-affirming hormones in	
			transmales (bone age of ≥15; median	
			[range]), GnRH analogue: 0.33 (0.25 to	
			0.39) g/cm3, gender-affirming hormones:	
			0.30 (0.23 to 0.41) g/cm3 (p≤0.01);	
			z-score GnRH analogue: 0.27 (-1.39 to	
			1.32), gender-affirming hormones: -0.27	
			(-1.91 to 1.29) (p=0.002)	

Appendix F Quality appraisal checklists

Newcastle-Ottawa tool for cohort studies

Question	
Domain: Selection	
1. Representativeness of the exposed cohort	Truly representative of the average [describe] in the community
	Somewhat representative of the average [describe] in the community
	Selected group of users e.g. nurses, volunteers
	No description of the derivation of the cohort
2. Selection of the non-exposed cohort	Drawn from the same community as the exposed cohort
	Drawn from a different source
	No description of the derivation of the non- exposed cohort
3. Ascertainment of exposure	Secure record (e.g. surgical records)
	Structured interview
	Written self-report
	No description
4. Demonstration that outcome of interest was not present at start of study	Yes / No
Domain: Comparability	
1. Comparability of cohorts on the basis of the design or analysis	Study controls for [select most important factor] Study controls for any additional factor [this criteria could be modified to indicate specific control for a second important factor]
Domain: Outcome	
1. Assessment of outcome	Independent blind assessment
	Record linkage
	Self-report
	No description
2. Was follow-up long enough for outcomes to occur	Yes [select and adequate follow up period for outcome of interest] No
3. Adequacy of follow up of cohorts	Complete follow up (all subjects accounted for)
	Subjects lost to follow up unlikely to introduce bias (small number lost to follow up [select an adequate %] follow up or description provided of those lost)
	Follow up rate [select an adequate %] and no description of those lost No statement
	ויט זומוכוווכווו

Appendix G Grade profiles

Table 2: Question 1. For children and adolescents with gender dysphoria, what is the clinical effectiveness of treatment with GnRH analogues compared with one or a combination of psychological support, social transitioning to the desired gender or no intervention? – gender dysphoria

		QUALITY			Summary of findings			IMPORTANCE	CERTAINTY
						ents/No of s (n/N%)	Effect		
Study	Risk of bias	Indirectness	Inconsistency	Imprecision	Intervention	Comparator	Result		
mpact on gene	ler dysphoria	a							
	ht Oandan D		1 (a a a live a /h a f			(h = f = +=
			¹ (version(s) not indicate more g	•	-	aseline (befo	ore GnRH analogues) ve	ersus follow-up	(before

Abbreviations: GnRH, gonadotrophin releasing hormone; *P*, P-value; SD, Standard deviation.

1 The UGDS is a validated screening tool for both adolescents and adults to assess gender dysphoria. It consists of 12 items, to be answered on a 1- to 5-point scale, resulting in a sum score between 12 and 60. The higher the UGDS score the greater the gender dysphoria.

2 Downgraded 1 level - the cohort study by de Vries et al. (2011) was assessed as at high risk of bias (poor quality overall; lack of blinding and no control group).

Table 3: Question 1. For children and adolescents with gender dysphoria, what is the clinical effectiveness of treatment with GnRH analogues compared with one or a combination of psychological support, social transitioning to the desired gender or no intervention? – mental health

		QUALITY				Summary	IMPORTANCE CERTAINT	CERTAINTY	
						ents/No of s (n/N%)	Effect		
Study	Risk of bias	Indirectness	Inconsistency	Imprecision	Intervention	Comparator	Result		
Impact on men	tal health								

	QUALITY					Summary	of findings	IMPORTANCE	CERTAINTY
						ents/No of s (n/N%)	Effect		
Study	Risk of bias	Indirectness	Inconsistency	Imprecision	Intervention	Comparator	Result		
Mean±SD Beck (Lower scores	•	• •	ne point at base	line (before G	nRH analogi	ues) versus :	follow-up (just before ge	ender-affirming	hormones).
1 cohort study de Vries et al 2011	Serious limitations ¹	No serious indirectness	Not applicable	Not calculable	N=41	None	Baseline: 8.31±7.12 GnRH analogue: 4.95±6.72 <i>P</i> =0.004	Critical	VERY LOW
indicate benefi	t) Serious	No serious	Not applicable	Not	N=41	None	Baseline: 18.29±5.54	Critical	VERY LOW
1 cohort study de Vries et al 2011	limitations ¹	indirectness		calculable			GnRH analogue: 17.88±5.24 <i>P</i> =0.503		
	• •	Al), time point a	at baseline (befor	re GnRH anal	ogues) versı	ıs follow-up	(just before gender-affi	rming hormone	s, lower
scores indicate									
scores indicate	Serious	No serious	Not applicable	Not	N=41	None	Baseline: 39.43±10.07	Critical	VERY LOW

Abbreviations: GnRH, gonadotrophin releasing hormone; P, P-value; SD, Standard deviation.

1 Downgraded 1 level - the cohort study by de Vries et al. (2011) was assessed as at high risk of bias (poor quality overall; lack of blinding and no control group).

Table 4: Question 1. For children and adolescents with gender dysphoria, what is the clinical effectiveness of treatment with GnRH analogues compared with one or a combination of psychological support, social transitioning to the desired gender or no intervention? – body image

		QUALITY				Summary	of findings	IMPORTA NCE	CERTAINTY	
					No of events/N (n/N		Effect			
Study	Risk of bias	Indirectness	Inconsistency	Imprecision	Intervention Comparator		Result			
Impact on body	y image									
Mean±SD Body	/ Image Scal	e (primary sexu	al characteristic	s), time point	at baseline (b	efore GnRH	analogues) versus follow-	up (just bei	fore gender	
affirming horm	-								Ū	
	Oprious	N	Not englischte	NI-4		News				
1 cohort study	Serious limitations ¹	No serious	Not applicable	Not	N=57	None	Baseline: 4.10±0.56	Important	VERY LOW	
de Vries et al 2011	IIIIIIauons	indirectness		calculable			GnRH analogue: 3.98±0.71 <i>P</i> =0.145			
Mean±SD Body	/ Image Scale	e (secondary se	exual characteris	stics), time po	int at baseline	e (before Gn	RH analogues) versus follo	w-up (just	before	
gender-affirmir	ng hormones	, lower scores	indicate benefit)							
1 askantatushi	Serious	No serious	Not applicable	Not	N=57	None	Baseline: 2.74±0.65	Important	VERY LOW	
1 cohort study de Vries et al	limitations ¹	indirectness		calculable	IN-37	NOTE	GnRH analogue: 2.82±0.68	important	VERTLOW	
2011	miniations	munectness		Calculable			<i>P</i> =0.569			
Mean±SD Body	/ Image Scale	e (neutral chara	cteristics), time	point at base	line (before G	nRH analogi	ues) versus follow-up (just	before gen	der-	
affirming horm	-	•	•		·	U		-		
-	-		•							
1 cohort study	Serious	No serious	Not applicable	Not	N=57	None	Baseline: 2.41±0.63	Important	VERY LOW	
de Vries et al	limitations ¹	indirectness		calculable			GnRH analogue: 2.47±0.56			
2011							<i>P</i> =0.620			

Abbreviations: GnRH, gonadotrophin releasing hormone; *P*, P-value; SD, Standard deviation.

1 Downgraded 1 level - the cohort study by de Vries et al. (2011) was assessed as at high risk of bias (poor quality overall; lack of blinding and no control group).

Table 5: Question 1. For children and adolescents with gender dysphoria, what is the clinical effectiveness of treatment with GnRH analogues compared with one or a combination of psychological support, social transitioning to the desired gender or no intervention? – psychosocial impact

		QUALITY				Summary	of findings	IMPORTA NCE	CERTAINTY	
					No of events/N (n/N		Effect			
Study	Risk of bias	Indirectness	Inconsistency	Imprecision	Intervention	Comparator	Result			
Psychosocial ii	mpact									
Mean [±SD] Chi	ildren's Glob	al Assessmen	t Scale score, at	baseline, higl	ner scores ind	licate benefit)			
1 cohort study Costa et al 2015	Serious limitations ¹	No serious indirectness	No serious inconsistency	Not calculable	n=101 58.72 [±11.38]	n=100 56.63 [±13.14]	<i>P</i> =0.23	Important	VERY LOW	
Mean [±SD] Chi	ildren's Glob	oal Assessmen	t Scale score, at	6 months ² (hi	gher scores i	ndicate bene	fit).			
1 cohort study Costa et al 2015	Serious limitations ¹	No serious indirectness	No serious inconsistency	Not calculable	n=101 60.89 [±12.17]	n=100 60.29 [±12.81]	<i>P</i> =0.73	Important	VERY LOW	
Mean [±SD] Chi	ildren's Glob	oal Assessmen	t Scale score, at	12 months ³ (h	nigher scores	indicate ben	efit).			
1 cohort study Costa et al 2015	Serious limitations ¹	No serious indirectness	No serious inconsistency	Not calculable	n=60 64.70 [±13.34]	n=61 62.97 [±14.10]	P=0.49	Important	VERY LOW	
Mean [±SD] Chi	ildren's Glob	oal Assessmen	t Scale score, at	18 months ⁴ (h	nigher scores	indicate ben	efit).			
1 cohort study Costa et al 2015	Serious limitations ¹	No serious indirectness	No serious inconsistency	Not calculable	n=35 67.40 [±13.93]	n=36 62.53 [±13.54]	<i>P</i> =0.14	Important	VERY LOW	
Mean [±SD] Chi	ildren's Glob	oal Assessmen	t Scale score, pa	articipants at 6	months com	pared to bas	eline (higher scores indic	ate benefit).		
1 cohort study Costa et al 2015	Serious limitations ¹	No serious indirectness	No serious inconsistency	Not calculable	N=101 N=101	None	Baseline: 58.72±11.38 6 months: 60.89±12.17 <i>P=</i> 0.19	Important	VERY LOW	
Mean [±SD] Chi	ildren's Glob	oal Assessmen	t Scale score, pa	articipants at 1	2 months cor	npared to ba	seline (higher scores indi	cate benefit).	
	Serious	No serious	No serious	Not	N=101	None	Baseline: 58.72±11.38	Important	VERY LOW	

		QUALITY				Summary	of findings	IMPORTA NCE	CERTAINTY	
					No of events/N (n/N		Effect			
Study	Risk of bias	Indirectness	Inconsistency	Imprecision	Intervention	Comparator	Result			
Mean [±SD] Chi	ldren's Glob	al Assessmen	t Scale score, pa	rticipants at 1	8 months cor	npared to ba	seline (higher scores indi	cate benefit).	
1 cohort study Costa et al 2015	Serious limitations ¹	No serious indirectness	No serious inconsistency	Not calculable	N=101 N=35	None	Baseline: 58.72±11.38 18 months: 67.40±13.93 <i>P</i> <0.001	Important	VERY LOW	
Mean [±SD] Chi	ldren's Glob	al Assessmen	t Scale score, pa	rticipants at 1	2 months cor	mpared to 6 r	months (higher scores ind	icate benef	it).	
1 cohort study Costa et al 2015	Serious limitations ¹	No serious indirectness	No serious inconsistency	Not calculable	N=101 N=60	None	6 months: 60.89±12.17 12 months: 64.70±13.34 <i>P</i> =0.07	Important	VERY LOW	
Mean [±SD] Chi	ldren's Glob	al Assessmen	t Scale score, pa	rticipants at 1	8 months cor	mpared to 6 r	months (higher scores ind	icate benef	it).	
1 cohort study Costa et al 2015	Serious limitations ¹	No serious indirectness	No serious inconsistency	Not calculable	N=101 N=35	None	6 months: 60.89±12.17 18 months: 67.40±13.93 <i>P</i> <0.001	Important	VERY LOW	
Mean [±SD] Chi	ldren's Glob	al Assessmen	t Scale score, pa	rticipants at 1	8 months cor	npared to 12	months (higher scores in	dicate bene	fit).	
1 cohort study Costa et al 2015	Serious limitations ¹	No serious indirectness	No serious inconsistency	Not calculable	N=60 N=35	None	12 months: 64.70±13.34 18 months: 67.40±13.93 <i>P</i> =0.35	Important	VERY LOW	
Mean [±SD] Chi compared to ba				all participant	ts (including t	hose not trea	ated with GnRH analogues	s) at 6 mont	hs²	
1 cohort study Costa et al 2015	Serious limitations ¹	No serious indirectness	Not applicable	Not calculable	N=201	None	Baseline: 57.73±12.27 6 months: 60.68±12.47 <i>P</i> <0.001	Important	VERY LOW	
Mean [±SD] Chi compared to ba				all participant	ts (including t	hose not trea	ated with GnRH analogues	s) at 12 mon	ths ³	
1 cohort study Costa et al 2015	Serious limitations ¹	No serious indirectness	No serious inconsistency	Not calculable	N=201 N=121	None	Baseline: 57.73±12.27 12 months: 63.31±14.41 <i>P</i> <0.001	Important	VERY LOW	

		QUALITY				Summary	of findings	IMPORTA NCE	CERTAINTY	
					No of events/N (n/N		Effect	NCE		
Study	Risk of bias	Indirectness	Inconsistency	Imprecision	Intervention	Comparator	Result			
				l participants	(including the	ose not treat	ed with GnRH analogues) a	t 18 month	s ⁴	
compared to ba	aseline (high	er scores indic	ate benefit).							
1 cohort study	Serious	No serious	No serious	Not	N=201	None	Baseline: 57.73±12.27	Important	VERY LOW	
Costa et al 2015	limitations ¹	indirectness	inconsistency	calculable	N=71		18 months: 64.93±13.85			
					/		<i>P</i> <0.001	1.10		
				l participants	(including the	ose not treat	ed with GnRH analogues) a	t 12 month	is compared	
to 6 months (hi	gner scores	Indicate benefi	<i>it)</i> .							
4 b - et - t - 	Serious	No serious	No serious	Not	N=201	None	6 months: 60.68±12.47	Important	VERY LOW	
1 cohort study Costa et al 2015	limitations ¹	indirectness	inconsistency	calculable	N=121		12 months: 63.31±14.41			
							<i>P</i> <0.08			
				ll participants	(including the	ose not treat	ed with GnRH analogues) a	t 18 month	s compared	
to 6 months (hi	gher scores	indicate benefi	it).							
	Serious	No serious	No serious	Not	N=201	None	6 months: 60.68±12.47	Important	VERY LOW	
1 cohort study Costa et al 2015	limitations ¹	indirectness	inconsistency	calculable	N=71		18 months: 64.93±13.85			
Costa et al 2015							<i>P</i> <0.02			
Mean±SD Child	lren's Globa	l Assessment S	Scale score, in al	ll participants	(including the	ose not treat	ed with GnRH analogues) a	t 18 month	s compared	
to 12 months (h	nigher score	s indicate bene	fit).							
	Serious	No serious	No serious	Not	N=121	None	12 months: 63.31±14.41	Important	VERY LOW	
1 cohort study Costa et al 2015	limitations ¹	indirectness	inconsistency	calculable	N=71		18 months: 64.93±13.85			
							<i>P</i> <0.45			
				point at base	line (before G	nRH analog	ues) versus follow-up (just	before gen	der-	
affirming horm	ones, higher	r scores indicat	e benefit).							
1 cohort study	Serious	No serious	Not applicable	Not	N=41	None	Baseline: 70.24±10.12	Important	VERY LOW	
de Vries et al	limitations ⁵	indirectness		calculable			GnRH analogue: 73.90±9.63			

		QUALITY				Summary	of findings	IMPORTA	CERTAINTY	
					No of events/N (n/N		Effect	NCE		
Study	Risk of bias	Indirectness	Inconsistency	Imprecision	Intervention	Comparator	Result			
Mean±SD Child hormones, low		•	T) score, time p	oint at baselin	e (before Gnl	RH analogue	s) versus follow-up (just b	efore gende	er-affirming	
1 cohort study de Vries et al 2011	Serious limitations ⁵	No serious indirectness	Not applicable	Not calculable	N=54	None	Baseline: 60.70±12.76 GnRH analogue: 54.46±11.23 <i>P</i> <0.001	Important	VERY LOW	
Mean±SD Child affirming horm		•	• /	e, time point a	t baseline (be	fore GnRH a	nalogues) versus follow-u _l	o (just befo	re gender-	
1 cohort study de Vries et al 2011	Serious limitations ⁵	No serious indirectness	Not applicable	Not calculable	N=54	None	Baseline: 61.00±12.21 GnRH analogue: 52.1±9.81 <i>P</i> <0.001	Important	VERY LOW	
affirming horm 1 cohort study de Vries et al 2011		•	• /	Not calculable	N=54	None	Baseline: 58.04±12.99 GnRH analogue: 53.81±11.86	Important	VERY LOW	
-		-	linical range Chi Jender-affirming			-	<i>P</i> =0.001 cale, time point at baseline it).	(before Gn	RH	
1 cohort study de Vries et al 2011	Serious limitations ⁵	No serious indirectness	Not applicable	Not calculable	N=54	None	Baseline: 44.4% GnRH analogue: 22,2% <i>P</i> =0.001	Important	VERY LOW	
Mean±SD Yout hormone, lowe	-	• •	e, time point at b	aseline (befor	e GnRH analo	ogues) versu	s follow-up (just before ge	nder-affirm	ing	
1 cohort study de Vries et al 2011	Serious limitations ⁵	No serious indirectness	Not applicable	Not calculable	N=54	None	Baseline: 55.46±11.56 GnRH analogue: 50.00±10.56 <i>P</i> <0.001	Important	VERY LOW	

		QUALITY				Summary	of findings	IMPORTA NCE	CERTAINTY	
					No of events/N (n/N		Effect			
Study	Risk of bias	Indirectness	Inconsistency	Imprecision	Intervention	Comparator	Result			
Mean±SD Youtl	h Self-Repor	t (internalising	T) score, time po	oint at baselin	e (before GnF	RH analogue	s) versus follow-up (just be	efore gende	er-affirming	
hormones, low	er scores ind	dicate benefit).								
4	Serious	No serious	Not applicable	Not	N=54	None	Baseline: 56.04±12.49	Important	VERY LOW	
1 cohort study de Vries et al	limitations ⁵	indirectness		calculable			GnRH analogue:	-		
2011							49.78±11.63			
							<i>P</i> <0.001			
Mean±SD Youtl	h Self-Repor	t (externalising	T) score, time p	oint at baselir	ne (before Gnl	RH analogue	es) versus follow-up (just b	efore gend	er-affirming	
hormones, low	er scores ind	dicate benefit).								
1 cohort study	Serious	No serious	Not applicable	Not	N=54	None	Baseline: 53.30±11.87	Important	VERY LOW	
i conort study			not applicable				GnRH analogue: 49.98±9.35	important		
de Vries et al	limitations	indirectness		calculatie						
de Vries et al 2011 Proportion of a	limitations ⁵	indirectness	linical range You	calculable	rt (internalisin	a T) score t	P=0.009	re GnRH ar	naloques)	
2011 Proportion of a	dolescents s	scoring in the c	linical range You ning hormones, l	ith Self-Repoi	•	• •		re GnRH ar	nalogues)	
2011 Proportion of a versus follow-u	dolescents s	scoring in the c	ning hormones, l	ith Self-Repoi	•	• •	P=0.009	re GnRH ar	• ,	
2011 Proportion of a	dolescents s p (just befor	scoring in the c re gender-affirn	-	ıth Self-Repoi lower scores i	indicate benef	fit).	P=0.009 ime point at baseline (befor Baseline: 29.6% GnRH analogue: 11.1%		very Low	
2011 Proportion of a versus follow-u 1 cohort study	dolescents s p (just befor Serious	scoring in the c re gender-affirn No serious	ning hormones, l	uth Self-Repor lower scores i	indicate benef	fit).	P=0.009 ime point at baseline (before Baseline: 29.6%		• ,	
2011 Proportion of a versus follow-u 1 cohort study de Vries et al 2011	dolescents s p (just befor Serious limitations ⁵	scoring in the c re gender-affirm No serious indirectness	ning hormones, l	uth Self-Repor lower scores i Not calculable	N=54	fit). None	P=0.009 ime point at baseline (befor Baseline: 29.6% GnRH analogue: 11.1%		• /	
2011 Proportion of a versus follow-u 1 cohort study de Vries et al 2011	dolescents s p (just befor Serious limitations ⁵	scoring in the c re gender-affirm No serious indirectness	ning hormones, l	uth Self-Repor lower scores i Not calculable	N=54	fit). None	P=0.009 ime point at baseline (befor Baseline: 29.6% GnRH analogue: 11.1%		VERY LOW	
2011 Proportion of a versus follow-u 1 cohort study de Vries et al 2011 Mean±SD Child 1 cross-sectional study	dolescents s p (just befor Serious limitations ⁵ Behaviour (scoring in the c re gender-affirm No serious indirectness Checklist score	ning hormones, l Not applicable e, transfemales (l	uth Self-Repor lower scores i Not calculable ower scores i	N=54 N=54 ndicate benef	fit). None	P=0.009 ime point at baseline (before Baseline: 29.6% GnRH analogue: 11.1% P=0.017	Important	VERY LOW	
2011 Proportion of a versus follow-u 1 cohort study de Vries et al 2011 Mean±SD Child 1 cross-sectional study Staphorsius et al	dolescents s p (just befor Serious limitations ⁵ Behaviour (Serious	scoring in the c re gender-affirm No serious indirectness Checklist score No serious	ning hormones, l Not applicable e, transfemales (l	<i>uth Self-Repor</i> lower scores i Not calculable ower scores i Not	N=54 N=54 ndicate benef	fit). None	P=0.009 <i>ime point at baseline (before</i> Baseline: 29.6% GnRH analogue: 11.1% <i>P</i> =0.017 GnRH analogue: 57.4 [±9.8]	Important	VERY LOW	
2011 Proportion of a versus follow-u 1 cohort study de Vries et al 2011 Mean±SD Child 1 cross-sectional study Staphorsius et al 2015	dolescents s p (just befor Serious limitations ⁵ Behaviour (Serious limitations ⁶	Scoring in the c re gender-affirm No serious indirectness Checklist score No serious indirectness	Not applicable Not applicable , transfemales (I Not applicable	<i>uth Self-Repor</i> lower scores i calculable ower scores i Not calculable	ndicate benef N=54 ndicate benef	fit). None fit N=10	P=0.009 ime point at baseline (before Baseline: 29.6% GnRH analogue: 11.1% P=0.017 GnRH analogue: 57.4 [±9.8] No GnRH analogue: 58.2	Important	VERY LOW	
2011 Proportion of a versus follow-u 1 cohort study de Vries et al 2011 Mean±SD Child 1 cross-sectional study Staphorsius et al 2015	dolescents s p (just befor Serious limitations ⁵ Behaviour (Serious limitations ⁶	Scoring in the c re gender-affirm No serious indirectness Checklist score No serious indirectness	ning hormones, l Not applicable e, transfemales (l	<i>uth Self-Repor</i> lower scores i calculable ower scores i Not calculable	ndicate benef N=54 ndicate benef	fit). None fit N=10	P=0.009 ime point at baseline (before Baseline: 29.6% GnRH analogue: 11.1% P=0.017 GnRH analogue: 57.4 [±9.8] No GnRH analogue: 58.2	Important	VERY LOW	
2011 Proportion of a versus follow-u 1 cohort study de Vries et al 2011 Mean±SD Child 1 cross-sectional study Staphorsius et al 2015	dolescents s p (just befor Serious limitations ⁵ Behaviour (Serious limitations ⁶	Scoring in the c re gender-affirm No serious indirectness Checklist score No serious indirectness	Not applicable Not applicable , transfemales (I Not applicable	<i>uth Self-Repor</i> lower scores i calculable ower scores i Not calculable	ndicate benef N=54 ndicate benef	fit). None fit N=10	P=0.009 ime point at baseline (before Baseline: 29.6% GnRH analogue: 11.1% P=0.017 GnRH analogue: 57.4 [±9.8] No GnRH analogue: 58.2	Important	VERY LOW	
2011 Proportion of a versus follow-u 1 cohort study de Vries et al 2011 Mean±SD Child 1 cross-sectional study Staphorsius et al 2015 Mean±SD Child	dolescents s p (just befor Serious limitations ⁵ Behaviour (Serious limitations ⁶	Scoring in the c re gender-affirm No serious indirectness Checklist score No serious indirectness Checklist score	ning hormones, l Not applicable e, transfemales (l Not applicable e, transmales (low	Ith Self-Repor lower scores i calculable ower scores i Not calculable wer scores ind	ndicate benef N=54 ndicate benef N=8 dicate benefit)	fit). None Tit N=10	P=0.009 ime point at baseline (before Baseline: 29.6% GnRH analogue: 11.1% P=0.017 GnRH analogue: 57.4 [±9.8] No GnRH analogue: 58.2 [±9.3]	Important Important	• •	

Abbreviations: GnRH, gonadotrophin releasing hormone; *P*, P-value; SD, Standard deviation.

1 Downgraded 1 level - the cohort study by Costa et al. (2015) was assessed as at high risk of bias (poor quality overall; lack of blinding and no control group).

2 6 months from baseline (after 6 months of psychological support – both groups).

3 12 months from baseline (delayed eligible gender dysphoria [GD] adolescents, after 12 months of psychological support; immediately eligible GD adolescents, after 12 months of psychological support + 6 months of puberty suppression).

4 18 months from baseline (delayed eligible gender dysphoria [GD] adolescents, after 12 months of psychological support; immediately eligible GD adolescents, after 12 months of psychological support + 6 months of puberty suppression).

5 Downgraded 1 level - the cohort study by de Vries et al. (2011) was assessed as at high risk of bias (poor quality overall; lack of blinding and no control group).

6 Downgraded 1 level - the cohort study by Staphorsius et al. (2015) was assessed as at high risk of bias (poor quality overall; lack of blinding and no randomisation).

Table 6: Question 1. For children and adolescents with gender dysphoria, what is the clinical effectiveness of treatment with GnRH analogues compared with one or a combination of psychological support, social transitioning to the desired gender or no intervention? – engagement with healthcare services

						Summa			
		QUALITY			No of events/No of patients% (n/N%)		Effect	IMPORTANCE	CERTAINTY
Study	Risk of bias	Indirectness	Inconsistency	Imprecision	Intervention	Comparator	Result		
Engageme	nt with heal								
Number (p	roportion) fa	niling to engag	ge with health c	are services	s (did not att	end clinic), at	t (up to) 9 years follow-up		
1 cohort study Brik et al 2018	Serious limitations ¹	No serious indirectness	Not applicable	Not calculable	9/214 (4.2%)	None	9 adolescents out of 214 failed to attend clinic and were excluded from the study (4.2%)	Important	VERY LOW
Loss to fo	llow-up								
1 cohort study Costa et al 2015	Serious limitations ²	No serious indirectness	Not applicable	Not calculable	201	None	The sample size at baseline and 6 months was 201, which dropped by 39.8% to 121 after 12 months and by 64.7% to 71 at 18 months follow-up. No explanation of the reasons for loss to follow-up are reported.	Important	VERY LOW

Abbreviations: GnRH, gonadotrophin releasing hormone.

1 Downgraded 1 level - the cohort study by Brik et al. (2018) was assessed as at high risk of bias (poor quality overall; lack of blinding and no control group). 2 Downgraded 1 level - the cohort study by Costa et al. (2015) was assessed as at high risk of bias (poor quality overall; lack of blinding and no control group). Table 7: Question 1. For children and adolescents with gender dysphoria, what is the clinical effectiveness of treatment with GnRH analogues compared with one or a combination of psychological support, social transitioning to the desired gender or no intervention? – stopping treatment

						Summa	IMPORTANCE	CERTAINTY	
		QUALITY			No of events/No of patients% (n/N%)				Effect
Study	Risk of bias	Indirectness	Inconsistency	Imprecision	Intervention Comparator			Result	
Stopping t	reatment								
Number (p	proportion) s	topping GnRH	l analogues, at	(up to) 9 yea	ars follow-up)			
1 cohort study Brik et al 2018	Serious limitations ¹	No serious indirectness	Not applicable	Not calculable	9/143 (6.2%)	None	9/143 adolescents stopped GnRH analogues (6.2%) ²	Important	VERY LOV
Number (p	proportion) s	topping from	GnRH analogu	es, at (up to)	13 years for	llow-up			
1 cohort study Khatchado urian et al 2014	Serious limitations ³	No serious indirectness	Not applicable	Not calculable	11/27 (42%)	None	11/26 stopped GnRH analogues (42%) ⁴	Important	VERY LO
Number (p	proportion) s	topping GnRH	l analogues bu	t who wishe	d to continu	e endocrine t	reatment, at (up to) 9 years fol	low-up	
1 cohort study Brik et al 2018	Serious limitations ¹	No serious indirectness	Not applicable	Not calculable	4/143 (2.8%)	None	4/143 adolescents stopped GnRH analogues but wished to continue treatment (2.8%)	Important	VERY LOW
	proportion) s	topping GnRH	l analogues wh	o no longer	wished gen	der-affirming	treatment, at (up to) 9 years fo	ollow-up	
1 cohort study Brik et al 2018	Serious limitations ¹	No serious indirectness	Not applicable	Not calculable	5/143 (3.5%)	None	5/143 adolescents stopped GnRH analogues and no longer wished to continue gender- affirming treatment (3.5%)	Important	VERY LO

Abbreviations: GnRH, gonadotrophin releasing hormone.

1 Downgraded 1 level - the cohort study by Brik et al. (2018) was assessed as at high risk of bias (poor quality overall; lack of blinding and no control group).

2 Median duration of 0.8 years (range 0.1 to 3.0). Five adolescents stopped treatment because they no longer wished to receive gender-affirming treatment for various reasons. In 4 adolescents (all transmales), although they wanted to continue treatments for gender dysphoria, GnRH analogues were stopped mainly because of adverse effects (such as mood and emotional lability).

3 Downgraded 1 level - the cohort study by Khatchadourian et al. (2014) was assessed as at high risk of bias (poor quality overall; lack of blinding, no control group and high number of participants lost to follow-up).

4 Because of transitioning to gender-affirming hormones or gender-affirming surgery, adverse effects (such as mood and emotional lability) or no longer wishing to pursue transition.

Table 8. Question 2. For children and adolescents with gender dysphoria, what is the short-term and long-term safety of GnRH analogues compared with one or a combination of psychological support, social transitioning to the desired gender or no intervention? – bone density

						Summa	rry of findings		
		QUALITY				ents/No of % (n/N%)	Effect	IMPORTANCE	CERTAINTY
Study	Risk of bias	Indirectness	Inconsistency	Imprecision	Intervention	Comparator	Result		
Bone dens	sity: change	in lumbar BM	AD						
Change in	lumbar spin	e BMAD from	baseline to 1 y	ear in trans	females				
1 observatio nal study Joseph et al. (2019)	Serious limitations ¹	No serious indirectness	Not applicable	Not calculable	N=31	None	Mean (SD), g/cm ³ Baseline: 0.235 (0.030) 1 year: 0.233 (0.029) p=0.459 z-score Baseline: 0.859 (0.154) 1 year: -0.228 (1.027) p=0.000	IMPORTANT	VERY LOW
Change in	lumbar spin	e BMAD from	baseline to 1 y	vear in trans	males				
1 observatio nal study Joseph et al. (2019)	Serious limitations ¹	No serious indirectness	Not applicable	Not calculable	N=39	None	Mean (SD), g/cm ³ Baseline: 0.196 (0.035) 1 year: 0.201 (0.033) p=0.074 z-score Baseline: -0.186 (1.230) 1 year: -0.541 (1.396) p=0.006	IMPORTANT	VERY LOW

						Summa	ary of findings		
		QUALITY				ents/No of % (n/N%)	Effect	IMPORTANCE	CERTAINTY
Study	Risk of bias	Indirectness	Inconsistency	Imprecision	Intervention	Comparator	Result		
Change in	lumbar spin	e BMAD from	baseline to 2 y	ears in trans	sfemales				
1 observatio nal study Joseph et al. (2019)	Serious limitations ¹	No serious indirectness	Not applicable	Not calculable	N=10	None	Mean (SD), g/cm ³ Baseline: 0.240 (0.027) 2 years: 0.240 (0.030) p=0.865 z-score Baseline: 0.486 (0.809) 2 years: -0.279 (0.930) p=0.000	IMPORTANT	VERY LOW
Change in	lumbar spin	e BMAD from	baseline to 2 y	ears in trans	smales				
1 observatio nal study Joseph et al. (2019)	Serious limitations ¹	No serious indirectness	Not applicable	Not calculable	N=21	None	Mean (SD), g/cm ³ Baseline: 0.195 (0.058) 2 years: 0.198 (0.055) p=0.433 z-score Baseline: -0.361 (1.439) 2 years: -0.913 (1.318) p=0.001	IMPORTANT	VERY LOW
Change in transfemal		D from starti	ng GnRH analo	gue (mean a	nge 14.9±1.9)	to starting g	ender-affirming hormones (me	ean age 16.6±1.	4) in
1 observatio nal study Klink et al. 2015	Serious limitations ²	No serious indirectness	Not applicable	Not calculable	N=11 N=12	None	Mean (SD), g/cm ³ GnRH analogue: 0.22 (0.03) Gender-affirming hormones: 0.22 (0.02) NS z-score GnRH analogue: -0.44 (1.10) Gender-affirming hormones: -0.90 (0.80) p-value: NS	IMPORTANT	VERY LOW
Change in transmales		D from starti	ng GnRH analo	gue (mean a	nge 15.0±2.0)	to starting g	ender-affirming hormones (me	ean age 16.4±2.	3) in

						Summa	ary of findings		
		QUALITY				ents/No of % (n/N%)	Effect	IMPORTANCE	CERTAINTY
Study	Risk of bias	Indirectness	Inconsistency	Imprecision	Intervention	Comparator	Result		
1 observatio nal study Klink et al. 2015	Serious limitations ²	No serious indirectness	Not applicable	Not calculable	N=18	None	Mean (SD), g/cm ³ GnRH analogue: 0.25 (0.03) Gender-affirming hormones: 0.24 (0.02) NS z-score GnRH analogue: 0.28 (0.90) Gender-affirming hormones: -0.50 (0.81) p-value: 0.004	IMPORTANT	VERY LOW
Change in	lumbar BMA	D from starti	ng GnRH analo	gue to starti	ng gender-a	ffirming horn	nones in transfemales (bone ag	ge of <15 years)
1 observatio nal study Vlot et al. 2017	Serious limitations ³	No serious indirectness	Not applicable	Not calculable	N=15	None	Median (range), g/cm ³ GnRH analogue: 0.21 (0.17 to 0.25) Gender-affirming hormones: 0.20 (0.18 to 0.24) NS z-score GnRH analogue: -0.20 (-1.82 to 1.18) Gender-affirming hormones: -1.52 (-2.36 to 0.42) p-value: <0.01	IMPORTANT	VERY LOW
Change in	lumbar BMA	AD from starti	ng GnRH analo	gue to starti	ng gender-a	ffirming horn	nones in transfemales (bone ag	ge of ≥1 <i>5</i>)	
1 observatio nal study Vlot et al. 2017	Serious limitations ³	No serious indirectness	Not applicable	Not calculable	N=5	None	Median (range), g/cm ³ GnRH analogue: 0.22 (0.18 to 0.25) Gender-affirming hormones: 0.22 (0.19 to 0.24) NS z-score GnRH analogue: -1.18 (-1.78 to 1.09)	IMPORTANT	VERY LOW

						Summa	ary of findings		
		QUALITY				ents/No of % (n/N%)	Effect	IMPORTANCE	CERTAINTY
Study	Risk of bias	Indirectness	Inconsistency	Imprecision	Intervention	Comparator	Result]	
							Gender-affirming hormones: -1.15 (-2.21 to 0.08)		
Change in	lumbar BMA	D from starti	ng GnRH analo	que to starti	ng gender-a	ffirming horn	p-value: p≤0.1 nones in transmales (bone age	of <14 years)	
•	-		•	•		U			
1 observatio nal study Vlot et al. 2017	Serious limitations ³	No serious indirectness	Not applicable	Not calculable	N=11	None	Median (range), g/cm ³ GnRH analogue: 0.23 (0.20 to 0.29) Gender-affirming hormones: 0.23 (0.19 to 0.28) NS z-score GnRH analogue: -0.05 (-0.78 to 2.94) Gender-affirming hormones: -0.84 (-2.20 to 0.87) p-value: ≤0.01	IMPORTANT	VERY LOW
Change in	lumbar BMA	D from starti	ng GnRH analo	gue to starti	ng gender-a	ffirming horn	nones in transmales (bone age	e of ≥1 <i>4</i>)	
1 observatio nal study Vlot et al. 2017	Serious limitations ³	No serious indirectness	Not applicable	Not calculable	N=23	None	$\begin{tabular}{lllllllllllllllllllllllllllllllllll$	IMPORTANT	VERY LOW
Bone dens	sity: change	in lumbar BM	D		•				
			baseline to 1 ye	ar in transfe	males				

						Summa	ry of findings		
		QUALITY				ents/No of % (n/N%)	Effect	IMPORTANCE	CERTAINTY
Study	Risk of bias	Indirectness	Inconsistency	Imprecision	Intervention	Comparator	Result		
1 observatio nal study Joseph et al. (2019)	Serious limitations ¹	No serious indirectness	Not applicable	Not calculable	N=31	None	Mean (SD), kg/m2 Baseline: 0.860 (0.154) 1 year: 0.859 (0.129) p=0.962 z-score Baseline: -0.016 (1.106) 1 year: -0.461 (1.121) p=0.003	IMPORTANT	VERY LOW
Change in	lumbar spin	e BMD from b	paseline to 1 ye	ar in transm	ales				
1 observatio nal study Joseph et al. (2019)	Serious limitations ¹	No serious indirectness	Not applicable	Not calculable	N=39	None	Mean (SD), kg/m2 Baseline: 0.694 (0.149) 1 year: 0.718 (0.124) p=0.006 z-score Baseline: -0.395 (1.428) 1 year: -1.276 (1.410) p=0.000	IMPORTANT	VERY LOW
Change in	lumbar spin	e BMD from b	paseline to 2 ye	ars in transf	emales				
1 observatio nal study Joseph et al. (2019)	Serious limitations ¹	No serious indirectness	Not applicable	Not calculable	N=10	None	Mean (SD), kg/m2 Baseline: 0.867 (0.141) 2 years: 0.878 (0.130) p=0.395 z-score Baseline: 0.130 (0.972) 2 years: -0.890 (1.075) p=0.000	IMPORTANT	VERY LOW
Change in	lumbar spin	e BMD from b	baseline to 2 ye	ars in transr	nales				
1 observatio nal study	Serious limitations ¹	No serious indirectness	Not applicable	Not calculable	N=21	None	Mean (SD), kg/m2 Baseline: 0.695 (0.220) 2 years: 0.731 (0.209) p=0.058	IMPORTANT	VERY LOW

						Summa	ary of findings		
		QUALITY				ents/No of % (n/N%)	Effect	IMPORTANCE	CERTAINTY
Study	Risk of bias	Indirectness	Inconsistency	Imprecision	Intervention	Comparator	Result	-	
Joseph et al. (2019)	lumbar BMI) from starting	n GnRH analog	ue (mean an	e 14 9+1 9) f	o starting go	z-score Baseline: -0.715 (1.406) 2 years: -2.000 (1.384) p=0.000 nder-affirming hormones (mea	un ago 16 6+1 4)	in
transfema		, nom starting	g Ommanalog	ue (mean ag	e 14.5±1.5) t	o starting ger	ider-anning normones (mea	<i>in uge 10.0±1.4)</i>	
1 observatio nal study Klink et al. 2015	Serious limitations ²	No serious indirectness	Not applicable	Not calculable	N=12 N=11	None	Mean (SD), g/m2 GnRH analogue: 0.84 (0.13) Gender-affirming hormones: 0.84 (0.11) NS z-score GnRH analogue: -0.77 (0.89) Gender-affirming hormones: -1.01 (0.98) NS	IMPORTANT	VERY LOW
Change in transmale) from starting	g GnRH analog	ue (mean ag	e 15.0±2.0) t	o starting gei	nder-affirming hormones (mea	n age 16.4±2.3)	in
1 observatio nal study Klink et al. 2015	Serious limitations ²	No serious indirectness	Not applicable	Not calculable	N=18	None	Mean (SD), g/m2 GnRH analogue: 0.95 (0.12) Gender-affirming hormones: 0.91 (0.10) p-value: 0.006 z-score GnRH analogue: 0.17 (1.18) Gender-affirming hormones: -0.72 (0.99) p-value: <0.001	IMPORTANT	VERY LOW
		in femoral ne							
Change in	femoral nec	k BMD from b	paseline to 1 ye	ar in transfe	males				
1 observatio nal study	Serious limitations ¹	No serious indirectness	Not applicable	Not calculable	N=31	None	Mean (SD), kg/m2 Baseline: 0.894 (0.118) 1 year: 0.905 (0.104) p=0.571	IMPORTANT	VERY LOW

						Summa	ry of findings		
		QUALITY				ents/No of % (n/N%)	Effect	IMPORTANCE	CERTAINTY
Study	Risk of bias	Indirectness	Inconsistency	Imprecision	Intervention	Comparator	Result		
Joseph et al. (2019)							z-score Baseline: 0.157 (0.905) 1 year: −0.340 (0.816) p=0.002		
Change fr	om baseline	to 1 year in fe	moral neck BM	iD in transm	aies				
1 observatio nal study Joseph et al. (2019)	Serious limitations ¹	No serious indirectness	Not applicable	Not calculable	N=39	None	Mean (SD), kg/m2 Baseline: 0.772 (0.137) 1 year: 0.785 (0.120) p=0.797 z-score Baseline: -0.863 (1.215) 1 year: -1.440 (1.075) p=0.000	IMPORTANT	VERY LOW
Change fro	om baseline	to 2 years in f	femoral neck B	MD in transf	emales		· · · ·		
1 observatio nal study Joseph et al. (2019)	Serious limitations ¹	No serious indirectness	Not applicable	Not calculable	N=10	None	Mean (SD), kg/m2 Baseline: 0.920 (0.116) 2 years: 0.910 (0.125) p=0.402 z-score Baseline: 0.450 (0.781) 2 years: -0.600 (1.059) p=0.002	IMPORTANT	VERY LOW
Change fr	om baseline	to 2 years in f	femoral neck B	MD in transr	nales				
1 observatio nal study Joseph et al. (2019)	Serious limitations ¹	No serious indirectness	Not applicable	Not calculable	N=21	None	Mean (SD), kg/m2 Baseline: 0.766 (0.215) 2 years: 0.773 (0.197) p=0.604 z-score Baseline: -1.075 (1.145) 2 years: -1.779 (0.816) p=0.001	IMPORTANT	VERY LOW

						Summa	ary of findings		
		QUALITY				ents/No of % (n/N%)	Effect	IMPORTANCE	CERTAINTY
Study	Risk of bias	Indirectness	Inconsistency	Imprecision	Intervention	Comparator	Result		
Bone dens	ity: change	in femoral neo	ck (hip) BMAD				•		
Change fro	om starting (GnRH analogu	ie to starting g	ender-affirm	ing hormone	es in femoral	neck BMAD in transfemales (b	one age of <15	years)
1 observatio nal study Vlot et al. 2017	Serious limitations ³	No serious indirectness	Not applicable	Not calculable	N=16	None	Median (range), g/cm3 GnRH analogue: 0.29 (0.20 to 0.33) Gender-affirming hormones: 0.27 (0.20 to 0.33) p≤0.1 z-score GnRH analogue: -0.71 (-3.35 to 0.37) Gender-affirming hormones: -1.32 (-3.39 to 0.21) p≤0.1	IMPORTANT	VERY LOW
Change in	femoral nec	k BMAD from	starting GnRH	analogue to	starting gei	nder-affirming	g hormones in transfemales (b	one age of ≥15)
1 observatio nal study Vlot et al. 2017	Serious limitations ³	No serious indirectness	Not applicable	Not calculable	N=6	None	Median (range), g/cm3 GnRH analogue: 0.30 (0.26 to 0.36) Gender-affirming hormones: 0.30 (0.26 to 0.34) NS z-score GnRH analogue: -0.44 (-1.37 to 0.93) Gender-affirming hormones: -0.36 (-1.50 to 0.46) NS	IMPORTANT	VERY LOW
Change in	femoral nec	k BMAD from	starting GnRH	analogue to	starting ger	nder-affirming	g hormones in transmales (boi	ne age of <14 y	ears)
1 observatio nal study	Serious limitations ³	No serious indirectness	Not applicable	Not calculable	N=10	None	Median (range), g/cm3 GnRH analogue: 0.31 (0.26 to 0.36) Gender-affirming hormones: 0.30 (0.22 to 0.35)	IMPORTANT	VERY LOW

						Summa	ary of findings		
		QUALITY				ents/No of % (n/N%)	Effect	IMPORTANCE	CERTAINTY
Study	Risk of bias	Indirectness	Inconsistency	Imprecision	Intervention	Comparator	Result		
Vlot et al. 2017							NS		
							z-score GnRH analogue: -0.01 (-1.30 to 0.91) Gender-affirming hormones: -0.37 (-2.28 to 0.47) NS		
Change in	femoral nec	k BMAD from	starting GnRH	analogue to	starting gei	nder-affirming	g hormones in transmales (boi	ne age of ≥14)	
1 observatio nal study Vlot et al. 2017	Serious limitations ³	No serious indirectness	Not applicable	Not calculable	N=23	None	Median (range), g/cm3 GnRH analogue: 0.33 (0.25 to 0.39) Gender-affirming hormones: 0.30 (0.23 to 0.41) p-value: ≤0.01 z-score GnRH analogue: 0.27 (−1.39 to 1.32) Gender-affirming hormones: −0.27 (−1.91 to 1.29) p-value: ≤0.01	IMPORTANT	VERY LOW
Bone dens	ity: change	in femoral are	a BMD				· · ·		
Change in transfema		D from startin	g GnRH analog	gue (mean ag	ge 14.9±1.9)	to starting ge	nder-affirming hormones (mea	an age 16.6±1.4) in
1 observatio nal study Klink et al. 2015	Serious limitations ²	No serious indirectness	Not applicable	Not calculable	N=14 N=6	None	Mean (SD), g/m2 GnRH analogue: 0.88 (0.12) Gender-affirming hormones: 0.87 (0.08) NS z-score GnRH analogue: -0.66 (0.77) Gender-affirming hormones: -0.95 (0.63) NS	IMPORTANT	VERY LOW

						Summa	ary of findings		
		QUALITY				ents/No of % (n/N%)	Effect	IMPORTANCE	CERTAINTY
Study	Risk of bias	Indirectness	Inconsistency	Imprecision	Intervention	Comparator	Result		
Change in transmales		D from startin	g GnRH analog	jue (mean ag	ge 15.0±2.0) i	to starting ge	nder-affirming hormones (me	an age 16.4±2.3) in
1 observatio nal study Klink et al. 2015	Serious limitations ²	No serious indirectness	Not applicable	Not calculable	N=18 N=13	None	Mean (SD), g/m2 GnRH analogue: 0.92 (0.10) Gender-affirming hormones: 0.88 (0.09) p-value: 0.005 z-score GnRH analogue: 0.36 (0.88) Gender-affirming hormones: -0.35 (0.79) p-value: 0.001	IMPORTANT	VERY LOW
Bone dens	sity: change	in femoral are	a BMAD	·			· · · ·		
transfema 1 observatio nal study Klink et al. 2015	les Serious limitations ²	No serious indirectness	Not applicable	Not calculable	N=12 N=10	None	Mean (SD), g/cm3 GnRH analogue: 0.28 (0.04) Gender-affirming hormones: 0.26 (0.04) NS z-score GnRH analogue: -0.93 (1.22) Gender-affirming hormones: -1.57 (1.74) p-value: NS	IMPORTANT	VERY LOW
transmales			ng Girkh analo	gue (mean à	age 15.0±2.0	, to starting g	lender-annining normones (m	eall aye 10.4±2.	.5) 111
1 observatio nal study Klink et al. 2015	Serious limitations ²	No serious indirectness	Not applicable	Not calculable	N=18 N=18	None	Mean (SD), g/cm3 GnRH analogue: 0.32 (0.04) Gender-affirming hormones: 0.31 (0.04) NS	IMPORTANT	VERY LOW
							z-score		

						Summa	rry of findings		
	QUALITY Study Risk of bias Indirectness Inconsistency Imprecision					ents/No of % (n/N%)	Effect	IMPORTANCE	CERTAINTY
Study	Study Risk of bias Indirectness Inconsistency Imprecision		Intervention	Comparator	Result				
							GnRH analogue: 0.01 (0.70) Gender-affirming hormones: –0.28 (0.74) NS		

Abbreviations: BMAD, bone mineral apparent density; BMD, bone mineral density; GnRH, gonadotrophin releasing hormone; NS, not significant; SD, standard deviation.

1 Downgraded 1 level - the cohort study by Joseph et al. (2019) was assessed as at high risk of bias (poor quality overall; lack of blinding and no control group).

2 Downgraded 1 level - the cohort study by Klink et al. (2015) was assessed as at high risk of bias (poor quality overall; lack of blinding, no randomisation, no control group and high number of participants lost to follow-up).

3 Downgraded 1 level - the cohort study by Vlot et al. (2017) was assessed as at high risk of bias (poor quality overall; lack of blinding and no control).

Table 9 Question 2: For children and adolescents with gender dysphoria, what is the short-term and long-term safety of GnRH analogues compared with one or a combination of psychological support, social transitioning to the desired gender or no intervention? – cognitive development or functioning

						Summa	ry of findings		
		QUALITY				ents/No of s% (n/N%)	Effect	IMPORTANCE	CERTAINTY
Study	Risk of bias	Indirectness	Inconsistency	Imprecision	Intervention	Comparator	Result		
Cognitive of	itive development or functioning (1 cross-sectional stu								
	cales: arithm transfemales		ary, picture arr	angement, a	nd block de	sign) at a sing	gle time point between GnRH a	nalogue treate	d and
1 Cross- sectional study Staphorsiu s et al. 2015	Serious limitations ¹	No serious indirectness	Not applicable	Not calculable	N=8 Mean (SD) 94.0 (10.3)	N=10 Mean (SD) 109.4 (21.2)	NR	IMPORTANT	VERY LOW
IQ (4 subso untreated t		etic, vocabul	ary, picture arr	angement, a	nd block de	sign) at a sing	le time point between GnRH a	nalogue treate	d and

						Summa	ry of findings		
		QUALITY				ents/No of % (n/N%)	Effect	IMPORTANCE	CERTAINTY
Study	Risk of bias	Indirectness	Inconsistency	Imprecision	Intervention Comparator		Result		
1 Cross- sectional study Staphorsiu s et al. 2015	Serious limitations ¹	No serious indirectness	Not applicable	Not calculable	N=12 Mean (SD) 95.8 (15.6)	N=10 Mean (SD) 98.5 (15.9)	NR	IMPORTANT	VERY LOW
Reaction ti	me at a sing	le time point	between GnRH	analogue tr	eated and u	ntreated trans	females		
1 Cross- sectional study Staphorsiu s et al. 2015	Serious limitations ¹	No serious indirectness	Not applicable	Not calculable	N=8 Mean (SD) 10.9 (4.1)	N=10 Mean (SD) 9.9 (3.1)	NR	IMPORTANT	VERY LOW
	me at a sing	le time point	between GnRH	analogue tr	eated and u	ntreated trans	males		
1 Cross- sectional study Staphorsiu s et al. 2015	Serious limitations ¹	No serious indirectness	Not applicable	Not calculable	N=12 Mean (SD) 9.9 (3.1)	N=10 Mean (SD) 10.0 (2.0)	NR	IMPORTANT	VERY LOW
Accuracy a	at a single tii	me point betw	veen GnRH ana	logue treate	d and untrea	ted transfema	ales		
1 cohort study Staphorsiu s et al. 2015	Serious limitations ¹	No serious indirectness	Not applicable	Not calculable	N=8 Mean (SD) 73.9 (9.1)	N=10 Mean (SD) 83.4 (9.5)	NR	IMPORTANT	VERY LOW
Accuracy a	at a single tii	me point betw	veen GnRH ana	logue treate	d and untrea	ted transmale	es		
1 cohort study Staphorsiu s et al. 2015	Serious limitations ¹	No serious indirectness	Not applicable	Not calculable	N=12 Mean (SD) 85.7 (10.5)	N=10 Mean (SD) 88.8 (9.7)	NR	IMPORTANT	VERY LOW

Abbreviations: GnRH, gonadotrophin releasing hormone; NR, not reported; *P*, P-value; SD, Standard deviation.

1 Downgraded 1 level - the cohort study by Staphorsius et al. (2015) was assessed as at high risk of bias (poor quality overall; lack of blinding and no randomisation).

Table 10: Question 2: In children and adolescents with gender dysphoria, what is the short-term and long-term safety of GnRH analogues compared with one or a combination of psychological support, social transitioning to the desired gender or no intervention? – other safety outcomes

						Summa	rry of findings		
		QUALITY				ents/No of % (n/N%)	Effect	IMPORTANCE	CERTAINTY
Study	Risk of bias	Indirectness	Inconsistency	Imprecision	Intervention Comparator		Result		
Other safe	ty outcomes	: change in s	hange in serum creatinine						
Change in	serum creat	tinine (micron	ol/l) between b	aseline and	1 year in tra	nsfemales			
1 observatio nal study Schagen et al. 2016	Serious limitations ¹	No serious indirectness	Not applicable	Not calculable	N=28	None	Mean (SD) Baseline: 70 (12) 1 year: 66 (13) p-value: 0.20	IMPORTANT	VERY LOW
Change in	serum creat	tinine (µmol/l)	between basel	ine and 1 ye	ar in transma	ales			
1 observatio nal study Schagen et al. 2016	Serious limitations ¹	No serious indirectness	Not applicable	Not calculable	N=29	None	Mean (SD) Baseline: 73 (8) 1 year: 68 (13) p-value: 0.01	IMPORTANT	VERY LOW
Other safe	ty outcomes	: liver enzyme	es				·		
Presence of	of elevated li	iver enzymes	(AST, ALT, and	glutamyl tra	ansferase) be	etween baseli	ine and during treatment		
1 observatio nal study Schagen et al. 2016	Serious limitations ¹	No serious indirectness	Not applicable	Not calculable	39	None	Glutamyl transferase was not elevated at baseline or during treatment in any subject. Mild elevations of AST and ALT above the reference range were present at baseline but were not more prevalent during treatment than at baseline.	IMPORTANT	VERY LOW

						Summa	ry of findings		
	QUALITY					ents/No of % (n/N%)	Effect	IMPORTANCE	CERTAINTY
Study	Risk of bias	Indirectness	Inconsistency	Imprecision	Intervention Comparator		Result		
							Glutamyl transferase, AST, and ALT levels did not significantly change from baseline to 12 months of treatment.		
	-	: adverse effe reporting adv							
		-pg							
1 cohort study Khatchado urian et al 2014	Serious limitations ²	No serious indirectness	Not applicable	Not calculable ²	27	None	3/27 adolescents ³	Important	VERY LOW

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; GnRH, gonadotrophin releasing hormone; P, P-value; SD, standard deviation.

1 Downgraded 1 level - the cohort study by Schagen et al. (2016) was assessed as at high risk of bias (poor quality overall; lack of blinding and no control).

2 Downgraded 1 level - the cohort study by Khatchadourian et al. (2014) was assessed as at high risk of bias (poor quality overall; lack of blinding, no control group and high number of participants lost to follow-up).

3 1 transmale developed sterile abscesses; they were switched from leuprolide acetate to triptorelin, and this was well tolerated. 1 transmale developed leg pains and headaches, which eventually resolved without treatment. 1 participant gained 19 kg within 9 months of initiating GnRH analogues.

Table 11: Question 4. From the evidence selected, are there any subgroups of children and adolescents with gender dysphoria that may derive more (or less) advantage from treatment with GnRH analogues than the wider population of children and adolescents with gender dysphoria? – critical outcomes

	QUALITY						Summary of findings		
						ents/No of s (n/N%)	Effect		
Study	Risk of bias	Indirectness	Inconsistency	Imprecision	Sex assigned at birth males	Sex assigned at birth females	Result		
Subgroups: sex	x assigned a	at birth males co	ompared with se	x assigned at	birth female	es			

		QUALITY				Summary of	of findings	IMPORTANCE	CERTAINTY
						ents/No of s (n/N%)	Effect		
Study	Risk of bias	Indirectness	Inconsistency	Imprecision	Sex assigned at birth males	Sex assigned at birth females	Result		
Impact on geno	ler dysphoria	9							
Mean [±SD] Utr	echt Gender	Dysphoria Sca	ale (version(s) no	ot reported), ti	ime point at	baseline (bei	fore GnRHa) versus foll	low-up (just bef	ore gender-
affirming horm	ones).								
1 cohort study de Vries et al 2011	Serious limitations ¹	No serious indirectness	Not applicable	Not calculable	n-NR ² score at T0 47.95 [±9.70] score at T1 49.67 [±9.47]	n-NR ² score at T0 56.57 [±3.89] score at T1 56.62 [±4.0]	<i>F-</i> ratio 15.98 (<i>df, errdf</i> . 1,39), <i>P</i> <0.001	Critical	VERY LOW
Mean [±SD] Bea hormones).	ck Depressic	on Inventory-II,	time point at bas	seline (T0 bef	ore GnRH ar	alogues) vei	rsus follow-up (T1 just l	before gender-a	ffirming
1 cohort study de Vries et al 2011	Serious limitations ¹	No serious indirectness	Not applicable	Not calculable	n-NR ² score at T0 5.71 [±4.31] score at T1 3.50 [±4.58]	n-NR ² score at T0 10.34 [±8.24] score at T1 6.09 [±7.93]	<i>F-</i> ratio 3.85 (<i>df, errdf</i> : 1,39), <i>P</i> =0.057	Critical	VERY LOW
Mean [±SD] Tra	it Anger (TP	l), time point at	t baseline (T0 be	fore GnRH an	alogues) vei	rsus follow-u	p (T1 just before gende	er-affirming hor	mones).
1 cohort study de Vries et al 2011	Serious limitations ¹	No serious indirectness	Not applicable	Not calculable	n-NR ² score at T0 5.22 [±2.76] score at T1 5.00	n-NR ² score at T0 6.43 [±2.78] score at T1 6.39	<i>F</i> -ratio 5.70 (<i>df, errdf</i> . 1,39), <i>P</i> =0.022	Critical	VERY LOW

		QUALITY				Summary	IMPORTANCE	CERTAINTY	
					No of events/No of patients (n/N%)				
Study	Risk of bias	Indirectness	Inconsistency	Imprecision	Sex assigned at birth males	Sex assigned at birth females	Result		
Mean [±SD] Tra	ait Anxiety (S	TAI), time poin	t at baseline (T0	before GnRH	analogues)	versus follo	w-up (T1 just before ger	nder-affirming h	ormones).
1 cohort study de Vries et al 2011	Serious limitations ¹	No serious indirectness	Not applicable	Not calculable	n-NR ² score at T0 4.33 [±2.68] score at T1 4.39 [±2.64]	n-NR ² score at T0 7.00 [±2.36] score at T1 6.17 [±2.69]	<i>F-</i> ratio 16.07 (<i>df, errdf.</i> 1,39), <i>P</i> <0.001	Critical	VERY LOW

Abbreviations: GnRH, gonadotrophin releasing hormone; NR, not reported; *P*, P-value; SD, Standard deviation.

1 Downgraded 1 level - the cohort study by de Vries et al. (2011) was assessed as at high risk of bias (poor quality overall; lack of blinding and no control group). 2 The overall sample size completing the outcome at both time points was 41.

Table 11: Question: 4. From the evidence selected, are there any subgroups of children and adolescents with gender dysphoria that may derive more (or less) advantage from treatment with GnRH analogues than the wider population of children and adolescents with gender dysphoria? – important outcomes

		QUALITY		•		Summa	ry of findings	IMPORTA NCE	CERTAINTY
						ents/No of s (n/N%)	Effect		
Study Subgroups: se	Risk of bias x assigned a	Indirectness	Inconsistency	Imprecision	Sex assigned at birth males birth female	Sex assigned at birth females S	Result		
Impact on body	y image								
Mean [±SD] Bo gender-affirmin			xual characteris	tics), time poi	nt at baselin	e (T0 before	GnRH analogues) versus fo	llow-up (T1	just before

		QUALITY				Summa	ry of findings	IMPORTA NCE	CERTAINTY		
						ents/No of s (n/N%)	Effect				
Study	Risk of bias	Indirectness	Inconsistency	Imprecision	Sex assigned at birth males	Sex assigned at birth females	Result				
1 cohort study de Vries et al 2011	Serious limitations ¹	No serious indirectness	Not applicable	Not calculable	n-NR ² score at T0 4.02 [±0.16] score at T1 3.74 [±0.78]	n-NR ² score at T0 4.16 [±0.52] score at T1 4.17 [±0.58]	<i>F-</i> ratio 4.11 (<i>df, errdf</i> : 1,55), <i>P</i> =0.047	5), Important VERY			
Mean [±SD] Boo before gender-a		• •	sexual characte	ristics), time	point at base	eline (T0 befo	ore GnRH analogues) versus	s follow-up	(T1 just		
1 cohort study de Vries et al 2011	Serious limitations ¹	No serious indirectness	Not applicable	Not calculable	n-NR ² score at T0 2.66 [±0.50] score at T1 2.39 [±0.69]	n-NR ² score at T0 2.81 [±0.76] score at T1 3.18 [±0.42]	<i>F</i> -ratio 11.57 (<i>df, errdf</i> : 1,55), <i>P</i> =0.001 ³	Important	VERY LOW		
Mean [±SD] Boo gender-affirmin	• •	•	aracteristics), tim	ne point at ba			nalogues) versus follow-up	(T1 just be	fore		
1 cohort study de Vries et al 2011	Serious limitations ¹	No serious indirectness	Not applicable	Not calculable	n-NR ² score at T0 2.60 [±0.58] score at T1 2.32 [±0.59]	n-NR ² score at T0 2.24 [±0.62] score at T1 2.61 [±0.50]	<i>F-</i> ratio 0.081 (<i>df, errdf</i> : 1,55), <i>P</i> =0.777 ³	Important	VERY LOW		
Psychosocial ii	mpact					· · ·					
Mean [±SD] Chi	ildren's Glob	oal Assessment	t Scale score, at	baseline.							
1 cohort study Costa et al 2015	Serious limitations ⁴	No serious indirectness	No serious inconsistency	Not calculable	n=not reported	n=not reported	<i>t</i> -test 2.15; <i>P</i> =0.03 ⁵	Important	VERY LOW		

		QUALITY				Summai	IMPORTA NCE	CERTAINTY	
						ents/No of s (n/N%)	Effect		
Study	Risk of bias	Indirectness	Inconsistency	Imprecision	Sex assigned at birth males	Sex assigned at birth females	Result		
					55.4	59.2			
					[±12.7]	[±11.8]			
gender-affirmin			i Scale score, un	në point at ba	senne (10 be	erore GNRH a	nnalogues) versus follow-up) (11 just de	fore
1 cohort study de Vries et al 2011	Serious limitations ¹	No serious indirectness	Not applicable	Not calculable	n-NR ⁶ score at T0 73.10 [±8.84] score at T1 77.33	n-NR ⁶ score at T0 67.25 [±11.06] score at T1 70.30	<i>F-</i> ratio 5.77 (<i>df, errdf</i> : 1,39), <i>P</i> =0.021	Important	VERY LOW
		r Checklist (tot	al T) score, time	point at base	[±8.69] line (T0 befo	[±9.44] ore GnRH and	alogues) versus follow-up (T1 just befo	re gender-
		r Checklist (tot No serious	al T) score, time	point at base			alogues) versus follow-up (F-ratio 2.64 (df, errdf: 1,52),	T1 just befo	-
Mean [±SD] Cha affirming horm 1 cohort study de Vries et al 2011	ones).			-	line (T0 befo	ore GnRH and	- / .	-	re gender- VERY LOW
1 cohort study de Vries et al 2011	ones). Serious limitations ¹	No serious indirectness r Checklist (int	Not applicable	Not calculable	n-NR ⁷ score at T0 59.42 [±11.78] score at T1 50.38 [±10.57]	n-NR ⁷ score at T0 61.73 [±13.60] score at T1 57.73 [±10.82]	<i>F</i> -ratio 2.64 (<i>df, errdf</i> : 1,52),	Important	VERY LOW

		QUALITY				Summa	ry of findings	IMPORTA NCE	CERTAINTY
						ents/No of s (n/N%)	Effect		
Study	Risk of bias	Indirectness	Inconsistency	Imprecision	Sex assigned at birth males	Sex assigned at birth females	Result	-	
Mean [±SD] Ch gender-affirmir		•	ternalising T) sco	ore, time poin	t at baseline	(T0 before (GnRH analogues) versus fol	low-up (T1	iust before
1 cohort study de Vries et al 2011	Serious limitations ¹	No serious indirectness	Not applicable	Not calculable	n-NR ⁷ score at T0 54.71 [±12.91] score at T1 48.75 [±10.22]	n-NR ⁷ score at T0 60.70 [±12.64] score at T1 57.87 [±11.66]	<i>F</i> -ratio 6.29 (<i>df</i> , <i>errdf</i> : 1,52), <i>P</i> =0.015	Important	VERY LOW
Mean [±SD] Yo hormones).	uth Self-Rep	ort (total T) scc	ore, time point at	baseline (T0	before GnRł	l analogues)	versus follow-up (T1 just b	efore gende	er-affirming
1 cohort study de Vries et al 2011	Serious limitations ¹	No serious indirectness	Not applicable	Not calculable	n-NR ⁷ score at T0 53.56 [±12.26] score at T1 47.84 [±10.86]	n-NR ⁷ score at T0 57.10 [±10.87] score at T1 51.86 [±10.11]	<i>F-</i> ratio 1.99 (<i>df, errdf</i> : 1,52), <i>P</i> =0.164	Important	VERY LOW
	•	ort (internalisir	ng T) score, time	point at base	line (T0 befo	re GnRH and	alogues) versus follow-up (1	1 just befo	re gender-
Mean [±SD] Yo affirming horm	ones).								

		QUALITY				Summa	ry of findings	IMPORTA NCE	CERTAINTY
					No of even patients	ents/No of s (n/N%)	Effect	NCE	
Study	Risk of bias	Indirectness	Inconsistency	Imprecision	Sex assigned at birth males	Sex assigned at birth females	Result		
1 cohort study de Vries et al 2011	Serious limitations ¹	No serious indirectness	Not applicable	Not calculable	n-NR ⁷ score at T0 48.72 [±11.83] score at T1 46.52 [±9.23]	n-NR ⁷ score at T0 57.24 [±10.59] score at T1 52.97 [±8.51]	<i>F</i> -ratio 9.14 (<i>df, errdf</i> : 1,52), <i>P</i> =0.004	Important	VERY LOW

Abbreviations: GnRH, gonadotrophin releasing hormone; NR, not reported; *P*, P-value; SD, Standard deviation.

1 Downgraded 1 level - the cohort study by de Vries et al. (2011) was assessed as at high risk of bias (poor quality overall; lack of blinding and no control group).

2 The overall sample size completing the outcome at both time points was 57.

3 There was a significant interaction effect between sex assigned at birth and BDI between T0 and T1; sex assigned at birth females became more dissatisfied with their secondary *F* (df, errdf), *P*: 14.59 (1,55), *P*<0.001) and neutral *F* (df, errdf), *P*: 15.26 (1,55), *P*<0.001) sex characteristics compared with sex assigned at birth males. 4 Serious limitations – the cohort study by Costa et al. 2015 was assessed as at high risk of bias (poor quality).

5 At baseline, CGAS scores were not associated with any demographic variable, in both sex assigned at birth males and females. There were no statistically significant differences in CGAS scores between gender dysphoric sex assigned at birth males and females in all follow-up evaluations (P>0.1; full data not reported).

6 The overall sample size completing the outcome at both time points was 41

7 The overall sample size completing the outcome at both time points was 54.

Glossary

Beck Depression	The BDI-II is a tool for assessing depressive symptoms. There
Inventory-II (BDI-II)	are no specific scores to categorise depression severity, but it is
	suggested that 0 to 13 is minimal symptoms, 14 to 19 is mild
	depression, 20 to 28 is moderate depression, and severe
	depression is 29 to 63.
Body Image Scale	The BIS is used to measure body satisfaction. The scale consists
(BIS)	of 30 body features, which the person rates on a 5-point scale.
	Each of the 30 items falls into one of 3 basic groups based on its
	relative importance as a gender-defining body feature: primary sex
	characteristics, secondary sex characteristics, and neutral body
Demo main angl	characteristics. A higher score indicates more dissatisfaction.
Bone mineral	BMAD is a size adjusted value of bone mineral density (BMD)
apparent density	incorporating body size measurements using UK norms in
(BMAD)	growing adolescents.
Child Behaviour	CBCL is a checklist parents complete to detect emotional and
Checklist (CBCL)	behavioural problems in children and adolescents.
Children's Global	The CGAS tool is a validated measure of global functioning on a
Assessment Scale	single rating scale from 1 to 100. Lower scores indicate poorer
(CGAS)	functioning
Gender	The roles, behaviours, activities, attributes, and opportunities that
-	any society considers appropriate for girls and boys, and women
	and men.
Gender dysphoria	Discomfort or distress that is caused by a discrepancy between a
	person's gender identity (how they see themselves regarding
	their gender) and that person's sex assigned at birth (and the
	associated gender role, and/or primary and secondary sex
	characteristics).
Gonadotrophin	GnRH analogues competitively block GnRH receptors to prevent
releasing hormone	the spontaneous release of 2 gonadotropin hormones, Follicular
(GnRH) analogues	Stimulating Hormone (FSH) and Luteinising Hormone (LH) from
	the pituitary gland. The reduction in FSH and LH secretion
	reduces oestradiol secretion from the ovaries in those whose sex
	assigned at birth was female and testosterone secretion from the
	testes in those whose sex assigned at birth was male.
Sex assigned at birth	Sex assigned at birth (male or female) is a biological term and is
	based on genes and how external and internal sex and
	reproductive organs work and respond to hormones. Sex is the
	label that is recorded when a baby's birth is registered.
Tanner stage	Tanner staging is a scale of physical development.
Trait Anger	The TPI is a validated 20-item inventory tool which measures the
Spielberger scales of	intensity of anger as the disposition to experience angry feelings
the State-Trait	as a personality trait. Higher scores indicate greater anger.
Personality Inventory	
(TPI) Tranagandar	Tronggondor ig a torm for someone wheee reader identify is not
Transgender	Transgender is a term for someone whose gender identity is not
(including transmale	congruent with their birth-registered sex. A transmale is a person
and transfemale)	who identifies as male and a transfemale is a person who
	identifies as female.

Utrecht Gender Dysphoria Scale (UGDS)	The UGDS is a validated screening tool for both adolescents and adults to assess gender dysphoria. It consists of 12 items, to be answered on a 1- to 5-point scale, resulting in a sum score between 12 and 60. The higher the UGDS score the greater the impact on gender dysphoria.
Youth Self-Report (YSR)	The self-administered YSR is a checklist to detect emotional and behavioural problems in children and adolescents. It is self- completed by the child or adolescent. The scales consist of a Total problems score, which is the sum of the scores of all the problem items. An internalising problem scale sums the anxious/depressed, withdrawn-depressed, and somatic complaints scores while the externalising problem scale combines rule-breaking and aggressive behaviour.

References

Included studies

- <u>Brik T, Vrouenraets L, de Vries M et al. (2020). Trajectories of Adolescents Treated with</u> <u>Gonadotropin-Releasing Hormone Analogues for Gender Dysphoria</u>. Archives of Sexual Behaviour. [Accessed 6 August 2020]
- Costa R, Dunsford M, Skagerberg E et al. (2015) Psychological Support, Puberty Suppression, and Psychosocial Functioning in Adolescents with Gender Dysphoria. Journal of Sexual Medicine. [online] Volume 12(11), Pages 2206-2214. Available at: <u>https://doi.org/10.1111/jsm.13034</u> [Accessed 7 August 2020]
- <u>de Vries A, Steensma T, Doreleijers T et al. (2011) Puberty Suppression in Adolescents</u> <u>with Gender Identity Disorder: A Prospective Follow-Up Study</u>. The Journal of Sexual Medicine Volume 8, Issue 8, August, Pages 2276-2283. [Accessed 11 August 2020].
- Joseph T, Ting J, Butler G (2019) The effect of GnRH analogue treatment on bone mineral density in young adolescents with gender dysphoria: findings from a large national cohort. Journal of pediatric endocrinology & metabolism 32(10): 1077-1081
- <u>Khatchadourian K, Shazhan A, Metzger D. (2014) Clinical Management of Youth with</u> <u>Gender Dysphoria in Vancouver</u>. The Journal of Pediatrics. Volume 164, Issue 4, April, Pages 906-911. [Accessed 14 August 2020]
- Klink D, Caris M, Heijboer A et al. (2015) Bone mass in young adulthood following gonadotropin-releasing hormone analog treatment and cross-sex hormone treatment in adolescents with gender dysphoria. The Journal of clinical endocrinology and metabolism 100(2): e270-5
- Schagen SEE, Cohen-Kettenis PT, Delemarre-van de Waal HA et al. (2016) Efficacy and Safety of Gonadotropin-Releasing Hormone Agonist Treatment to Suppress Puberty in Gender Dysphoric Adolescents. The journal of sexual medicine 13(7): 1125-32
- <u>Staphorsius A, Baudewijntje P, Kreukels P, et al. (2015) Puberty suppression and executive functioning: An fMRI-study in adolescents with gender dysphoria.</u>
 <u>Psychoneuroendocrinology</u> Volume 565. Pages 190-199. [Accessed 10 August 2020]

• Vlot, Mariska C, Klink, Daniel T, den Heijer, Martin et al. (2017) Effect of pubertal suppression and cross-sex hormone therapy on bone turnover markers and bone mineral apparent density (BMAD) in transgender adolescents. Bone 95: 11-19

Other references

- World Health Organisation (2018) International Classification of Diseases 11. Available from <u>https://icd.who.int/</u> [online; accessed 20 August 2020]
- <u>American Psychiatric Association. (2013). Diagnostic and statistical Manual of Mental</u> <u>Disorders (DSM-5) (5th ed).</u> Washington, DC and London: American Psychiatric Publishing. pp.451-460. [accessed 20 August 2020]
- <u>NHS England (2013). NHS Standard contract for gender identity development service</u> for children and adolescents [accessed 20 August 2020]

Copyright

© NICE 2021. All rights reserved. Subject to Notice of rights